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6	 Abbreviations	&	Definitions
Abbreviations & Definitions1. 
1D   monodimensional
2D   two-dimensional
3D   three-dimensional
1,6 anGNS	 	 N-sulfo-amino-1,6-anhydro-2-deoxy-β-D-glucopyranose
1,6 anMNS	 	 N-sulfo-amino-1,6-anhydro-2-deoxy-β-D-mannopyranose
2,5 anM6S	 	 2,5-anhydro-6-O-sulfo-2-deoxy-β-D-mannopyranose
Aβ		 	 	 amyloid-β
AT   Antithrombin III
COSY   Correlation Spectroscopy
CS   Chondroitin Sulfate
CW   Continuous-Wave
DU   4, 5-unsaturated uronic acid
DLS   Dynamic Light Scattering
DT   relaxation Delay Time
DS   Dermatan Sulfate
FGF(s)   Fibroblast Growth Factor(s)
FGFR(s)  FGF receptor(s)
FID   Free-Induction Decay
Fn   Fourier number
FT   Fourier Transform or Transformation
GAG(s)  Glycosaminoglycan(s)
GalA   Galacturonic acid
GlcA/G	 	 β-D-glucuronic	acid
GlcN	 	 	 α-D-glucosamine
GlcNNAc,6S/ANA  N-acetylated, 6-O-sulfated-D-glucosamine
GlcNNS   N-sulfated-D-glucosamine
GlcN6S   6-O-sulfated-D-glucosamine
GlcNNS,6S/A  N, 6-O-disulfated-D-glucosamine
GlcNNS, 3, 6S/A*  N-sulfated-3,6-O-sulfated-D-glucosamine
IdoA/I		 	 α-L-iduronic	acid
I2S/IS	 	 	 2-O-sulfated-α-L-iduronic	acid
Hep(s)   Heparin(s)
HSQC   Heteronuclear Single Quantum Correlation
INEPT   Insensitive Nuclei Enhancement by Polarization Transfer
LB   Line Broadening
LMWH   Low Molecular Weight Hep
Mn   number-average mean molecular weight
MW   weight-average mean molecular weight
NMR    Nuclear Magnetic Resonance
NOE   Nuclear Overhauser Effect or Enhancement
NOEEXP  experimental NOE value
NOECALC  theoretical NOE value
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NOESY   NOE SpectroscopY
trNOE   transferred NOE
OSCS   OverSulfated CS
PFG   Pulse Field Gradient
rf   radio frequency
ROESY  Rotating frame NOE Spectrosopy
RT    Room Temperature
S/N   Signal-to-Noise ratio
STD   Saturation Transfer Difference
tmix   mixing time
TOCSY   TOtal Correlation SpectroscopY
UFH    Unfractionated Hep
vLMWH   very Low Molecular Weight Hep
WATERGATE  WATER suppression by Gradient Tailored Excitation
Symbols
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Symbols2. 
1JC-H   one-bond proton-carbon coupling constant
3JH-H   three-bond proton-proton coupling constant
°C   Celsius degree
D   polydispersity (MW/Mn) 
dn/dc	 	 	 specific	refractive	index	increment (mL/g)
kB   Boltzman constant ((1.38E-23((Kg*m2)/(sec2*°K)))
Kd   dissociation constant (mM)
koff   unbinding constant (sec-1)
l   laser wavelenght (nm)
n   refractive index
h		 	 	 viscosity	coefficient	(Kg/(sec*m))
Q   scattering angle (90 °)
ppm   parts per million
Rh   hydrodynamic radius (nm)
tc   Rotational correlation time
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Introduction3. 
The extracellular matrix3.1. 
Cells	are	not	the	unique	constituent	of	animal	tissues,	a	major	part	is	filled	by	a	network	of	macro-
molecule within the extracellular space, this is called extracellular matrix (ECM) (Fig. 1). ECM is 
mainly constituted by locally secreted proteins and polysaccharides: (1) polysaccharide chains of the 
class called glycosaminoglycans (GAGs), which are usually found covalently linked to protein in 
the	form	of	proteoglycans	(PG)	and	(2)	fibrous	proteins,	including	collagen,	elastin,	fibronectin	and	
laminin, which have both structural and adhesive functions. PG molecules in connective tissue form a 
highly	hydrated,	gel-like	network	in	which	the	fibrous	proteins	are	embedded.	The	polysaccharide	gel	
resists compressive forces on the matrix while permitting the rapid diffusion of nutrients, metabolites 
and	hormones	between	the	blood	and	the	tissue	cells.	The	collagen	fibers	both	strengthen	and	help	
to	organize	the	matrix	and	rubber-like	elastin	fibers	give	it	resilience.	Finally,	many	matrix	proteins	
help cells attachment to the appropriate locations (Alberts et al., 2002). The complex structure of the 
ECM is the site in which all inter cellular communication takes place, but that how this is regulated 
is only now starting to be addressed. This communication must result in all the usual outcomes as-
sociated with higher organisms, including cell growth, differentiation and development (Capila and 
Linhardt, 2002). GAGs (and especially heparan sulfate) are known to be critically involved in most 
major cellular signaling networks, so understanding the composition of the ECM, their characteristics 
and interactions will be vital to making progress in this area.
Collagen Fiber GAG
Laminin
Scaold protein
Proteoglycan
IntegrinLipid bilayer
Figure 1. Schematic representation of animal extracellular matrix. 
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Glycosaminoglycans3.1.1. 
Glycosaminoglycans are anionic polysaccharide chains composed by peculiar repeating disaccharide 
units. One of the two sugars in the repeating disaccharide is always an amino sugar (N-acetylglu-
cosamine or N-acetylgalactosamine), which in most cases is sulfated. The second sugar is usually a 
uronic acid (glucuronic or iduronic). Because there are sulfate or carboxyl groups on most of their 
sugars, GAGs are highly negatively charged, for this reason they are the most anionic molecules 
produced by animal cells. Four main groups of GAGs are distinguished according to their sugars, 
the type of linkage between the sugars and the number and location of sulfate groups: (1) hyaluronan 
(hyaluronic acid, HA), (2) chondroitin sulfate (CS), dermatan sulfate (DS), (3) keratan sulfate and (4) 
heparan sulfate (HS) and heparin (Hep) (Fig. 2). 
-Ser
Ser-
Ser-
Ser-
-Ser
Xylose
Galactose
Glucuronic Acid
Iduronic Acid
N-acetylated Galactosamine
N-acetylated Glucosamine
Sulfate
Dermatan sulfate
Chondroitin sulfate
Hyaluronic acid
Core protein
Keratan sulfate
Heparan sulfate
Heparin
Figure 2. Schematic representation of different glycosaminoglycans .
Since polysaccharide chains are rigid and hydrophilic, GAGs tend to adopt highly extended confor-
mations that occupy a huge volume relative to their mass and they form gels even at very low con-
centrations. Their high density of negative charges attracts a cloud of cations, most notably Na+ and 
Ca2+ (Ferro et al., 1990; Mulloy and Forster, 2000), that are osmotically active, thus causing large 
amounts of water to be sucked into the matrix. This creates a swelling pressure, or turgor, that enables 
the	matrix	 to	withstand	compressive	 forces	 (in	contrast	 to	collagen	fibrils,	which	 resist	 stretching	
forces). The cartilage matrix that lines the knee joint, for example, can support pressures of hundreds 
of atmospheres in this way. The GAGs in connective tissue usually constitute less than 10% of the 
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weight	of	the	fibrous	proteins,	but,	because	they	form	porous	hydrated	gels,	the	GAG	chains	fill	most	
of the extracellular space, thus providing mechanical support to the tissue. Due to this important 
structural function, genetic diseases affecting GAG biosynthesis have severe consequences (i.e. mu-
copolysaccharidoses),	for	example	in	one	rare	human	genetic	disease,	there	is	a	severe	deficiency	in	
the synthesis of the dermatan sulfate. The affected individuals have a short stature, prematurely aged 
appearance and generalized defects in their skin, joints, muscles and bones. It should be emphasized, 
that in invertebrates and plants other types of polysaccharides often dominate the extracellular matrix 
(Alberts et al., 2002). 
Heparan sulfate/ Heparin3.1.2. 
HS family is composed by HS and Hep, molecules sharing some structural features (composed of 
alternate	units	of	α-D-glucosamine	 (GlcN)	and	uronic	acid,	either	β-D-glucuronic	acid	 (GlcA)	or	
α-L-iduronic	acid	(IdoA),	joined	together	by	(1	->	4)	glycosidic	linkages.	In	heparan	sulfate	the	GlcN	
can be either N-sulfated or N-acetylated (Dreyfuss et al., 2009). Cellular localization, their occur-
rence in the animal kingdom and their biological functions, are the features differentiating them: HS 
is ubiquitous to the cell surface of both vertebrate and invertebrate species (Cassaro and Dietrich, 
1977) (Fig. 3), where Hep is not evolutionary conserved as HS and it is synthesized and stored by 
mast cells in vertebrates (Nader et al., 1999). Furthermore, heparin shows higher degree of sulfation 
(DoS) (2.3–2.8 sulfates/disaccharide) when compared to HS (0.6–1.5 sulfates/disaccharide) (Drey-
fuss et al., 2009). HS also has a domain structure of short, highly sulfated regions separated by longer 
regions of low sulfated, GlcA-rich stretches. Heparin, on the other hand, is richer in IdoA units and 
lacks this domain structure.
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F igure 2 - D istribution of sulfated
glycosam inoglycans in the ani-
mal kingdom .
Figure 3.  Distribution of sulfated glycosaminoglycans in the animal kingdom (Nader et al., 1999).
Negative charge high density and the big structural heterogeneity lead HS/Hep to easily interacts with 
proteins, such as proteases, growth factors, chemokines, lipid-binding proteins, pathogen proteins, 
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adhesion proteins and nutritional metabolisms (Capila and Linhardt, 2002; Esko and Selleck, 2002; 
Lindahl et al., 2007; Bishop et al., 2007; Ori et al., 2008). 
HS/Hep biosynthesis and Hep structural properties3.1.3. 
HS/Hep, DS and CS are synthesized as proteoglycans, in which they are linked to serine residues in 
defined	 core	 proteins	 through	 a	 glucuronyl-galactosyl-galactosyl-xylosyl	 tetrasaccharide	 sequence	
called	linkage	region	(LR)	GlcAβ	(1->3)	Galβ	(1->3)	Galβ	(1->4)	Xylβ-1-O-Ser	{LR	content	varies	
widely depending on the origin of heparin [i.e. it is lower than 1% in bovine lung heparins and up to 
5% in porcine mucosal heparins (Lindahl, 1996; Iacomini et al., 1999, 1999)]. There are no evidences 
for an LR role in biological activities, but some authors suggest an implication in antiangiogenic 
properties of heparin/HS (Hanhenberger et al.,	1993)}.	Ser	residue	into	the	core	protein	is	modified	
by xylosyltranferase (XylT) in the endoplasmic reticulum (ER) and the cis-Golgi (Esko and Selleck, 
2002;	Prydz	and	Dalen,	2000).	XylT	catalyses	the	transfer	of	a	Xyl	residue	through	a	β-linkage	from	
UDP-Xyl to a Ser residue in the core protein substrates (Fig. 4), the amino acid sequences of which 
are conserved as Ser-Gly-X-Gly (where Gly and X stand for glycine and any amino acid, respective-
ly) as revealed by comparison with the GAG attachment sites in the core proteins (Esko and Zhang, 
1996).	Although	human	and	rats	β-XylTs	have	been	cloned	(Gotting	et al., 2000), the catalytic role of 
the second one has not been shown yet and its biological function remain unclear. Subsequently, two 
Gals are attached to the Xyl residue by galactosyltransferase-I and galactosyltransferase-II (GalT-I 
and	GalT-II)	(Fig.	4).	GalT-I	is	one	of	the	seven	β1-4GalT	family	members,	which	appears	to	have	
exclusive	specificity	for	the	donor	substrate	UDP-Gal.	On	the	other	hand	GalT-II	witch	transfers	Gal	
from	UDP-Gal	to	a	β-linked	Gal	residue	is	one	of	the	six	β1-3GalT	family	members	(Bai	et al., 2001). 
Lastly	the	LR	is	completed	by	the	transfers	of	a	GlcA	through	a	β1-3	linkage	from	UDP-GlcA	to	
Galβ1-3Galβ1-4Xylβ1-O-Ser	(Fig.	4),	which	is	catalysed	by	the	glucuronyltransferase-I	(GlcAT-1)	
(Kitagawa et al., 1998; Tone et al., 1999). Chain polymerisation of the repeating disaccharide region 
in	heparin	and	HS	is	evoked	by	the	transfer	of	the	αGlcNAc	residue	from	UDP-GlcNAc	to	the	LR	
tetrasaccharide, which is mediated by GlcNNAcT-I	(Fig.	4).	The	addition	of	β1-4-linked	GalNNAc to the 
LR	by	β1-4N-	acetylgalactosaminyltransferase-I	(GalNAcT-I)	initiates	the	formation	of	the	repeating	
disaccharide in CS and DS. N-deacetylation and N-sulfation of GlcNNAc residues in heparin and HS 
are	initial	modifications	of	precursor	chains	and	essential	for	all	the	subsequent	modifications	(Fig.	4).	
Both reactions are catalysed by the bifunctional enzymes GlcNNAc N-deacetylase/N-sulfotransferase 
(NDSTs). This complex chain of events leads to the synthesis of a wide variety of GAG molecules 
with different sequences and due to this great varieties they can bind a wide array of ligands mediating 
and triggering biological functions: cell matrix assembly, cell adhesion (Xian et al., 2010), cell/tissue 
differentiation (Yan and Lin, 2009), cell migration, cell recognition, cell proliferation, cell survival, 
endocytosis, haemostasis, angiogenesis, defense mechanism (Dreyfuss et al.,	2009)	and	inflammation	
(Li and Vlodavsky, 2009). Heparin is the most homogeneous molecule of the HS/Hep family and its 
chains are made up of various combinations of building blocks. The distribution of those building 
blocks generate different charged regions characterised by peculiar disaccharide repeating unit. The 
less charged sequences are mainly concentrated towards the reducing side of the chains (R) thus the 
typical disaccharide is GlcA-GlcNNAc (NA domain). On the nonreducing side (NR) there is the highest 
sulfate groups concentration (NS domain), since the most abundant disaccharide is Ido2S-GlcNNS,6S 
(TSD). In the middle there is a mixed domain (NA/ NS domain) mainly characterised by a GlcA-
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GlcNNS	disaccharide	repeating	unit	(Fig.	5),	some	of	the	heparin	chains	contain	a	specific	sequence	
constituting the antithrombin III (AT) binding domain (AT-bd). This sequence is the pentasaccharide 
β-D-N-acetylated,6-O-sulfated	glucosamine	(GlcNNAc,6S/ANA)-α(1->4)-D-glucuronic	acid	(GlcA/G)-
β(1->4)-D-N-sulfated,3,6-O-sulfated	 glucosamine	 (GlcNNS,3,6S/A*)-α(1->4)-D-2-O-sulfated	 iduron-
ic acid (IdoA2S/IS)-α(1->4)-D-N-sulfated,6-O-sulfated	 glucosamine	 (GlcNNS,6S/A) (abbreviated in 
ANAGA*ISA) shown in Fig. 5. HS/Hep composition varies depending on animal and organ origin and 
also	on	the	purification	procedures	(Fig.	5	and	Table	1;	Loganathan	et al., 1990; Bianchini, 1997).
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As it was demonstrated, TSD units represent more than 60 % (heparins obtained from porcine mu-
cosa up to 60–75% and heparins obtained from bovine lung up to 85% (Guerrini et al., 2001; Sudo 
et al., 2001). TSD characterises the longer segment of NS domain and this segment is often referred 
to as constituting ‘‘regular regions’’ and is the major contributor to the polyelectrolytic properties 
of heparin. TSD segments length is known for limited heparin types and only in statistical terms, 
through	oligosaccharides	size	profiling	on	oxidated	(at	nonsulfated	uronic	acid	level)	and	depolimer-
ised	haparin:	pig	mucosal	heparin	is	statistically	characterised	by	8-12	TSD	units,	whereas	human	fi-
broblast derived HS is statistically characterised by up to 5 TSD units (Fransson et al., 1980; Sjoberg 
et al., 1980). 
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Avarage Number in One Heparin Chain
Species Tissue
N-acetyl AT
Binding site
N-sulfo AT
Binding site
Trisulfated
Disaccharide
Disulfated
Disaccharide
Porcine intestine 0.5 (0.3-0.7) 0.1 10 (10-15) 1.2 (1-2)
Bovine lung 0.3 0.3 14 1.0
Bovine intestine 0.3 0.3 10 1.7
Ovine intestine 0.7 0.4 11 1.4
Hen intestine 0.3 0.2 6.7 1.7
Clam - 0.5 0.4 5.0 1.9
Heparin composition from different species and organs. Numbers in parenthesis indicate a range of values typically observed (adapted from Table 1. 
Loganathan et al., 1990).
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Figure 6. Schematic representation of the typical trisulfated disaccharide (TSD) characterising the NS domain. Sulfate groups (green circles) are 
highlighted.
 
GAG sequence conformations: local rigidity and flexibility 3.1.4. 
Heparin and related polysaccharides tridimensional structures have long been elusive and a mat-
ter of controversy (Casu et al., 1986). One of the most problematic issue in GAG 3D modeling has 
been the evaluation of the conformation of their iduronic acid residues, critical to determine the 
polysaccharide chains conformations. Molecular mechanics studies on monomeric IS methyl glyco-
side led to understand that the iduronate ring could be present in three equienergetic conformations: 
1C4, 2S0 and 4C1 (Fig. 7) (Ragazzi et al., 1986). The 1C4 and 2S0 geometries are similar for the two 
conformations: helices with regular arrays of three sulfate groups on both sides. However, spacing 
between sulfate groups on adjacent residues is different for the two local conformations and the 
sulfate forms cluster in different ways along the chain axis (Fig. 7). The population of individual 
conformers depends on the structure of neighbouring units and sulfation of the IdoA residue, as sug-
gested by Nuclear Magnetic Resonance (NMR) spectroscopic data (Ferro et al., 1986). For exam-
ple, in heparin/HS the ratio of the 1C4 and 2S0 conformers of the 2-O-sulfated IdoA residue is about
60: 40. When IS is preceded by a 3-O-sulfated GlcNNS,3S,6S residue, as in the pentasaccharide sequence 
of the AT-bd, the 2S0 form is more represented than the 1C4 form (Ragazzi et al., 1987; Mikhailov et 
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al., 1997). The 4C1 form is selected by IS when the iduronate residue is located in terminal positions of 
heparin/HS sequence (Ferro et al., 1986). Iduronate position within Hep/Hs sequence is not the only 
factor affecting the conformational equilibrium, it might also be affected by ionic strength and spe-
cific	counterions:	in	fact,	it	was	demonstrated	that	the	equilibrium	of	the	IS residues of heparin (Ferro 
et al., 1990) and heparin oligosaccharides (Ferro et al., 1990; Mulloy and Forster, 2000) is driven by 
Ca2+ ions towards to 1C4 form. IdoA “plasticity” has been suggested to help the most effective docking 
of the anionic groups of the GAG toward to basic groups of proteins (Mulloy et al., 1993), complete 
conformational	maps	analysis	confirm	iduronate	capability	to	assume	one	out	of	three	(or	all	three)	
possible conformations (Ragazzi et al., 1986; Casu et al., 1988). Moreover, modeling and NMR data 
(Hricovini et al., 2001) indicates that no basic groups in the binding site are within reach of the 2-O-
sulphate group of IdoA2-SO3. Thus this group is not directly involved in the binding process, but 
appears to be the main driving force affecting the conformational equilibrium in IdoA2-SO3 towards 
the skew form (Fig. 8 A) (Hricovini et al., 2001). Another important Hep structural features is its 
linearity that is not continuous, this concept came up as a consequence of crystal structures analysis 
of heparin oligosaccharide-protein complexes, at the protein- GAG interaction site was noticed a lost 
of linearity in the polysaccharidic chain and the comparison of “kinks”. These kinks seem to be a 
signature of complex formation, together with a different conformation of an iduronate residue than 
GAG chain portions not involved in binding (Raman et al., 2003). As illustrated in Fig. 8 A, evalua-
tion of the conformation of pentasaccharide complexed with AT in solution has also indicated that the 
IS residue is not directly involved in binding, probably GAG molecules use IS plasticity to drive the 
preceding trisaccharide sequence (ANA-G-A*) towards the appropriate conformation in order to better 
fit	the	protein	moiety	(Hricovini	et al., 2001). Notably, Hricovini et al. (2001) shown that the IdoA 
residues,	belonging	to	pentasaccharide	flanking	sequences,	assume	different	conformations	depend-
ing	their	location	at	the	reducing	or	nonreducing	side	of	the	pentasaccharide.	These	findings	suggest	
that the conformation of the iduronate residues (2S0 and 1C4 for IdoA located at the nonreducing and 
reducing side of the ANAGAISA	sequence)	could	enhance	the	AT	affinity	of	ANAGA*ISA containing 
oligosaccharides, either by optimizing contacts between ANAGA*ISA and AT or promoting additional 
contacts involving the ANAGA*ISA extensions (Guerrini et al., 2008 [b]).
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Figure 4 Conformation of the heparin pentasaccharide in complex with AT
Structure of AGA*IAM in the AT binding site. The corresponding dihedral angles at the glycosidic linkages are shown in Table 3. The IdoA2-SO3 residue is in the twisted-boat
2S0 conformation,
the remaining residues are in the 4C1 chair conformation. AT amino acids : Arg, red ; Asn, orange ; Lys, pink ; Asp, blue ; Ile, grey ; Cys, yellow ; Ala, white ; Pro, green.
state and in the presence of AT. As the computed NOEs vary
with glycosidic linkage geometry, our data suggest that the
variation in conformation occurs at the A–G and I–A
M
linkages
in AGA*IA
M
during its binding to AT. The transferred NOE
data further indicate that the addition of other functional groups
into the core pentasaccharide structuremay also result in diﬀerent
stereochemistry at the glycosidic linkages in the modiﬁed ana-
logue–AT complex with respect to the AGA*IA
M
–AT complex.
An analysis of the pentasaccharide structure in the complex
with AT suggests, on the basis of NMR experimental data
interpreted with molecular modelling, that the AGA*IA
M
struc-
ture in the complex diﬀers from that in free solution. The NMR-
derived 3D structure agrees with not only the transferred NOEs
but is also in agreement with the observed non-bonded inter-
actions between positively chargedAT amino acids in the binding
site and the negatively charged sulphates and carboxylates in the
pentasaccharide [25–27]. For example, the computed distance
between the nitrogen atom in the NH
�
group in Arg-129 and the
sulphur atom in the 6-SO−
�
group in A is 4.3 A� , corresponding
well with the expected strong interaction [25] between these
two groups. Similarly, spatial closeness was observed for the
NH
�
group of Lys-125 and both the 6-SO−
�
group in A and
the carboxyl group in G. The computed distances were 3.5 A�
(the distance between the NH
�
group in Lys-125 and oxygen in
the C�O group in G) and 3.8 A� (the distance between the NH
�
group and sulphur in the 6-SO−
�
group in A; the distance in the
solid-state of the modiﬁed analogue is 4.4 A� ). Strong non-
bonded interaction can also be expected between the N-SO−
�
group in the A* residue and Arg-13 as well as Lys-114 due to
short inter-atomic distances between the sulphate and both
amino acids.
The lack of any dipolar interaction between the 2-O-sulphate
group and the amino acid in the receptor, as observed in the
present modelling and NMR data, and the crystal state [17],
� 2001 Biochemical Society
A.              B.
A-helix
D-helix
Figure 8. AT-ANAGA*ISA complex. A. NMR spectroscopy (Hricovini et al., 2001): pentasaccharide is represented as sticks, sulfate groups are rep-
resented as yellows and red sticks. B.	X-ray	diffraction	(modified	from	Jin	et al., 1997) :AT-pentasaccharide interaction involve D-helix (yellow) and 
A-helix (red). The two models mainly diverge for reducent ANNS,6S.
Coagulation and he ri3.1.5. 
The coagulation cascade is a sequence of enzymatic events. Most plasma coagulation factors circu-
lat  as inactiv  proenzymes (serin  proteases) which are synthesized by the liver. These enzymes are 
proteolitically cleav d, thus inducing their activation, by the activated factors that precede them in the 
cascade. The cascade is traditionally divided in intrinsic (contact activation) and extrinsic (tissue fac-
tor) pathway. The intrinsic pathway is activated by the complex Factor XII (Hageman Factor, FXII), 
its cofactor high molecular weight kininogen HMWK, collagen and prekallikrein. The complex leads 
to the activation of FXII that cleaves the Factor XI (FXIa) and the cascade proceeds until the crucial 
point of Factor X activation (FXa), where the two pathways converge. Stream while the extrinsic path-
way is activated in vivo by tissue factor (lipoprotein expressed and released by activated leukocytes, 
activated	endothelial	cells,	subendothelial	smooth	muscle	cells	and	subendothelial	fibroblasts	of	vas-
cular injury). Although the two pathway converge at FX activation, there is an important interconnec-
tion: activated Factor VII (FVII, from extrinsic pathway) participate in the activation of the Factor IX 
(FIX, intrinsic pathway). When the two pathways converge an important reaction is catalysed which 
requires activated Factor V (FVa) and FXa: prothrombin (factor II, FII) is cleaved by FXa leading to 
thrombin formation (FIIa) (Fig. 9). Thombin is a multifunctional enzyme that acts in the coagulation 
cascade	in	four	important	points:	1)	it	converts	fibrinogen	into	fibrin,	causing	the	formation	of	insolu-
ble	fibers,	2)	activates	Factor	XIII	that	crosslinked	fibrin	generating	a	higly	stable	clot,	3)	increases	
and accelerates coagulation cascade inducing a positive feedback through activation of FV, FVIII, 
FXI and 4) it strongly activates platelets, thus causing granules release and platelets aggregation (Fig. 
9). Over the last 20 years heparin studies have contributed to elucidate the molecular basis of the anti-
coagulant and antithrombotic activities of heparin, in particular their inhibition of FXa and thrombin, 
the	final	two	proteases	of	the	coagulation	cascade.	Heparin	anticoagulant	properties	are	exerted	en-
hancing AT inhibition activity over FXa and thrombin from 300 to 1000 fold and to a minor extent 
Hep is also capable to accelerate heparin cofactor II (HCFII, which selectively inhibits thrombin). AT 
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and HCFII are structural homologous (Baglin et al., 2002), but where AT binds only heparin, HCFII 
also binds DS, in fact are involved different polysaccharides sequences as previously shown in Table 
2 (Tollefsen, 1992). Anticoagulant effects are also associated with GAG-induced release of tissue fac-
tor pathway inhibitor (TFPI) from vascular endothelium (Brooze, 1995; Hoppensteadt et al., 2003; 
Newall et al., 2010). The activity of both AT and HCFII is dramatically increased by binding with 
heparin.	Heparin	sequences	that	specifically	bind	to	HCFII	have	not	been	identified.	In	fact,	HCFII	
seems	to	be	bound	by	heparin	rather	nonspecifically	(Tollefsen,	1992;	Bourin	and	Lindahal,	1999;	
Petitou, 1988). However, it is reasonable to assume that sequences of the TSD (Fig. 6) are the major 
sites for HCFII binding. The present informations about the mechanism of the interaction between 
heparin, AT and thrombin and related structural aspects are largely based on physico-chemical studies 
of these systems in solution (Olson and Björk, 1992; Olson and Björk, 1992 [b]) and on X-ray diffrac-
tion studies (Jin et al., 1997; Li et al., 2004). Since these studies and their biological implications are 
covered	in	other	chapters	of	this	thesis,	the	present	chapter	briefly	discusses	only	current	information	
on heparin sequences involved in the above interactions and the dependence of these interactions on 
the size of GAG sequences and the location of active sites in these sequences. The search for minimal 
sequences binding to AT and HCFII and inducing inhibition of thrombin mediated by these cofactors 
has led to understanding the size-dependence of GAG activities associated with interaction with the 
two protease inhibitors. AT-, as well as HCFII-mediated inhibition of thrombin, need relatively long 
heparin chains as a requisite for binding to both the inhibitor and the enzyme in a ternary complex. 
The	minimum	heparin	size	for	significant	HCFII	binding	was	a	hexasaccharide	corresponding	to	three	
TSD	units;	full	affinity	for	HCFII	is	practically	reached	at	eight	monosaccharide	residues	(Tollefsen,	
1992). Thrombin inhibition requires a minimum chain length of 16–18 monosaccharide residues 
(Laurent, 1978). On the other hand, AT-mediated inhibition of Factor Xa requires only the pentasac-
charide sequence of the active site for AT (reviewed in Bourin and Lindahal, 1999, Casu and Lindahl, 
2001, Muñoz and Linhardt, 2004).This observation was at the basis of the introduction of low mo-
lecular weight heparins (LMWHs) as antithrombotic agents blocking the coagulation cascade at the 
level of FXa. Low molecular weight heparin are heparin salt having an average MW less than 8000 
Da and at least 60% of all molecules must have a MW less than 8000 Da (Linhardt and Gunay, 1999). 
LMWHs are obtained by chemical or enzymatic depolymerisation of unfractionated heparin (UFH), 
that	introduce	modification	at	the	reducing	and/or	nonreducing	end	of	the	obtained	molecular	species.	
As a pharmaceutical agent LMWH should respect some rules: a) appropriate MW with a low polydis-
persity;	2)	anti-FXa/	anti-FIIa	ratio	must	be	>	1;	3)	molecular	structure	cannot	has	much	artifacts;	4)	
toxic agent must be eliminated; 5) production reproducibility, minimum number of process steps and 
high yielding. Nowadays the industrial process are not so performace in respect to all the points, but 
still high quality LMWH are produced and used for pharmacological treatment (Linhardt and Gunay, 
1999). Being only marginally involved in the inhibition of thrombin and in side effects associated 
with full-length heparin, LMWH species were thought to reduce the hemorrhagic risks. However, the 
major advantage of LMWHs over conventional heparin for certain therapeutic indications is their bet-
ter bioavailability. Depolymerisation procedures used for obtaining LMWHs may occasionally cleave 
the AT-bd, less represented in LMWHs than in conventional heparins (Fareed et al., 1999), as observed 
upon partial digestion with heparinase 1 (Shriver et al., 2000; Avci et al., 2002). On the other hand, a 
synthetic pentasaccharide closely reproducing the structure of the AT-bd (as a methyl glycoside, in a 
variant	in	which	the	first	GlcN	residue	is	N-sulfated	instead	of	N-acetylated)	and	based	on	exclusive	
inhibition of Factor Xa was proved to be an effective antithrombotic agent (Petitou et al., 2004). 
21 Introduction
Intrinsic pathway
Extrinsic pathway
Surface injury
Disrupted Cell Membranes
Factor XII Factor XIIa
Factor XI Factor XIa
Factor IX Factor IXa
Ca2+
Kallikrein
Collagen
HMWK
Prekallikrein
Ca2+
Phospholipids
VIIa
Ca2+
1) 1)
4) -Platelets activation & granules release
    -Platelets aggregation 
2)
2)
3)
3)
3)
Ca2+
AT
HCII
TFPI
Factor X Factor XFactor Xa
Factor VIII Factor VIIIa
Factor XIII
Factor XIIIa
Factor V Factor Va
Fibrinogen Fibrinmonomer
Fibrin
multimer
Clot/
crosslinked
fibrin
Factor II
Prothrombin
Factor IIa
Thrombin
Factor VIIFactor VIIa
Ca2+
Tissue Factor
UFH
LMWH
AT
UFH
LMWH
AT
UFH
LMWH
HMWK
Figure 9. Schematic representation of the coagulation cascade. Intrinsic and extrinsic pathway are shown (the orange box isolates the extrinsic path-
way	and	yellow	written	molecules	belong	exclusively	to	extrinsic	pathway).	Factor	IIa	effects	are	highlighted:	1)	conversion	from	soluble	fibrinogen	to	
insoluble	fibrin	fibers,	2)	Factor	XIIIa	activation	and	consequent	clot	formation,	3)	activation	enhancement	of	Factor	V,	Factor	VIII	and	Factor	XI,	4)	
granules release from activated platelets and their aggregation. Green arrows indicate molecular conversion from an inactive to an active form; yellow 
arrows indicate activation induction; blue arrows indicate acceleration effect over AT, heparin induced; red hammers indicate inhibition effects and black 
arrows	indicate	fibrin	polymerisation	till	clot	formation.	HMWK=	high	molecular	weight	kininogen;	AT=	antithrombin	III;	HCFII=	heparin	cofactor	II;	
TFPI= tissue factor pathway inhibitor; UFH= unfractionated heparin; LMWH= low molecular weight haparin.
Synthetic oligosaccharide chemistry has made an important contribution to establish the rela-
tionships between structure and AT-mediated activities (van Boeckel and Petitou, 1993; Bau-
er et al., 2002; Petitou et al., 2004). A pentasaccharide with an additional 3-O-sulfate group (on 
the	fifth	 residue)	with	 respect	 to	ANAGA*ISA was shown to be even more active than the natural 
pentasaccharide (van Boeckel and Petitou, 1993). Moreover, a systematic study of extension 
of	 the	 heparin	 chain	 on	 both	 sides	 of	 the	 pentasaccharide	 sequence	 has	 confirmed	 that	 the	 chain	
extension required to bind thrombin in the ternary complex with heparin and AT must be at least 
14	 monosaccharide	 residues	 long	 and	 definitely	 established	 that	 such	 an	 extension	 must	 be	 to-
ward the nonreducing terminal of the heparin chain (Petitou et al., 1999). The actual location 
of	 thrombin	 in	 the	 ternary	 complex	 was	 also	 confirmed	 by	 studies	 using	 neo-glycoconjugates	
(Rong et al., 1999) and conclusively by X-ray diffraction studies (Iozzo and San Antonio, 2001). 
Heparin as a pharmaceutical agent3.2. 
Heparin	 has	 been	 used	 as	 pharmaceutical	 agent	 from	 the	first	 decades	 of	 the	 last	 century	 for	 the	
prevention and initial treatment of thrombosis (Murray and Best, 1938; Lam et al., 1941). Pharma-
ceutical grade heparin was derived for decades from different animal sources, mainly bovine lung 
and porcine intestine (Linhardt and Gunay, 1999), but after the bovine spongiform encephalopathy 
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(BSE) comparison the European Agency for the Evaluation of Medicinal Products (EMEA) together 
with the World Health Organization (WHO) decided to apply the “precautionary principle", as a 
consequence, medications prepared from bovine tissues were forbidden (EMEA, 1998). In the last 
decade pharmaceutical heparins were most commonly isolated in tons quantities from porcine intes-
tines (Coyne, 1981), generating a big business (Baxter heparin business is $30 million dollar/year; 
Zoll, Kranz and Borgess, LCC); as a consequence industrial and pharmaceutical heparin production 
process	are	 tightly	guarded.	Mainly	 these	production	processes	are	divided	 in	five	basic	 steps:	1)	
preparation	of	tissue;	2)	extraction	of	heparin	from	tissue;	3)	recovery	of	raw	heparin;	4)	purification	
of	heparin;	and	5)	recovery	of	purified	heparin.	Preparation	of	the	tissue	(1)	begins	with	collection	
at the slaughterhouse, where it remains also for the extraction step (2) and the raw heparin recovery 
step (3) (Fig. 10 A). The constituents of crude heparin include heparin itself, other related GAGs, 
including HS, DS, CS and HA and some percentage of nonpolysaccharidic components, such as 
nucleic	acid	and	proteins.	The	purification	of	the	resulting	raw	heparin	is	performed	under	current	
good manufacturing practices (cGMP) conditions and is designed to deal with potential impurities 
originating from the starting material or introduced during raw heparin extraction (Fig. 10 B). Such 
impurities may be in the form of other GAGs, extraneous counterions, heavy metals, residual protein 
or	nucleotides,	solvent,	salts	other	than	heparin,	bacterial	endotoxins,	bioburden	and	viruses.	Specific	
commercial methods of purifying heparin are tightly guarded industrial secrets set forth in a drug 
master	file	submitted	to	the	FDA	and	foreign	regulatory	authorities.	The	yield	of	USP	heparin	from	
American	pigs	is	typically	30,000–	50,000	international	unit	(IU,	IU	of	heparin	is	defined	as	being	
the required amount of solution to prolong the clotting of 1 ml of whole blood for three minutes), 
corresponding to ~300 mg per animal; China is the leader state for raw heparin production and ex-
port). Small amounts (1–7%) of DS is present in some pharmaceutical grade heparins, but can be 
virtually eliminated using good manufacturing processes (Linhardt et al., 1988; Neville et al., 1989). 
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Figure 10. Flow chart of the preparation of heparin from animal tissues. Chart A is performed under little or no regulatory control in rural communi-
ties while chart B is performed under current good manufacturing practices (cGMP) in FDA-inspected facilities.
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Heparin crisis3.2.1. 
Pharmaceutical heparin security has been an hot topic due to the great difference in quality treatment 
between	no	cGMP	steps	and	cGMP	steps	and	quality	control	procedures	applied	to	certificate	heparin.	
As shown in Fig. 10 A heparin treatment steps are potentially danger for public health, because in the 
slaughterhouse raw material extraction steps are not subjected to the high quality procedure guaran-
teed by cGMP, in addiction heparin is a natural occurring molecule derived from a living organism, so 
naturally	existed	proteins,	nucleic	acids,	DS	and	etc	impurities	are	difficult	to	be	removed	completely.	
In late 2007 and into early 2008, a spike in serious allergic-type adverse events was associated with ad-
ministration of heparin (i.e. heparin crisis), patients became ill with anaphylactoid symptoms, possibly 
caused by activation of the contact plasma system (WHO, 2008; Guerrini et al., 2009; Sasisekharan 
and Shriver, 2009), whereas, up to heparin crisis, the most serious documented adverse event associ-
ated with heparin, aside from a potential bleeding risk, was thrombocytopenia (Battistelli et al., 2010; 
Otis	and	Zehnder,	2010).	Fig.	11	shows	the	progression	of	the	heparin	crisis	from	the	first	event	until	
the end of the 2008. It is estimated that several score patients died as a result of this incident and many 
more suffered illness (246 reported in the USA between January 1st, 2007 and May 31st, 2008; Kishi-
moto et al., 2008; FDA, 2009). This led to a multifaceted investigation into the root cause for this dra-
matic	increase	in	reactions.	Concomitant	with	the	initial	identification	of	the	contaminant	as	“heparin-
like” by the US FDA, screening methods were introduced, based on capillary electrophoresis (CE) 
and proton nuclear magnetic resonance (1H NMR) (FDA, 2008). Subsequently, contaminated heparin 
lots were detected in a number of countries, including Germany, France, Italy, Japan, Denmark and 
Australia (Laurencin et al.,	2008).	Following	extensive	efforts,	a	major	contaminant	was	identified,	
over-sulfated chondroitin sulfate (OSCS) (Guerrini et al., 2008), which is not a naturally occurring 
substance. Key to this analysis was the use of multidimensional NMR, including heteronuclear sin-
gle quantum coherence (HSQC) and heteronuclear multiple bond correlation (HMBC) experiments 
which determined the sulfation pattern of the disaccharide repeat, the epimeric state of the uronic 
acid and the glycosidic linkage pattern which characterised the disaccharide repeat as a tetrasulfated 
chondroitin sulfate-like unit. Ultimate proof-of-structure was obtained when a synthesised version 
of	OSCS	matched	the	HSQC	profile	of	the	contaminant	in	heparin	(Fig.	12)	(Guerrini	et al., 2008). 
 
Heparin	crisis	timeline	from	the	first	clinical	reports	in	November	2007	through	the	epidemiological	findings	published	in	December	2008	Figure 11. 
(Sasisekharan and Shriver, 2009). 
In concert with the analytical studies, biological characterisation of the contaminant correlated the 
presence and extent of contamination with anaphylactoid reactions. It was found that the contami-
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nant was capable of activating the contact system both in vitro and in vivo, using porcines as a 
model system (Kishimoto et al., 2008). In a follow-up study, epidemiological evidences indicat-
ed that patients exhibiting the allergic-like symptoms, including hypotension, nausea and short-
ness of breath were found to likely have received OSCS-contaminated heparin (Blossom et al., 
2008).Thus, taken together these studies enable some measure of resolution to the heparin crisis 
and point to the fact that OSCS was likely the causative agent in the onset of anaphylactoid re-
sponses	 in	 patients.	 Sufficient	 proof	 has	 been	 provided	 that	 the	 adverse	 effects	 observed	 for	 re-
called heparins are correlated with their content of OSCS (Kishimoto et al., 2008; Blossom et al., 
2008). No additional serious anaphylactic events have been reported after the discovery of the 
OSCS contamination. In response to these recent developments, including the development of 
screening tests for heparin, the United States Pharmacopoeia (USP) and European Pharmacopoeia 
(EP) requirements for heparin have been revised. The USP has indicated that the monograph for 
heparin, which currently includes the NMR and CE screening methods, will be further revised to 
incorporate additional testing. Similarly the EP monograph is also currently undergoing revision.
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DS
NMR analysis of standard UFH and heparin OSCS contaminated. Figure 12. A. 1H spectra overimposition of pure UFH (bottom), natural UFH with 
natural DS (middle) and UFH with OSCS contamination (upper). B. HSQC spectra of UFH (black spectrum) and contaminated heparin with OSCS 
(red spectrum). 
Heparin quality control 3.2.2. 
Pharmaceutical	agents	are	usually	uniquely	identifiable	molecules,	absolutely	homogeneous	as	a	con-
sequence of their synthetic origin and for sure, their chemo-physical properties are well documented 
and easily measurable (i.e. m/z, CD, NMR, HPLC, CE, etc.). Heparin is unlike most modern pharma-
ceutical	agents	in	that	it	does	not	conform	to	a	single,	or	even	a	small	number,	of	defined	chemical	en-
tities but, rather, is inherently variable in structure (chain length varies within sample; sequence varies 
within a sample, even if chain length is the same; sometimes they are isomeric in terms of uronate 
and/or	sulfate	positions).	It	is	important	to	realise,	therefore,	that	there	can	be	no	single,	absolute	defi-
nition by which to decide in favour of acceptance or rejection of a test sample, yet some judgement 
must still be made by manufacturers and regulatory bodies based on rational measurements, or crite-
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ria. All of these variables must be accommodated by a generic analytical method, but what should the 
analytical	testing	strategy	encompass?	Before	June	2008	heparin	quality	control	was	certified	by	1)	
activity and 2) biochemical contamination assays. 1) activity tests: activated partial thromboplastin 
time (aPTT is an in vitro test to measure thrombus time formation after the addiction of heparin dose 
to human blood sample; acceptability range is between 30-40 sec), activating clotting time (ACT 
is an in vitro test to measure thrombus time formation after the addiction of heparin dose to human 
blood sample; acceptability range is between 70-180 sec), anti Factor Xa activity (anti-Xa is an in 
vitro chromogenic test performed on human blood/plasma to measure the anti Factor Xa activity in 
terms	of	IU/mg;	acceptability	range	is	between	170->190	IU/mg),	anti	Factor	IIa	activity	(anti-IIa	is	
an in vitro chromogenic test performed on human blood/plasma to measure the anti Factor IIa activity 
in	terms	of	IU/mg;	acceptability	range	is	between	170->190	IU/mg);	2)	biochemical contamination 
tests: protein content (acceptable content < 1%), nucleic acid content (acceptable content ~0.3 %) and 
DS content (acceptable content < 1%). These kind of test are not able to detect tainted substances if 
that molecules do not change heparin activities, in other worlds they cannot provide any information 
about structural differences between heparin and an eventual contaminant. One "lesson learned" from 
heparin crisis is the importance and necessity to get structural and activity informations at the same 
time to certify complex drug pharmaceutical agents identity, as for heparin. Taking a look to chemi-
cal similarities/differences between heparin (Fig. 13 A), CS (Fig. 13 B) and OSCS (Fig. 13 C) could 
help	to	understand	how	much	is	important	this	perspective	change:	1)	heparin	is	α-D-glucosamine	
sulfated	polysaccharide,	whereas	chondroitin	sulfate	is	β-D-galactosamine	sulfated	polysaccharide,	
as OSCS; 2) heparin anomeric bond connects the iduronate C1 atom to glucosamine through an 
α-(1->4)	covalent	bond,	whereas	chondroitin	sulfate	connects	glucuronate	C1	atom	to	galactosamine	
through	an	β-(1->3)	covalent	bond,	as	OSCS;	3)	heparin	amine	group	of	 the	glucosamine	residue	
is mainly substituted by a sulfate group, whereas chondroitin is exclusively substituted by N-acetyl 
group, as OSCS; 4) sulfation level are very different, in fact heparin DoS~2.5, CS DoS~2 (Suguma-
ran and Silbert, 1988) and OSCS DoS~4 (Maruyama, 1998). All these structural features do not alter 
the activity test results (over sulfation enhances OSCS coagulation activity, Kishimoto et al., 2008; 
Blossom et al., 2008), so the absence of any structural analytical test allowed the tainted heparin to 
be released on the heparin commercial circuit.
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Chemical structures of major repeat units. (Figure 13. A–C) Schematic of major disaccharide repeat units of heparin (A), CS (B) and OSCS (C). For 
chondroitin sulfate, R1-R4 can be either sulfated or unsubstituted.
Heparin the bridge between glycomics and proteomics 3.3. 
The great physiological and biological impact of GAGs and in particular of HS/Hep is mainly ascribed 
to the big interaction network commonly established by Hep and proteins. The number of proteins 
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interacting with heparin growth with time and these increasing knowledge highlight its central role 
in biological phenomena control (Capila and Linhardt, 2002; Esko and Selleck, 2002; Lindahl et al., 
2007; Bishop et al., 2007; Ori et al., 2008; Gandhi and Mancera, 2008). Different structural (NMR 
spectroscopy and X-ray crystallography) and molecular modeling approaches have been used to elu-
cidate the 3D features and structure-activity relationships of protein-GAG interactions (Sasisekharan 
et al., 2006). Table 2 shows a list of heparin-interacting proteins, for the most the crystallized com-
plex with heparin oligosaccharides was resolved (for NCAM (Neural Cell Adhesion Molecule), IL-8 
(interleukin-8) and AP-1 (amyloid P-1) the complex with GAGs are not available), optimal length 
required	for	binding	and	their	binding	affinities	can	be	found	in.	The	most	updated	list	of	GAG-bind-
ing proteins can be freely consulted at MatrixDB (freely available database focused on interactions 
established by extracellular proteins and polysaccharides; Chautard et al., 2009; MatrixDB) (reviews 
are Ori et al., 2008; Gandhi and Mancera, 2008). Due to their anionic nature, GAGs interact mainly 
through ionic interactions with basic amino acids: sulfated and carboxylated groups on heparin chains 
show	great	affinity	 for	highly	positively	charged	protein	surfaces.	 It	was	observed	 that	 in	heparin	
binding proteins arginine and lysine are 200% and 300 % respectively enriched, compare to the 
remaining protein sequence (Caldwell et al., 1996). The arginine and lysine binding strength were 
compared and arginine binds 2.5 times more than lysine, in fact arginine establishes a major number 
of hydrogen bond and electrostatic interactions through its guanidino group with GAG sulfate groups, 
as	a	consequence	Arg/Lys	ratio	could	define	the	affinity	of	a	binding	site	in	a	protein	for	GAGs	(Hile-
man et al., 1998). Although the importance of electrostatic interactions, proteins-GAGs binding can-
not be correctly described without considering all the others interactions involved in. In fact also van 
der Waals (VDW) forces, hydrogen bonds and hydrophobic interactions are involved in the binding 
between proteins and GAGs (it was observed that asparagine and glutamine are commonly present in 
heparin-binding domain and they can establish hydrogen bond; Hileman et al., 1998). Polar residues 
are also important interaction sites, serine and glycine residues provide minimal steric constraints 
and	good	flexibility	for	the	interaction	with	GAGs	(Caldwell	et al., 1996). Protein-GAG interactions 
seem not to be exclusively dependent from protein aminoacidic sequence and/or electrostatic and non 
electrostatic interactions. With the exclusion of AT-bd, heparin-binding sites do not show absolute 
dependency	on	specific	sequences	or	protein	folds.	Beside	some	similarities	can	be	noticed	among	
heparin-binding sites within families of proteins (i.e. FGF families), more often a graded series of 
activities has been observed, associated with structures possessing little or no apparent similarity in 
substitution pattern. It now seems likely that it is the combination of overall conformation, charge 
distribution	and	flexibility	exhibited	by	a	stretch	of	a	GAGs,	or	a	GAG	oligosaccharide,	that	deter-
mines the extent of binding or activities. This argument is supported by the observation that compa-
rable structural changes and activities can be induced by other (nonGAGs) sulfated carbohydrates, 
for	example,	the	effect	on	angiogenesis	induced	by	a	sulfated	exopolysaccharide	on	fibroblast	growth	
factor-2 (FGF-2), or vascular endothelial growth factor (VEGF) (Parish et al., 1999; Matou et al., 
2005). However, by means of pure heparin/HS oligosaccharide standards, minimal binding sequences 
preferentially	recognized	by	some	GAG	binding	proteins	have	been	defined	(Table 3). The interac-
tion	between	the	pentasaccharide	and	AT	is	the	only	real	specific	binding	between	a	GAG	molecule	
and protein so far described. Thanks to number of analogues of the AT pentasaccharide, the func-
tion	and	essentiality	of	its	functional	groups	were	demonstrated.	Lack	or	modification	of	one	of	the	
essential functional group such as, 6-O-sulfate belong to ANNA, the entire G residue, N-sulfate and 
3-O-sulfate belong to A* and the N-sulfate of the reducing glucosamine abolish or drastically reduce 
the	affinity	to	AT	(Petitou	et al., 2004; van Boeckel and Petitou, 1993). The presence of the heparin 
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Protein Name Protein Type PDB code GAG binding sequence dimension Kd References
NCAM
Adhesion 
protein - 5-mer 126 nM Herndon et al., 1999
Fibronectin
Adhesion 
protein 1FNH 8- to 14-mer
10-100 
nM Sharma et al., 1999
IL-8 Chemokine - 18- to 20-mer 37	μM
Spillmann et al., 1998;
Krieger et al., 2004
Annexin V Extracellular protein 1G5N 4- to 8-mer 20 nM Capila et al., 2001 
AP-1 Glycoprotein - 4- to 5-mer μM Hernaiz et al., 2002
FGF-1 Growth factor
1AXM, 
2AXM 4- to 6-mer nM
DiGabriele et al., 1998; 
Guerrini et al., 2002 
FGF-2 Growth factor
1BFB, 
1BFC 4- to 6-mer nM
Faham et al., 1996; 
Guglieri et al., 2008 
FGFR-1 Receptor 1FQ9 12-mer nM Schlessinger et al., 2000
FGFR-2 Receptor 1E0O 12-mer nM Pellegrini et al., 2000
Thrombin Serpin/protease 1TB6 16- to 18-mer nM
Byun et al., 1996;
Li et al., 2004
AT Serpin
1AZX, 
1E03, 1NQ9 5-mer 50 nM
Choay et al., 1983; 
Jin et al., 1997; 
Johnson et al., 2003; 
McCoy et al., 2003;
Petitou et al., 2004
AT	⁄	FXa Serpin/protease 2GD4 5-mer
100–
200 nM Johnson et al., 2006
Characteristics of some of the known complexes between heparin or heparan sulphate fragments and proteins.Table 2. 
Molecular interactors Minimal binding sequences References
Hep: IL-8 IS-GlcNNS,6S-IS-GlcNNS,6S-IS-GlcNNS,6S Spillmann et al., 1998
Hep: Tat IS-GlcNNS,6S-IS-GlcNNS,6S-IS-GlcNNS,6S Rusnati et al., 1999
Hep: Anexin V IS-GlcNNS,6S-IS-GlcNNS,6S Capila et al., 2001
Hep: AP-1 IS-GlcNNS,6S-IS-GlcNNS,6S-IS-GlcNNS,6S Hernaiz et al., 2002
Hep: FGF-1 GlcNNS,6S-IS-GlcNNS,6S-IS Guerrini et al., 2002
Hep: FGF-2 GlcNNS-IS-GlcNNS-IS Guglieri et al., 2008
Hep: HCFII IS-GlcNNS,6S-G-GlcNNAc,6S-I-GlcNNS,3,6S Linhardt et al., 1986
Hep: heparanase GlcNNS,6S-I-GlcNNAc,6S-I-GlcNNS-G2S-GlcNNAc,6S-I Li and Vlodavsky, 2009
Heparin minimal binding sequences for IL-8, Tat, Anexin V, AP-1, FGF-1, FGF-2 HCFII and heparanase binding. IL-8= interleukin-8; Tat= Table 3. 
HIV-1-trans-activating	protein;	AP-1=	amyloid	P-1;	FGF-1=	fibroblast	growth	factor-1;	FGF-2=	fibroblast	growth	factor-2;	HCFII=	heparin	cofactor	
II.
AT-bd came up from three independent studies in 1976 (Lam et al., 1976; Hook et al., 1976; Anders-
son et al.,	1976),	those	works	clarified	that	most	of	the	anticoagulant	activity	of	heparin	is	attributable	
to	species	with	high	affinity	(HA)	for	AT.	ANAGA*ISA structural elucidation (Casu et al., 1981) was a 
real mile stone for heparin structural research together with the discovery that 3-O-sulfate group from 
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A* is an essential component of the AT-bd (Lindahl et al., 1980). Although the informations about 
the AT-bd, its location along the heparin chain is still uncertain. Rosenfeld and coworkers suggested 
that this domain could be located prevalently towards the NR end of the molecule (Rosenfeld et al., 
1988), others evidences in literature proposed more random distribution (Pejler et al., 1987). The 
binding	specificity	of	pentasaccharide	with	AT	was	recently	confirmed	studying	the	interaction	be-
tween ANAGA*ISA containing oligosaccharides and the protein. NMR studies on AT-octasaccharides 
complex shown that (octasaccharides bearing ANAGA*ISA towards the reducing or nonreducing end), 
despite the different location of the pentasaccharide along the chain and the structure of the prolong-
ing	saccharide	units,	the	whole	pattern	of	contacts	identified	in	the	pentasaccharide-AT	complex	are	
maintained for all octasaccharides (Guerrini et al., 2008 [b]).
Antithrombin III3.3.1. 
Antithrombin III (MW~58000) is the most studied heparin interactors and belong to the serine pro-
tease	inhibitor	(serpin)	family.	The	identification	of	serpins	as	a	protein	family	is	dated	back	to	the	80s	
based	on	the	sequence	similarities	of	AT,	α1-antitrypsin	and	ovalbumin	(Hunt	and	Dayhoff,	1980),	
structure	analysis	also	reveal	the	similarities	between	AT,	α1-proteinase	inhibitor,	HCFII	and	plas-
minogen activator inhibitor (PAI-1) (Gettins et al., 1996; Gettins and Serpin, 2002). Serpins are evo-
lutionary conserved and their implication in different physiological aspects are documented (Fig. 14; 
Silverman et al., 2001). Not all the serpin family members are capable to inhibit serine proteases, 
some of them show others functions as cell signalling or hormone carriers (Gettins et al., 1996). 
Antithrombin is a major regulator of blood clotting, a plasma protein that inactivates a number of pro-
teinases of the coagulation cascade, especially thrombin and FXa (Olson et al., 1993) (Fig. 9). AT inhi-
bition rates are relatively slow under physiological conditions, but the combination of the high plasma 
concentration (~2.3 mM) and Hep/HS interaction leads to a rapid inactivation of the targets (Damus et 
al., 1973; Rosenberg et al., 1973). AT is a glycoprotein with 432 residues and it can be found in two 
forms:	α-antithrombin	(major	form	with	four	Asn	residues	glycosylated)	and	β-antithrombin	(minor	
form and whereas Asn135 is not glycosylated). Several AT crystal structures are available and they show 
9	α-helices	surrounding	3	β-sheets	(Schreuder	et al., 1994; Carrell et al., 1994; Skinner et al., 1997). Of 
these	secondary	structures,	two	features	are	striking:	a	dominant	five-stranded	β-sheet	A	approximately	
in the centre of the inhibitor and an exposed 15-residue sequence containing the reactive bond Arg393-
Ser394, the so-called reactive centre loop (RCL) at the ‘‘top’’ of the molecule (Fig. 15 A). Two residues, 
P15-P14 (Gly379-Ser380)	at	the	N-terminal	end	of	the	reactive	centre	loop,	are	inserted	as	a	short	β-strand	
in-between	strands	3	and	4	of	β-sheet	A	in	the	inhibitor	(Fig. 15 A). This feature is called the partial 
insertion of RCL and undergoes some major changes during the process of proteinase inhibition (see 
below). The structure of AT cleaved at the reactive bond is similar to intact AT except for the complete 
insertion	of	RCL	as	strand	4a	in	β-sheet	A	(Fig. 15 B). This structural change results in the movement 
of the P1 residue from the ‘‘top’’ of the molecule to the ‘‘bottom,’’ a distance of approximately 70 Å.
This	conformational	change	following	cleavage	by	the	target	enzyme	leads	to	significant	thermody-
namic stabilization of the molecule (Bruch et al., 1988; Kaslik et al.,	1997).	Crystal	structure	of	the	α1-
proteinase inhibitor – trypsin complex (Huntington et al., 2000) and biochemical results (Plotnick et al., 
1996; Calugaru et al., 2001) indicate that the structural change following cleavage of the P1-P1' bond is 
critical for the disruption of the catalytic triad of the proteinase, thereby resulting in the inactivation of the 
enzyme. AT inactivation of thrombin and factor Xa proceeds in similar manner (Björk and Olson, 1997).
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well documented. However the role of human serpins in some other
types of biologic processes awaits further validation (Fig. 3).
Ov-serpins (B Clade) —In 1993 amino acid similarities among
chicken ovalbumin (ov), PAI2 (SERPINB2), and MNEI (SERPINB1)
led to the identication of a subgroup of the serpin superfamily (13).
The N and C termini of the ov-serpins are shorter than the prototyp-
ical serpin 1AT, and they also lack a classical secretory signal
peptide. At present, there are 13 human ov-serpins (see Supplemen-
tal Data, Table B). They map to 6p25 and 18q21 and fall into two
classes based on a single dierence in gene structure (14). Like
ovalbumin, many of the 18q21 serpin genes have an exon encoding a
polypeptide loop between helices C and D (CD loop) that may con-
tribute to accessory functions.
Unlike ovalbumin itself, most ov-serpins reside intracellularly
with a cytoplasmic or nucleocytoplasmic distribution. However,
several ov-serpins (PAI2, megsin (SERPINB7), MNEI, maspin
(SERPINB5), and the SCCAs (SERPINB3 and -4)) may function
extracellularly as they are released from cells under certain condi-
tions. Release may be facilitated by an embedded, noncleaved hy-
drophobic N-terminal signal sequence and appears to involve both
conventional and non-endoplasmic reticulum-Golgi secretory path-
ways (15). Regardless of how ov-serpins are released from cells,
those with RSL cysteine or methionine residues are susceptible to
oxidative inactivation and are likely to have a limited half-life in
the extracellular milieu.
With the possible exception of maspin, all human ov-serpins are
functional, competitive inhibitors of serine or cysteine proteinases.
Several members of the group inhibit more than one proteinase, and
dual reactive sites (utilization of more than one P1 residue) have been
described for PI6 (SERPINB6), PI8 (SERPINB8), PI9, SCCA1,
SCCA2, and MNEI (for example see Ref. 16). However, the CD loops
of the ov-serpins have the potential to interact with other proteins.
For example, the CD loop of PAI2 is required for its cell survival
function (17) and is a target for transglutamination (18). Bomapin
(SERPINB10; like the chicken ov-serpin, MENT, see below) carries a
nuclear localization signal in its CD loop that presumably interacts
with a nuclear importin (19).
The physiological functions of ov-serpins are still emerging. PAI2
may play a role in the regulation of extracellular matrix remodeling
through the inhibition of uPA, as high PAI2 and low uPA levels
correlate with a positive prognosis in breast cancer (20). Also, PAI2
may have a structural role inside some cells (perhaps keratino-
cytes) as suggested by its ability to spontaneously polymerize and
undergo transglutamination (21).
Many ov-serpins reside in proteinase-secreting cells (22). For
example, PI9, a potent inhibitor of granzyme B, is also present in
cytotoxic lymphocytes. Because PI9 can protect cells against gran-
zyme B-mediated apoptosis, it probably protects cytotoxic lympho-
cytes from autodestruction due to misdirected granzyme B. A sim-
ilar cytoprotective role can be envisaged for PI6, PI8, MNEI, PAI2,
and the SCCAs. In addition, endogenous or exogenous ov-serpins
may protect bystander cells and tissue from proteolytic damage.
Studies in rats show that recombinant MNEI delivered to the
airways prevents lung injury by neutrophil proteinases and point
to its potential in treating inammatory lung disease (23).
The ability of many ov-serpins to inhibit more than one protein-
ase and their presence in epithelial cells suggest that they play a
role in barrier function or host defense against microbial or viral
proteinases. For example, PI9 inhibits Bacillus subtilisin, and PI8
inhibits furin, a subtilisin-related enzyme (24, 25). Additional func-
tions of ov-serpins include the regulation of: 1) cell growth or
dierentiation, as exemplied by the role of megsin in megakaryo-
cyte dierentiation (26), 2) tumor cell invasiveness and motility, as
shown by the inhibitory role of maspin in breast and prostate
tumors (27), and 3) angiogenesis (see below).
MENT —Grigoryev et al . (28) isolated a novel serpin, MENT,
from the nuclei of terminally dierentiated chicken hematopoietic
cells. MENT is an ov-serpin with a CD loop that contains a nuclear
localization signal, a lamin-like chromatin binding domain, and an
A-T hook DNA binding motif. The molecule has a relatively high pI
(9 versus 5– 6.5 for that of other serpins) with the majority of
positive charges clustering near the CD loop. Thus, MENT appears
to utilize the CD loop to bind tightly to nucleosomes with an
apparent stoichiometry of 2:1. MENT is the major non-histone
chromatin protein in dierentiated nuclei and is concentrated in
the heterochromatin. MENT induces higher order chromatin com-
paction when it is expressed ectopically in cells or added to isolated
nuclei in vitro . Although MENT contains a viable RSL, target
proteinases have yet to be identied.
Neuroserpin —Neuroserpin, which inhibits tPA, uPA, trypsin,
and nerve growth factor in vitro , is secreted from neurons, glia,
and neuroendocrine cells (29). Neuroserpin may play a therapeutic
role in protecting the brain from ischemic injury. In a rat stroke
model, neuroserpin expression was increased in neurons located
within the ischemic penumbra, and intracerebral injections of the
protein reduced the stroke volume by 64% and the number of
apoptotic cells by 50% (30).
In a familial form of early onset dementia and encephalopathy,
toxic intraneuronal inclusions contained neuroserpin polymers.
Molecular analysis in two pedigrees revealed mutations (S49P and
S52R) in the B-helix (31). These mutations are similar to that seen
in 1AT Siiyama, in which an S53F mutation facilitates premature
opening of -sheet A and the formation o oop-sheet polymers. In
turn, these polymers precipitate and accumulate in the cytoplasm
until normal cellular function is disrupted.
Serpins and Alzheimer ’s Disease —ACT (SERPINA3) and, to a
lesser extent, other serpins are found within the brillary amyloid
plaques of brains from patients with Alzheimer ’s disease, one of the
most common forms of dementia (reviewed in Ref. 32). Although
the pathogenesis of this disorder is complex, the extracellular ac-
cumulation of A -(1– 42)-peptide brils may be neurotoxic by bind-
ing to low density lipoprotein receptors and interfering with cho-
lesterol metabolism. ACT appears to facilitate bril formation by
serving as a chaperone for the A -(1– 42)-peptide. The peptide
inserts into B-sheets A and C of ACT in which it assumes a
-strand conformation. Upon RSL cleavage, A -(1– 42)-peptide is
released into the extracellular milieu, in which the -strand pep-
tide is now more prone to polymerize.
F IG . 3. Biological functions of human serpins. Human serpins are
involved in a diversity of biologic functions ( italics ). For some serpins ( red
type), their biologic functions appear to be related directly to proteinase
inhibition. For others ( green type), their activity does not require proteinase
inhibition, or their role in the biologic process has not been dened.
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Figure 14. Physiological functions of human serpins. Human serpins are involved in a diversity of biologic functions (italics). For some serpins (red 
type), their biological functions appear to be related directly to proteinase inhibition. For others (green type), their activity does not require protei ase 
inhibition,	or	their	role	in	the	biologic	process	has	not	been	defined	(adapted	from	Silverman	et al., 2001).
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Figure 15. Ribbon	diagram	of	native	(A)	and	cleaved	(B)	plasma	AT.	The	structure	of	plasma	AT	was	obtained	from	PBD	(file	name	‘1ath’).	The	
RCL is shown in red. Reactive bond residues Arg393 (P1)-Ser394	(P10)	is	shown	are	space-fill	representation,	whereas	P14-P15	residues	(Glu381-Gly380) 
are shown in capped sticks form. The P1 residue, in an exposed ori ntation in the nativ  st ucture, m ves from the ‘top’ of he m lecule to the ‘bottom’ 
following cleavage with a proteinase. The proteinase, i.e. factor Xa, moves with the P1 residue to the bottom of the inhibitor and gets covalently trapped. 
RCL	is	inserted	as	strand	4	in	6-stranded	β-sheet	A	(adapted	from	Desai,	2004).
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AT is activated by Hep binding3.3.2. 
Heparin can activate AT inhibition activity by two mechanisms: a) AT/Hep interaction through 
ANAGA*ISA pentasaccharide (called AT conformational activation) and b) bridging mechanism. 
a) AT conformational activation leads to RCL expulsion with a conformational change of the P1-P1' 
reactive centre (Björk and Olson, 1997; Craig et al., 1989; Chuang et al., 2001; Olson and Björk, 
1992 [b]; Fig. 17 A), the conformational change allows a better recognition from FXa resulting in 
accelerated cleavage of the P1-P1' bond and rapid formation of the covalent inhibition complex (Fig. 
15 B; Fig. 17 A). This mechanism induces a poor acceleration of thrombin inhibition: only twofold 
(Desai, 2004).
b)	after	AT	bound	to	Hep	pentasaccharide	(Fig.	17	A),	thrombin	interacts	and	binds	to	a	nonspecific	
site of the same heparin chain forming the ternary complex AT-Hep-thrombin (Fig. 17 B; Li et al., 
2004). Heparin bridging guides thrombin to encounter the inhibitor with a diffusion movement, the 
heparin minimum binding sequence to allow the bridging mechanism was estimated in ~18 residues 
(Petitou et al., 1999; Duchaussoy et al., 1999). The bridging mechanism was demonstrated to have 
an important role also in vivo: at physiological Ca2+ concentrations UFH enhances FXa inhibition of 
~40-fold suggesting that longer chains bind to an exosite on the enzyme (Rezaie et al., 1998). Like-
wise, a bell-shaped dependence of acceleration on the concentration of heparin chains, characteristic 
of a bridging mechanism, was observed. Mutagenesis of the basic residues in the thrombin heparin-
binding site and structural studies of the ternary complex (Jin et al., 1997; Li et al., 2004; Johnson 
et al., 2006) shown the principal amino acids involved in the bridging mechanism (Fig. 16): Arg47, 
Lys114, Lys125 and Arg129	were	identified	as	the	most	important	in	the	heparin	binding	site	of	AT	using	
mutant and recombinant ATs (Sheehan and Sadler, 1994; Ye et al., 1994; He et al., 1997; Tsiang et 
al., 1997). These basic residues participate in ionic interactions with the negatively charged groups 
of heparin, as observed in the crystal structure of an AT-pentasaccharide complex. Residues Arg129, 
Lys114 and Arg47 are critical for the heparin-induced conformational change of AT, contributing to the 
resulting	AT-Hep	high	affinity	binding	(Jin	et al., 1997; Johnson et al., 2003; McCoy et al., 2003; Li 
et al., 2004; Johnson et al., 2006). 
Thrombin and AT interactions established with heparin. Letter code on heparin stands for nonreducing end (A) and reducing end (P). The Figure 16. 
interactions with thrombin and AT are indicated by lines, with solid lines indicating a salt bridge, dashed lines hydrogen bonds, dashed-dotted lines for 
water-mediated hydrogen bonds and dotted lines for potential interactions (only for Lys240) (adapted from Li et al., 2004).
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A R T I C L E S
antithrombin-binding pentasaccharide and a highly sulfated 
thrombin-binding site, separated by nonsulfated linkers. These
mimetics efficiently catalyze antithrombin inhibition of both factor
Xa and thrombin and cause none of the side effects associated with
unfractionated heparin16. To understand the molecular mechanism
by which physiological and therapeutic glycosaminoglycans acceler-
ate antithrombin inhibition of thrombin, we have solved the crystal
structure of the complex between antithrombin, catalytically inert
thrombin and a heparin mimetic to a resolution of 2.5 Å. The struc-
ture reveals a heparin-bridged encounter complex with extensive
active site and exosite interactions which explain, in molecular detail,
the basis of the antithrombotic properties of heparin.
RESULTS
Overall structure
The bridging role of heparin is immediately clear from the structure 
of the antithrombin–thrombin–heparin ternary complex (Fig. 1b).
High-quality electron density is observed for the entirety of the
heparin chain, with every nonhydrogen atom clearly resolved
(Fig. 1b). The interaction interface between antithrombin and
thrombin is close, with a total surface area of 2,795 Å2 buried, in con-
trast to contacts observed for two other serpin–protease Michaelis
complexes for which crystal structures have been determined 
(!1-antitrypsin and Manduca Sexta serpin 1B with trypsin, 1,320 Å
2
and 1,773 Å2, respectively17,18). The antithrombin–thrombin–
heparin complex more closely resembles the Michaelis complex
between heparin cofactor II (HCII) and thrombin19 (buried surface
area, 3,446 Å2), however the position of thrombin relative to the ser-
pin in the two complexes is different. In the HCII–thrombin complex,
thrombin is docked on the back, left-hand side of HCII (oriented as in
Fig. 1b) thus requiring heparin chains >30 units in length to form a
bridge. The position of thrombin on HCII also requires the full exten-
sion of the hinge region of the reactive center loop (RCL) of HCII. In
contrast, the hinge region of antithrombin is flexible and cannot be
fully modeled into electron density. Six residues of the reactive center
loop, P9–P14 (nomenclature of Schechter and Berger20), are not seen
in the structure, and the distance between P15 and P8 of 13.5 Å is
nearly identical to that observed in the native structure where hinge-
region residues P15 and P14 are inserted as strand 4 in "-sheet A
(Fig. 1a). Thus the hinge region of antithrombin is highly flexible, and
may insert into "-sheet A before cleavage of the P1-P1# bond by
thrombin. Indeed, there is evidence in the electron density for inser-
tion of P15 Gly into "-sheet A (Fig. 1c), and close examination of the
top of strands 3 and 5 A on either side of the hinge region reveals a
more open conformation, with one fewer "-sheet hydrogen bond
than in the described heparin-activated structure21 (PDB entry 1E03)
(Fig. 1c). The flexibility of the hinge region indicates a probable equi-
librium within the ternary complex between a partially inserted,
native-like, antithrombin conformation, and the fully loop-expelled
conformation previously observed21.
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Figure 1 Heparin catalysis of thrombin inhibition by antithrombin. (a) The
binding of the specific heparin pentasaccharide to antithrombin induces a
global conformational change involving the expulsion of the hinge region
(circled) of the reactive center loop (RCL, yellow) from the central "-sheet 
A (red), and extension (yellow) of the A and D helices (green and cyan,
respectively). The expulsion of the hinge region increases the flexibility of
the RCL and liberates the P1 Arg (green ball-and-stick). The flexibility of the
C-terminal portion of the RCL (P# side) is limited, despite a three-residue
insertion (orange), owing to a tight hydrogen-bonded turn. (b) Stereo
representation of the crystal structure of the ternary complex between
antithrombin (colored as above), thrombin (magenta) and heparin (ball-
and-stick, with blue 2Fo – Fc electron density contoured at 1$). Thrombin is
docked toward the heparin-binding site of antithrombin, and makes several exosite interactions. The expulsion of the hinge region is not required to form this
complex, but the P# side of the RCL (orange) has been elongated. (c) Density (calculated as in b) of the hinge region of antithrombin in its complex with
thrombin and heparin (yellow) reveals the insertion of P15 Gly into "-sheet A, and a larger opening between strands 3 and 5A than seen for pentasaccharide-
bound antithrombin alone (gray). It has been shown that high-affinity binding is not inconsistent with a native-like hinge conformation, as demonstrated by
the structure in PDB entry 1NQ9 (ref. 42) (brown). (d) A comparison of the conformations of the P# region of the RCL of pentasaccharide activated
antithrombin (gray) to that of antithrombin in the complex with thrombin and heparin (yellow, oriented as in a and b) reveals the requirement for 
P# elongation through the breaking of hydrogen bonds.
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AT/Heparin binding and catalysis of thrombin inhibition by AT. (A) AFigure 17. NAGA*ISA binding to AT induces a conformational change leading 
to	hinge	region	expulsion	(circled)	of	RCL	(yellow)	from	the	central	β-sheet	A	(red)	and	extension	(yellow)	of	the	A	and	D	helices	(green	and	cyan,	
respectively).	As	a	consequence	P1	Arg	is	liberated	(green	ball-and-stick).	The	flexibility	of	the	C-terminal	portion	of	the	RCL	(P'	side)	is	limited,	de-
spite a three-residue insertion (orange square), owing to a tight hydrogen-bonded turn. (B) Stereo representation of the crystal structure of the ternary 
complex between AT (coloured as above), thrombi  (magenta) and heparin (ball-and-stick). Thrombin is docked toward the heparin-binding site of AT 
and makes several exosite interactions. The expulsion of the hinge region is not required to form this complex, but the P' side of the RCL (orange) has 
been elongated (adapted from Li et al., 2004).
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The role of extensions of the active pentasaccharide sequence3.3.3. 
The major pharmaceutical agents for cardiovascular therapies are UFH and LMWH (Camporese et 
al., 2009), although, as mentioned before, in some cases UFH treatment induced bleeding problem 
and thrombocytopenia (Battistelli et al., 2010; Otis and Zehnder, 2010). The lower molecular size of 
LMWHs, compared with heparin, involves a more predictable pharmacological action, sustained an-
tithrombotic activity and better subcutaneous bioavailability (Mousa, 2007). LMWHs consist of com-
plex mixture of fragments ranging from tetra to hexadecasaccharides and somewhat higher oligosac-
charides (Viskov et al., 2009; Bisio et al., 2009; Zang et al., 2008). Apart from tetrasaccharides, about 
one	out	of	five	chains	of	LMWHs	contain	the	active	sequence	ANAGA*ISA (Bisio et al., 2009), in ad-
diction very little is known about ANAGA*ISA	flanking	sequences.	Earlier studies on tetrasaccharides 
sequences adjacent to the AT-binding site have demonstrated two possible variants of AT-binding se-
quences, suggesting a possible role of the extensions of these sequences on binding to AT (Loganath-
an et al., 1990). Longer AT-binding sequences, such as decasaccharides, were also previously isolated 
(Toida et al.,	1996).	The	influence	of	the	position	of	the	pentasaccharide	sequence	along	the	oligosac-
charide chains together with the knowledge of the role of the residues prolonging the active sequence 
toward both its reducing and nonreducing side are among the major goals of current heparin research 
(Guerrini et al., 2006; Guerrini et al., 2008 [b]). Although the active pentasaccharide ANAGA*ISA is 
taken	as	paradigm	for	a	unique	heparin	sequence	targeting	a	specific	protein	(i.e.	AT)	(Petitou	et al., 
2004), different mechanisms have been proposed for its interaction with AT in terms of position and 
conformation of sugar residues. The possibility of a shift along the AT D-helix for sequences longer 
than pentasaccharide was taken into consideration (Belzar et al., 2000). Independent crystallographic 
and NMR studies on the structure of complexes of AT with ANAGA*ISA and ANAGA*ISA-containing 
oligosaccharides suggested that the position of the pentasaccharide in the protein binding region is 
unique (Jin et al., 1997; Hricovini et al., 2001; Li et al., 2004; Guerrini et al., 2006; Johnson et al., 
2006; Guerrini et al., 2008 [b]). These studies provided information on both the ring conformation of 
the monosaccharide residues and the geometry of the glycosidic linkages of the AT-bound pentasac-
charide.	The	uronic	acid	flanking	AT-bd	or	within	it	strongly	affect	AT/oligosaccharide	complex	af-
finity,	as	it	was	demonstrated	for	the	unmodified	glucuronic	acid	residue	(Casu	and	Lindahl,	2001;	
Petitou et al., 2004). The 2-O-sulfate group of the 2-O-sulfated iduronic acid residue was shown to 
contribute to the binding to AT only indirectly, by favouring the 2S0 conformation of the iduronate 
ring. Indeed, the 2-OSO3 group appears to be the main driving force in affecting the shift of the con-
formational equilibrium of the sulfated iduronate residue towards the skewboat form, thus enhancing 
dipolar contact between the ANAGA*ISA reducing disaccharides with AT aminoacids (Hricovini et al., 
2001). However, the contribution of the IS	to	the	AT	affinity	may	be	less	essential	when	the	size	of	oli-
gosaccharides is larger than an octasaccharides (Chen et al., 2007). Although IS acts as the major actor 
for ANAGA*ISA binding properties, published data suggest also an important role for 6-O-sulfate group 
of the A residue at the reducing end of ANAGA*ISA, in fact its absence in synthetic pentasaccharides 
results	in	a	decrease	in	the	affinity	for	AT	(van	Boeckel	and	Petitou,	1993).	Recently	our	laboratory	in	
collaboration	with	Sanofi-Aventis	demonstrated	the	active	role	of	residues	prolonging	the	pentasac-
charide sequence toward both its reducing and nonreducing end for some octasaccharides isolated 
from enoxaparin (Guerrini et al., 2006; Guerrini et al.,	2008	[b]).	The	affinity	of	these	octasaccha-
rides (Fig. 18) for AT depends not only on the location of the pentasaccharidic sequence ANAGA*ISA 
along	 the	 oligosaccharide	 chain,	 but	 may	 be	 also	 strongly	 affected	 by	 the	 structure	 of	 flanking	
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0.024, 0.242, and 4.75 �M, respectively, a salt concentration
dependence substantially in agreement with the data reported
by Olson et al. (22). In the presence of 0.5 M NaCl (the salt
concentration used in the NMR studies), OCTA-1, OCTA-2,
and OCTA-3 bound the serpin with a moderately higher affin-
ity than fondaparinux (Table 2), whereas OCTA-4 bound AT
with a 20-fold lower Kd (0.24 �M). This latter interaction was
also investigated in the presence of 0.1 and 0.25 M NaCl. We
found Kd values of 1.5 and 13.0 nM, respectively, here again 2
values lower by more than 1 order of magnitude than those
measured for the binding of fondaparinux to AT (Table 2).
The plots of log Kd versus log[Na�] shown in Fig. 3 illustrate
the Na� concentration dependence of OCTA-4 and fondapa-
rinux-AT interactions. Assuming that fondaparinux and
OCTA-4 behave as polyelectrolytes in solution,we analyzed the
effect ofNa� concentration on their binding toATaccording to
the theory of macromolecule-polyelectrolyte interactions. This
approach, used by Record et al. (29) to investigate ligand
nucleic acid interaction in the presence ofmonovalent ions,was
also used by others to investigate the effect of the salt concen-
tration on the binding properties of heparin or pentasaccharide
to antithrombin (22, 30, 31), thrombin (32), fibroblast growth
factor (33), or peptide (34). Complex formation between a poly-
electrolyte with bound counterions (Na�) such as an oligosac-
charide (fondaparinux or OCTA-4) and a protein (AT) is
accompanied by an entropically favorable release of Na� from
the oligosaccharide chain by cationic residues located within
the binding site of the protein. Although this process (the poly-
electrolyte effect (29)) accounts for the ionic component of the
global interaction of AT with the oligosaccharide, its nonionic
component results from hydrogen bonding and/or hydropho-
bic interactions. For these systems the whole interaction is
described by Equation 3, which relates the observed equilib-
rium dissociation constant Kd to the Na� concentration (29),
log Kd� log Kdn-i� Z � log �Na�� (Eq. 3)
where Kdn-i is the equilibrium dissociation constant character-
izing the nonionic component at 1 M NaCl; Z is the number of
ionic interactions (or ion pairs) formed between oligosaccha-
ride and AT, and � is the fraction of Na� counterion bound to
oligosaccharide per unit of charge.�, a parameter related to the
axial charge density of the polyelectrolyte, was determined to
be 0.8 for heparin (30, 32). Equation 3 predicts a linear depend-
FIGURE 1. Structure of octasaccharides OCTA-1, OCTA-2, OCTA-3, and OCTA-4. The AGA*IA sequence is highlighted in the dashed frame. Reducing end
AGA*IA extensions of OCTA-1 and OCTA-2 (I�-A�) differ in degree of sulfation being trisulfated in OCTA-1 (IdoUA2S-GlcNNS,6S, in blue) and monosulfated in
OCTA-2 (IdoUA-GlcNNAc,6S, in yellow). Nonreducing end AGA*IA extensions of OCTA-3 (in blue) andOCTA-4 (in yellow) differ from each other in the structure of
their uronic acid residues, which are the common iduronic acid (I�) in OCTA-3 and the unusual glucuronic acid (G�) in OCTA-4.
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The AFigure 18. GA*ISA sequence is highlighted in the dashed frame. Reducing end ANAGA*ISA extensions of OCTA-1 and OCTA-2 (I''-A'') dif-
fer in degree of sulfation being trisulfated in OCTA-1 (IS-GlcNNS,6S, in blue) and monosulfated in OCTA-2 (I-GlcNNAc,6S, in yellow). Nonreducing end 
ANAGA*ISA extensions of OCTA-3 (in blue) and OCTA-4 (in yellow) differ from each other in the structure of their uronic acid residues, which are the 
common iduronic acid (I') in OCTA-3 and the unusual glucuronic acid (G') in OCTA-4. 
sequences. Notably, the presence of glucuronic acid instead of iduronic acid before the pentasac-
charide	moiety	increases	one	order	of	magnitude	the	affinity	toward	AT	(Guerrini	et al., 2008 [b]).
Amyloid-3.3.4. β
Heparan sulfate proteoglycans (HSPGs) are involved in many biological process and also in certain 
n urodegene ve diseases. PGs or GAGs are associated with a variety of amyloid deposits and 
amyloid-β	(Aβ)	deposit,	this	is	an	amyloidogenesis	hallmark	and	especially	for	Alzheimer	disease	
(AD) (Castillo et al., 1997; van Horssen et al., 2003; Watanabe et al., 2004; Gruys et al., 2006). GAGs 
are also involved in other neurodegenerative diseases: Gerstmann-Straussler syndrome, Creutzfeldt-
Jakob disease, scrapie (Snow et al., 1990), mucopolysaccharidoses (Ginsberg et al., 1999), Parkin-
s n’  diseas  (Liu et al., 2005) and other neuromuscular diseases (Peat et al , 2008), all of which 
share	genesis	of	senile	plaques	(SPs),	cerebrovascular	amyloids	and	neurofibrillary	tangles	(NFTs)	
(Perlmutter et al., 1990; Su et al., 1992; Bame et al., 1997; Verbeek et al., 1999; van Horssen et al., 
2003). GAGs pathological functions in these disease is still not clear, suggesting the need for research 
in this area (Watanabe et al., 2004).
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Alzheimer disease3.3.5. 
Worldwide, approximately 18 million people suffer from Alzheimer’s disease, with this number pro-
jected to increase to approximately 34 million people by the year 2025 (Hebert et al., 2003). It was 
estimated at least $100 billion as a consequence of direct and indirect annual costs of caring for in-
dividuals with Alzheimer’s disease in the US alone (Ernst and Hay, 1994). As a prospective, number 
of patients affected, economical and social impact will dramatically increase in the future, for these 
reasons therapeutic strategies are growing in interest during the last 20 years. Alzheimer disease is 
a	complex	pathology	with	neurobiological	and	pathological	features:	neurologically,	first	onsets	are	
mild	cognitive	 impairments,	deficits	 in	short-term	memory,	 loss	of	spatial	memory	and	emotional	
imbalances. The end point of this pathological progression is a total loss of executive function (Pimp-
likar et al.,	2009).	Pathologically,	it	is	observed	the	presence	of	Aβ	plaques	(Glenner	and	Wong,	1984)	
and intracellular tangles of hyperphosphorylated tau protein (Braak and Braak, 1998; Ballatore et al., 
2007). It is not clear the spatial and temporal connection between dementia and plaques deposition, 
hyperphosphorylated tau and insoluble tangles are initially observed in the limbic system (entorhinal 
cortex,	hippocampus,	dentate	gyrus)	and	then	progress	to	the	cortical	region,	while	Aβ	plaque	depo-
sition	starts	 in	the	frontal	cortex	to	spread	over	the	entire	cortical	region.	Aβ-peptides	are	derived	
from the proteolityc cleavage of the transmembrane amyloid precursor protein (APP, 695 amino 
acids)	(Cole	and	Vassar,	2008):	the	β-site	APP-cleaving	enzyme	(BACE	1)	operates	an	extracellular	
cleavage at Asp+1 position of APP, (596-597 of the APP sequence) generating one extracellular big 
fragment	(APPsβ)	and	another	transmembrane	fragment	(C99).	The	transmembrane	fragment	is	the	
substrate	of	γ-secretase	[a	protein	complex	containing	presenilin	(PS)]	that	with	an	intra-membrane	
cleavage at Val+40 or Ala+42	position	of	C99	fragment	generates	the	Aβ-peptides	and	the	amyloid	pre-
cursor	protein	intracellular	domain	(AICD),	the	first	released	in	the	extracellular	environment	and	the	
second	diffuses	in	the	cytol.	γ-secretase	can	generate	different	peptides	[40	amino	acids	Aβ	(Aβ1-40) 
and/or	42	amino	acids	Aβ	(Aβ1-42)] depending on the cleavage site (Fig. 19). Presence and accumula-
tion	of	Aβ-peptides	could	not	be	enough	to	cause	AD,	because	Aβ-peptides	were	found	in	both	nor-
mal and AD brain (Ashall and Goate, 1994). 
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APP	processing.	BACE1	and	the	γ-secretase	complex	sequentially	cleave	APP	to	generate	Aβ.	1)	BACE	1	cleavage	of	APP,	2)	C99	frag-Figure 19. 
ment	cleavage	from	γ-secretase	complex.	3)	Aβ	liberation	in	the	extracellular	environment	and	AICD	release	in	the	cytosol.	
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A3.3.6. β structure 
The high content of amyloidic peptide deposit in the AD brain is a typical hallmark for Alzheimer 
disease. Hardy and Selkoe (2002) suggested the so called amyloid cascade hypotesis as a model for 
dementia diseases progression characterised by amyloid deposit: 1) accumulation of missense muta-
tions	in	APP	and/or	PS	genes	causes	an	hyper	synthesis	and	accumulation	of	Aβ1-42, 2) peptides accu-
mulation induces the condition to trigger amyloid aggregation and fibrils/plaque formation, 3) soluble 
aggregates start to alterate the synapse functions, 4) amyloid accumulation initiates inflammation 
(complement system activation and leukocytes recruitment), 5) inflammation side effects cause syn-
aptic and neuritic injury, 6) that, becoming worst, alterate the neuron membrane homeostasis and ions 
exchange properties, 7) kinases and phosphatases are misregulated leading to the tau protein tangles 
formation	and	finally	8)	to	dementia	(neuron	dysfunctions	and	neuron	death).	Experimental	evidenc-
es in the last years suggest that the real neurotoxic effects might be caused by soluble aggregates, 
thus	plaques	accumulation	might	be	the	final	consequence	of	Aβ	aggregation	(Carotta	et al., 2006; 
Pimplikar et al., 2009; Kuperstein et al., 2010). Different approaches were applied to elucidate the 
molecular structure (Serpell et al., 2000; Tycko, 2006) and mechanism (Harper et al., 1999; Aguilar 
and Small. 2005; Bellesia and Shea, 2009; Di Fede et al.,	2009)	of	oligomerisation	and	fibril	forma-
tion,	nevertheless	the	fibrillogenesis	mechanism	is	still	not	completely	understood:	the	first	onset	is	
characterised	by	the	formation	of	small	Aβ	oligomers	(between	6	to	8	unit,	called	seeds);	aggregating	
seeds	organize	in	a	super	structure	(β-sheet	structure)	with	a	β-sheet	spacing	between	10-11	Å,	this	
generates	the	fibrillar	precursor	(protofibrils/protofilaments)	with	a	diameter	between	25-30	Å,	thus	
protofibrils	assembly	leads	to	the	fibril	formation	(composed	by	several	protofilaments,	five	or	six	
with	a	diameter	between	60-80	Å).	Finally,	fibril	accumulation	causes	plaque	deposit.	Whether	these	
small	 intermediates	 interact	directly	 to	 form	protofibrils	and	 then	 these	elongate	 to	 form	the	 fully	
formed	fibril,	or	whether	protofilaments	are	formed	first	and	then	associate	together	remains	ambigu-
ous.	A	schematic	representation	of	the	fibrillisation	events	is	shown	in	Fig. 20.
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Figure 20. Hierarchy	structure	of	Aβ	peptide.	The	monomer	is	folded	into	a	double	β-strand	structure,	that	interacting	each	others	generate	amyloidic	
fibril.
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Structure prediction studies (Soto et al., 1994) have indicated that the C-terminal 10 residues and resi-
dues	17-21	of	Aβ	shown	the	greatest	hydrophobicity	while	the	C-terminus	(from	residue	28)	shown	
a	high	probability	for	β-sheet	structure.	Residues	9-21	shown	a	lower	probability	for	β-sheet.	Two	
β-turns	are	predicted	between	residues	6	and	8	and	residues	23	and	27	(Soto	et al., 1994; Kirschner 
et al., 1987). These characteristics are highlighted in Fig. 21. 
Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala
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Figure 21. Aβ-peptides	aminoacid	sequence	and	predicted	structures.	On	top	three	letter	amino	acidic	code.	The	red	line	indicates	Aβ1-40 sequence 
end.
Recently NMR (Petkova et al., 2006; Tycko, 2006; Yu et al., 2009) and molecular modeling (Urbanc 
et al., 2004; Urbanc et al.,	2004	[b])	studies	succeeded	to	solve	the	Aβ	monomer/oligomer	structure:	
secondary structure is characterised by a not ordered region from Asp1 to Ser8,	two	β-strand	structures	
(the	first	from	Gly9 to Val24 and the second from Ile32->Val40/Ile42) and a loop from Gly25 to Leu31 con-
necting	the	first	to	the	second	β-strand	(Fig.	22	A).	NMR	measurements	indicate	in-register	parallel	
alignment of neighbouring peptide chains for residues Val12–Val39 and are consistent with disorder in 
the	N-terminal	segment;	the	tertiary	structure	allows	monomer	to	organize	in	parallel	β-sheet	perpen-
dicular	to	the	major	protofibril	axis	(Fig.	22	B,	C)	and	finally	the	fibril	structure	is	characterised	by	
cross	β-structure	between	protofilaments	(Fig. 22 D).
supported by the observation of a single set of 13C NMR chemical shifts for nearly all carbon
sites, particularly for side-chain sites of I31, M35, and V39 that are located at the interface
between molecular layers. Lower symmetry would be expected to split the 13C NMR lines of each
site into two components of equal intensity. Only D23, V24, and K28 exhibit two resolved sets
of chemical shifts in agitated Ab1–40 samples, possibly due to two coexisting conformations in the
non-b-strand segment.
(a)
L34
V39
V12
F19
D23
K28
(c)
(b)
(d )
Fig. 15. Structural model for the protoﬁlament in Ab1–40 ﬁbrils prepared with gentle agitation (Petkova et al.
2006), exhibiting the morphologies and NMR signals shown in Figs. 4, 8, 10a, 12–14. Residues 1–8 are
conformationally disordered and are therefore omitted. The long axis of the ﬁbril is perpendicular to the
page in panels (a)–(c). The long axis is vertical and parallel to the page in panel (d ). (a) All-atom represen-
tation of a pair of peptide molecules. Residues 10–22 and 30–40 have b-strand conformations, forming two
separate in-register, parallel b-sheets. The protoﬁlament is a four-layered b-sheet structure with C2 sym-
metry about its long axis. Blue double-headed arrows indicate side-chain–side-chain and side-chain–back-
bone contacts established by 2D 13C–13C NMR measurements as in Fig. 12. Purple double-headed arrows
indicate contacts established by measurements of 15N–13C dipole–dipole couplings, as in Fig. 16. (b) Average
structure resulting from 10 independent molecular dynamics/energy minimization runs on a cluster of 12
peptide molecules, with interatomic distance and backbone torsion angle restraints dictated by solid-state
NMR data. Hydrophobic, polar, negatively charged, and positively charged side-chains are colored green,
purple, red, and blue respectively. The four-layered b-sheet structure is stabilized primarily by hydrophobic
interactions in the core of the protoﬁlament. Polar and charged side-chains are on the exterior, with the
exception of oppositely charged K28 and D23 side-chains, which form salt bridges. (c, d ) Cartoon re-
presentations, with residues 12–21 in red and residues 30–40 in blue. A left-handed twist of 0�833x/A˚ is
imposed, although direct experimental constraints on the twist in agitated Ab1–40 protoﬁlaments are not yet
available.
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Figure 22. Structural	model	for	the	protofilament	in	Aβ1–40	fibrils	(Petkova	et al.,	2006).	The	long	axis	of	the	fibril	is	perpendicular	to	the	page	in	pan-
els (a)–(c). The long axis is vertical and arallel to the page in pan l (d). (a) All-atom representatio  of a pair of peptide molecules. Residues Tyr10–Glu22 
and Ala30–Val40	have	β-strand	conformations,	forming	two	separate	in-register,	parallel	β-sheets.	The	protofilament	is	a	four-layered	β-sheet	structure	
with C2 symmetry about its long axis. Blue double-headed arrows indicate side-chain–side-chain and side-chain–back-bone contacts. Purple double-
headed arrows indicate contacts established by measurements of 15N–13C ipole–dipole coupli gs. (b) Average structure resulting from 10 independent 
molecular dynamics/energy minimization runs on a cluster of 12 peptide molecules, with interatomic distances and backbone torsion angle restraints 
dictated by solid-stateNMR data. Hydrophobic, polar, negatively charged and positively charged side-chains are coloured green, purple, red and blue 
respectively.	The	four-layered	β-sheet	structure	is	stabilized	primarily	by	hydrophobic	 nteractions	in	the	core	of	the	protofilament.	Polar	and	charged	
side-chains are on the exterior, with the exception of oppositely charged Lys28 and Asp23 side-chains, which form salt bridges. (c, d) Cartoon representa-
tions, with residues Val12–Ala21 in red and residues Ala30–Val40 in blue (adapted from Tycko, 2006). 
37 Introduction
Interaction between A3.3.7. β and GAG
Aβs	and	APPβs	bind	with	high	affinity	to	both	the	core	protein	and	the	GAG	side	chains	of	vascular	
heparan sulfate PG (HSPG) (Kjellen and Lindahl, 1991). GAGs, such as KS, DS and CS, have an es-
pecially	high	affinity	for	Aβs,	suggesting	that	the	position	and	distribution	of	the	sulfate	groups	on	the	
GAG	backbone	are	important	for	Aβs–GAG	interactions	(Narindrasorasak	et al., 1991; Buee et al., 
1993	[a],[b]).	Aβ-GAG	binding	site	was	identified	as	residues	13–16	(His-His-Gln-Lys)	and	it	repre-
sents	a	unique	site	for	targeting	inhibition	of	Aβ	fibril	formation	(Fraser	et al., 1992; van Horssen et 
al., 2003). His13 in particular is an important residue and is considered critical for GAG interaction 
(McLaurin	and	Fraser,	2000).	Aβs-GAG	interactions	have	been	studied	with	a	variety	of	biophysical	
techniques,	 such	as	 circular	dichroism	 (CD)	 spectroscopy,	fluorescence	 spectroscopy,	NMR	spec-
troscopy, electron microscopy and surface plasmon resonance [SPR, a biosensor technology useful 
for analyzing the extension and dissociation reaction of proteins (Myszka et al., 1999)].Using SPR 
(Ariga et al.,	2010),	GAGs	interaction	profiles	were	studied	at	pH	4.5	[Aβ-GAG	interaction	is	pH	
dependent (Brunden et al.,	 1993)]	 after	 immobilizing	Aβ1–40,	Aβ1–42	 and	Aβ25–35 [Aβ25–35 is a small 
synthetic amyloid composed of 10 amino acids with a very poor aggregation activity, but keeping 
cytotoxic effect (Forloni et al., 1996; Yan et al.,	1996)]	and	the	results	shown	that	Aβs	interact	with	
GAGs	with	different	binding	affinities	in	the	following	rank	order:	Aβ1–40	>	Aβ25–35	>	Aβ1–42. Most 
recently	as	further	evidence	for	Aβs-GAG	interaction,	(Madine,	2009)	it	was	reported	a	procedure	in	
which a 13C-labeled N-acetyl derivative of the GAG heparin ([13C-CH3]NAcHP) was used as a probe 
for	 analysing	 protein-GAG	 interactions	 in	 amyloid	 fibrils	 using	 solid-state	NMR	 (ssNMR)	 spec-
troscopy.	NAcHP	emulates	heparin	by	enhancing	aggregation	and	altering	the	fibril	morphology	of	
Aβ1–40	and	α-synuclein,	the	major	protein	component	of	the	Lewy	bodies	associated	with	Parkinson’s	
disease. 13C-ssNMR	spectra	confirmed	the	presence	of	[13C-CH3]NAcHP	in	Aβ1–40	fibril	deposits	and	
detected dipolar couplings between the glycan and Arg5	at	the	Aβ1–40 N-terminus, suggesting that the 
two species are intimately mixed at the molecular level. That procedure provides a basis for further 
investigations	of	polypeptide–glycan	interactions	within	amyloid	fibrils.	
Can GAG act as therapeutic agents for amyloidogenic disorders?3.3.8. 
Potential therapeutic strategies for amyloidosis include reducing the production of amyloidogenic 
precursor	 proteins	 and	Aβs,	 interfering	with	 fibrillogenesis	 and	 enhancing	 amyloid	 clearance	 are	
under	consideration	(Hirschfield	and	Hawkins,	2003).	Identifying	structure–activity	relationships	be-
tween	Aβ	and	different	GAGs	as	well	as	dependence	conditions	of	GAG	binding	is	necessary	for	suc-
cessfully	developing	and	evaluating	GAG-specific	therapeutic	interventions	(McLaurin	et al., 1999). 
GAGs	may	act	not	only	 to	promote	fibril	 formation	and	aggregation	of	Aβs,	 as	described	above,	
but	also	to	protect	aggregated	Aβ	from	proteolytic	degradation	(McLaurin	et al., 1999; Leveugle et 
al.,	1998).	The	latter	effect	is	believed	to	be	competitively	inhibited	by	certain	other	GAGs.	The	Aβ	
-GAG interaction may be mediated by a unique binding site that could serve as a target for inhibiting 
amyloid	formation,	either	through	competition	for	GAG	binding	or	by	specifically	targeting	the	GAG-
binding	site.	As	shown	above,	the	His-His-Gln-Lys	peptide	in	Aβ	is	an	essential	region	for	amyloid	
formation.	Drugs	 targeting	 that	 region,	 therefore,	may	effectively	block	 the	β-structural	 transition	
necessary	for	fibril	nucleation.	That	therapeutic	strategy	is	supported	by	in vitro studies (McLaurin 
and	Fraser,	2000).	HSs	are	known	to	bind	to	Aβ	and	in	turn	interfere	with	its	fibrillogenesis.	HSs	are	
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interesting candidates for therapeutic intervention (Gervais et al., 2001), because of the multiple roles 
that HS plays in organ development and in organ and cell functions. Of course, the potential side 
effects of targeting HS biosynthesis for therapeutic purposes should be considered. The interaction 
of HSPGs and GAGs can be inhibited by other sulfated compounds, such as HS, DS and pentosan 
polysulfate (Leveugle et al., 1994). Drugs manufactured by chemical synthesis, isolated from natu-
rally	occurring	polysaccharides	(with	or	without	chemical	modification),	or	manufactured	by	use	of	
recombinant enzymes (GlcA C5-epimerase; sulfotransferases) with appropriate saccharide substrates 
should prove useful in inhibiting the binding of HSPGs and GAGs (Kuberan, 2003; Lindahl et al., 
2007). Knowledge on the role of HSPGs in AD pathology should lead to their therapeutic use (van 
Horssen et al., 2003), especially LMWHs, which can interfere with the interaction between HSPGs 
and	Aβ	to	stop	or	prevent	amyloidogenesis.	Both	HSPGs	and	LMWHs	can	reduce	the	progression	of	
inflammation-associated	amyloidosis	(Kisilevsky	et al., 1995; Kisilevsky and Svarek, 2002). Several 
LMWH compounds are reported to have that capability and may provide a potential therapeutic strat-
egy for treating amyloid diseases, especially AD. Zhu et al. (2001) reported that dramatic inhibition 
of amyloidosis was observed after injecting the LMWHs enoxaparin and dalteparin in a amyloid A 
(AA)	amyloidosis	mouse	model.	LMWHs	can	reverse	the	process	of	amyloidosis	and	inhibit	fibril	
formation	by	blocking	formation	of	β-pleated	structures.	GAG	mimetics	can	inhibit	this	binding	and	
block	formation	of	β-pleated	sheets	and	adherence	of	disaccharides	(Walzer	et al., 2002) and also 
efficiently	inhibit	the	stimulatory	effect	of	heparin	on	APP	secretion	(Leveugle	et al., 1994). Small-
molecule	anionic	disulfides	(MW	900–1,000)	are	reported	(Kisilevsky	et al., 1995) to inhibit the in 
vitro	acceleration	of	Aβ	fibril	formation	by	HS.	Administered	orally,	these	compounds	substantially	
reduced	murine	splenic	AA	amyloid	progression	and	also	interfered	with	HS-stimulated	β-peptide	
fibril	aggregation.	In	addition,	anionic	compounds	cross	the	blood–brain	barrier	(BBB)	in vivo and 
have	exhibited	protective	effects	against	Aβ-induced	cytotoxicity	as	well	as	inhibition	of	the	forma-
tion	of	β-pleated	sheets	(McLaurin	et al., 1999; Gervais et al., 2001; Zhu and Kindy, 2001). These 
compounds,	which	have	an	antiamyloid	profile	combined	with	the	ability	to	cross	the	BBB,	are	prom-
ising therapeutics for amyloid disorders (Gervais et al., 2001). Furthermore, an LMWH, 4-deoxy ana-
logue of N-acetylglucosamine, attenuated plaque formation and improved neuropathology of AD in 
animal models (Kisilevsky and Svarek, 2002; Kisilevsky et al.,	2003).	A	beneficial	effect	of	LMWHs	
(certoparin	and	C6)	as	a	preventative	and/or	 therapeutic	 treatment	of	an	Aβ-induced	rat	model	of	
neuropathology has also been reported (Walzer et al.,	2002).	LMWHs	may	prevent	Aβ	from	forming	
its	neurotoxic	β-pleated	sheet	conformation	in vivo,	subsequently	blocking	Aβ-induced	neuropathol-
ogy.	In	addition,	heparin	oligosaccharides	are	known	to	exhibit	antiinflammatory	properties	as	well	
as inhibitory effects on proteoglycan assembly and may prove useful as neuroprotective agents (Ma 
et al., 2007). Recently, Dudas et al. (2008) examined the neuroprotective properties of ‘‘neuroparin’’ 
(C3), a low-molecular-weight GAG (~2.1 kDa), in animal models with characteristic AD lesions. 
Oral	administration	of	C3	can	prevent	Aβ25–35-induced tau-2 immunoreactivity (Dudas et al., 2002). 
Administration of C3 attenuates AF64A-stimulated (AF64A is the ethylcholine mustard aziridinium 
ion),	low-affinity	nerve	growth	factor	receptor-immunoreactive	axonal	varicosities	in	the	rat	septum	
and also increases dendritic arborization of hippocampal CA1 neurons. For those reasons, C3 may 
possess neuroprotective properties against many of the characteristic neural lesions in AD. Because 
C3 can cross the BBB, it could represent an entirely new class of agents that can penetrate the BBB 
and	inhibit	Aβ-PG	binding	for	the	treatment	of	neurodegenerative	disorders.	Phase	I	clinical	studies	
have,	in	fact,	been	completed	and	proved	supportive;	the	efficacy	of	one	of	the	compounds	is	cur-
rently	being	tested	in	a	human	phase	III	trial.	For	that	reason,	C3	may	prove	beneficial	in	the	treatment	
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of AD and other vascular dementia and senile dementia of the AD type (Ma et al., 2003). In addition 
to	C3,	a	specific	disaccharide	(CSPG-DS)	from	the	enzymatic	degradation	of	chondroitin	sulfate	pro-
teoglycan, was found to promote central nervous system recovery by modulating both neuronal and 
microglial behavior (Rolls, 2004). In neurons, CSPG-DS induced neurite outgrowth and protected 
against neuronal toxicity and axonal collapse in vitro. In light of experimental and clinical results ob-
tained from studies addressing the role of heparan sulfate in amyloid deposition, it is anticipated that 
additional novel antiamyloid therapeutic targets will be developed by rational design. Li et al. (2005) 
generated transgenic mice that overexpress human heparanase and recently this model demonstrated 
resistance to amyloid induction (Lindahl et al.,	2007)	further	underscores	the	significance	of	GAGs	in	
the disease process. Knowledge of GAG involvement in amyloid formation has led to new strategies 
in drug development for this group of diseases (Kisilevsky et al., 1995, 2004; Zhu and Kindy, 2001) 
and	agents	that	inhibit	the	interaction	between	GAGs	and	fibril	protein	precursors	are	presently	being	
tested in trials in human amyloidosis.
Materials & Methods
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Materials & Methods4. 
Oligosaccharides purification from pig mucosa heparin 4.1. 
with or without standard sulfation pattern
Oligosaccharides tinzaparin derived were prepared from a porcine mucosa tinzaparin Hep with an 
average Mw of 5500 Da. Two different kind of oligosaccharides were prepared as follows: 
a] fractionation and desalting: 150 mg of commercial LMWH (tinzaparin (Tinza), LEO-pharma, 
Ballerup,	Denmark,	depolymerised	through	enzymatic	β-elimination	(Linhardt,	2001)	by	the	man-
ufacturer) was fractionated using semi preparative size exclusion chromatography, thus, di, tetra, 
hexa, octa, deca and dodeca-saccharidic fractions were isolated with Bio-gel P (Bio-Rad Laboratories 
S.r.l, Segrate, Italy) as stationary phase and NH4Cl 0.25 M as mobile phase. Fractions were desalted 
with	an	ultrafiltration	step	with	YC05	Amicon	bioseparation	filter	(Millipore	Corporation,	Billerica,	
MA, USA) and with a desalting step through Toyopearl HW-40 (Tosoh Bioscience LLC, Minato-Qu, 
Tokio,	Japan)	as	stationary	phase	and	10%	EtOH	as	mobile	phase.	In	the	elution	profile	of	tinzaparin	
it is possible to distinguish 9 peaks (sample codes: decasaccharide [(T) dp10], hexasaccahride [(T) dp 
6] and other samples not used during this thesis work), corresponding to oligomers ranging from di 
to dodecasaccharides and a nonresolved group of peaks in the part of the chromatogram containing 
higher oligomers. All the intermediate products were checked by 13C NMR analysis. (Table 4).
b] Hep dp 2 was obtained after deaminative reduction of a UFH, fractionated and desalted as previ-
ously described (see point a]) (Table 4). 
Enoxaparin	 (Enoxa)	was	 supplied	by	Sanofi-Aventis	Pharma	 (Milan,	 Italy)	as	 injectable	Clexane;	
Dalteparin (Dalte) was from Pharmacia AB (Stockholm, Sweden) as injectable Fragmin (Table 4).
Octa-3,	Octa-5	and	Octa-6	were	provided	by	the	manufacturer	(Sanofi-Aventis,	Paris,	France)	and	
they	were	purified	as	reported	in	literature	(Guerrini	et al., 2008 [b]) (Table 4; Fig. 18). The table 
below resume Hep /Hep oligosaccharide codes and features (Table 4) .
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Code Description MW Chemical 
modification
Depolymerisation 
method
Saccharide sequence Animal
UFH Na UFH 17000 NO NO (IS-GlcNNAc, 6S)≈13//(IS-GlcNNS, 6S)≈13 Sus Domesticus
Hep dp 2 disaccharide Na
Hep derived
582 NO Deaminative reduction IS-2,5 anM6S Sus Domesticus
Dalte Na Fragmin [Dalteparin 
(LMWH)]
6900 NO Deaminative reduction (IS-GlcNNAc, 6S)≈3-IS-2,5 anM6S//(IS-GlcNNS, 
6S)≈3-IS-2,5 anM6S
Sus Domesticus
Enoxa Na Clexane [Enoxaparin 
(LMWH)]
5300 NO Chemical	β-elimination ΔU2S-GlcNNS, 6S-(IS-GlcNNS, 6S)≈7-IS-2,5 
anM6S//ΔU2S-GlcNNS, 6S-(IS-GlcNNAc, 6S)≈7-
IS-2,5 anM6S
Sus Domesticus
Tinza Na InnoHep [Tinzaparin 
(LMWH)]
8300 NO Enzymatic 
β-elimination
ΔU2S-GlcNNS, 6S-(IS-GlcNNS, 6S)≈10 Sus Domesticus
(T) dp 6 hexasaccharide 
Na Tinzaparin derived
2057 NO Enzymatic 
β-elimination
ΔU2S-GlcNNS, 6S-(IS-GlcNNS, 6S)≈2 Sus Domesticus
(T) dp 10 decasaccharide 
Na Tinzaparin derived
4154 NO Enzymatic 
β-elimination
ΔU2S-GlcNNS, 6S-(IS-GlcNNS, 6S)≈4 Sus Domesticus
BL Hep Na Hep 21600 NO NO (IS-GlcNNS, 6S)≈5 Bos Taurus
Octa-3 octasaccharide 
Na Hep derived
2376 NO Enzymatic 
β-elimination
ΔU2S-GlcNNS, 6S-IS-ANA-G-A*-IS-A Bos Taurus
Octa-5 octasaccharide 
Na Hep derived
2360 NO Enzymatic 
β-elimination
ΔU2S-GlcNNS, 6S-IS-ANA-G-A*-IS-1,6 
anMNS
Bos Taurus
Octa-6 octasaccharide 
Na Hep derived
2360 NO Enzymatic 
β-elimination
ΔU2S-GlcNNS, 6S-IS-ANA-G-A*-IS-1,6 
anGNS
Bos Taurus
Table 4. Heparin sample and oligosaccharide Hep derived list. Code column contains Ronzoni Institute code, description column gives general in-
formation	on	Hep	and	oligosacchiaride	samples,	chemical	modification	column	shows	sulfation/acetylation	modification	done	to	the	specified	samples,	
saccharide sequence column reveals monosaccharide sample sequence compositions and animal column shows binomial system nomenclature Hep 
animal origin. BL= bovine lung.
Construction and use of a library of 4.2. bona fide heparin 
employing 1H NMR and multivariate analysis
Heparin library composition4.2.1. 
A library was constructed which contained 28 samples (making a total of 158 spectra) (Table 5), 
provided by several commercial European manufacturers of heparin and National Institute for Bio-
logical Standards and Control (NIBSC) [including the 5th, 6th Hep International Standard and 6th Hep 
International	Standard	candidates	which,	it	should	be	noted,	were	originally	defined	in	terms	of	their	
biological activity, not their structural characteristics]. The commercial Hep samples were considered 
bona fide samples, according to 2009 Pharmacopeial forum, with acceptable content of DS N-acetyl 
signal [2.08 ± 0.02 ppm; it must be below 1% of the Hep N-acetyl signal (2.05 ± 0.02 ppm)] and cur-
rent criteria of the manufacturer. For this illustrative example of a Hep library (of necessity, limited in 
scope), samples have been characterised and selected to represent structural variability arising from 
the principal European manufacturing processes (including different oxidation levels) related to com-
mercial Heps. The quality of the standard heparin library is critical in any comparison and every effort 
should	be	made	to	include	only	those	samples	in	which	the	highest	confidence	regarding	provenance	
and characteristics can be placed, for whatever purpose the comparison is being made. 
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1D and 2D NMR spectroscopy for heparin library4.2.2. 
For each Hep samples, 20 mg were dissolved in 0.6 mL of 0.15 mM Na trimethyl-silyl-3-propionic 
acid (TSP) solution in deuterium oxide. TSP was added both for spectrum calibration and as a con-
trol of spectral resolution. 1D and 2D 1H-13C HSQC spectra were measured at 21 °C on a Bruker 
AVIII-600 instrument (operating at the 600.13 MHz 1H observation frequency) equipped with a cryo-
genic TXI 5 mM probe (Bruker, Karlsruhe, Germany). Measurements were accepted for Principal 
Component Analysis (PCA) when the line width of the TSP signal was equal or less than 1 Hz (± 0.1 
Hz)). Water presaturation power corresponding to 5 Hz was applied during 12 s of relaxation time. 
Typically, 32 transients were acquired into 32768 data points covering a spectral width of 10800 Hz. 
A	shifted	π/3	squared	cosine	function	was	applied	before	FT	and	all	spectral	data	sets	were	processed	
using TOPSPIN (v. 2.2) software supplied by the manufacturer. The residual water signal lies in a 
region between about 4.8 ppm and 4.6 ppm, depending on the set temperature (i.e. 21 °C to 40 °C). 
Within this range the water signal shifts from the region of H5 of iduronate residues (4.75 - 4.86 ppm) 
to that of the anomeric protons belonging to glucuronic acid and linkage region residues (4.7 - 4.6 
ppm).	Since	the	content	of	linkage	region	and	different	glucuronic	acid	sequences	can	significantly	
change within different Hep batches, signal shifting in this region must be accommodated. Water 
signal at 21 °C is centred at 4.812 (± 0.1 Hz), in this conditions presaturation weakly affects both 
iduronate signal and linkage region signals. We decided to run 1H NMR at this temperature, in order 
to collect the most of the informations. 1H-13C HSQC experiments (Palmer et al., 1991; Kay et al., 
1992; Schleucher et al., 1994) were acquired with 16 scans for 320 increments in the F1 dimension. 
The	matrix	size	1	K	x	512	was	zero	filled	2	K	x	1	K	by	application	of	a	squared	cosine	function	prior	
to FT. A LB of 1.0 Hz and 0.3 Hz, respectively for F2 and F1, was applied before FT and all spectral 
data sets were processed using TOPSPIN (v. 2.2) software supplied by the manufacturer. DoS have 
been calculated as previously described (Guerrini et al., 2005). The table below resume Hep codes 
and features used to build heparin library.
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Code PCA 
code
Kind Chemical modi-
fication
Animal
G3000 4.1 Na UFH NO Sus Domesticus
G6686 1.1 Na. Hep. Commercial NO Sus Domesticus
G6687 1.2 Na. Hep. Commercial NO Sus Domesticus
G6213 2.1.1 Na. Hep. Commercial NO Sus Domesticus
G6214 2.1.2 Na. Hep. Commercial NO Sus Domesticus
G6215 2.1.3 Na. Hep. Commercial NO Sus Domesticus
G6808 2.2.1 Na. Hep. Commercial (mild oxidation) KMnO4 oxidation Sus Domesticus
G6812 2.2.2 Na. Hep. Commercial (mild oxidation) KMnO4 oxidation Sus Domesticus
G6815 2.2.3 Na. Hep. Commercial (mild oxidation) KMnO4 oxidation Sus Domesticus
G6726 2.3.1 Na. Hep. Commercial (high oxidation) KMnO4 oxidation Sus Domesticus
G6727 2.3.2 Na. Hep. Commercial (high oxidation) KMnO4 oxidation Sus Domesticus
G6728 2.3.3 Na. Hep. Commercial (high oxidation) KMnO4 oxidation Sus Domesticus
A1688 3.1 Na. Hep. Commercial NO Sus Domesticus
A1689 3.2 Na. Hep. Commercial NO Sus Domesticus
A1846 3.3 Na. Hep. Commercial NO Sus Domesticus
A1506 4.2 Na. Hep. Commercial NO Sus Domesticus
A1618 4.3 Na. Hep. Commercial NO Sus Domesticus
A1721 4.4 Na. Hep. Commercial NO Sus Domesticus
A1858 4.5 Na. Hep. Commercial NO Sus Domesticus
A1922 4.6 Na. Hep. Commercial NO Sus Domesticus
A1404 5.1 Na. Hep. Commercial NO Sus Domesticus
A1600 5.2 Na. Hep. Commercial NO Sus Domesticus
A1774 5.3 Na. Hep. Commercial NO Sus Domesticus
A1482 6C.1 W candidate for 6 °Na Hep. Int. Std. NO Sus Domesticus
A1483 6C.2 X candidate for 6 °Na Hep. Int. Std. NO Sus Domesticus
A1484 6C.3 Y candidate for 6 °Na Hep. Int. Std. NO Sus Domesticus
A1485 IS6 6 °Na Hep. Int. Std. NO Sus Domesticus
A1487 IS5 5 °Na Hep. Int. Std. NO Sus Domesticus
Table 5. Heparin samples used for 1H NMR spectra acquisition and PCA analysis. PCA code is arbitrary to keep safe manufacturer privacy.
Heparin library analysis by PCA4.2.3. 
Before the analysis took place the spectra were aligned, cut to remove the regions containing water 
and solvent, normalised to the average area under the spectra [the area under the spectra was calcu-
lated using the Matlab (R2010a) function trapz (The MathWorks ltd, Cambridge, United Kingdom)], 
mean-centred and then scaled, using one of these methods: autoscaling, Pareto scaling and Vast scal-
ing.	Mean	 centring	 removes	 the	 first	 principal	 component,	which	 otherwise	 contains	 the	 average	
spectral features. PCA was performed using R (version 2.9.0. R Development Core Team (2010). 
R: A language and environment for statistical computing. R Foundation for Statistical Computing, 
Vienna, Austria. ISBN 3-900051-07-0, http://www.R-project.org.), utilising the Princomp algorithim. 
PCA was performed on a wide spectral region, 6.00-1.95 ppm [with regions 4.912 - 4.730, 3.881 - 
3.868, 3.680 - 3.633, 3.363 - 3.355 and 3.010 - 2.220 ppm were excluded].
PCA	is	a	nonparametric	technique	(i.e.	one	that	does	not	rely	on	selecting	or	defining	any	values	be-
fore the analysis begins), which reduces a complicated set of data to a number of lower, independent 
dimensions, or principal components. These dimensions/principal components explain the overall 
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variance (Expl. Var.) within the original dataset, with one variable within the dataset being described 
as a summation of the derived principal components (Eq. 1). 
     Xij=Lj1Si1+Lj2Si2+…+LjpSip+E    (Eq. 1)
Where Xij is a dataset containing j spectra with i spectral readings (i.e. 1.00 – 2.00 ppm), which can 
be described as p principal components, where L are the component loadings [related to the spectra] 
and	S	are	the	component	scores	[related	to	the	spectral	features].	The	final	term,	E,	is	the	residual	
unexplained variance, or error, that cannot be explained by the linear summation.
The proportion of the variance in the data, that is explained by each component, can be analysed 
through a scree plot (i.e. Fig. 24 A) and the spectral information contained in each component can be 
extracted and interpreted in the form of component scores which, in this case, will contain features 
resembling 1H NMR spectra (i.e. Fig. 24 C).	For	a	single	contaminant	(which	does	not,	by	defini-
tion, already form part of the library), the variance from the library spectra will be described by one 
principal component. In the case of multiple, structurally distinct contaminants in the same sample, 
the variance will also be explained by a single principal component. PCA is unable to distinguish 
between one or many contaminants in a single sample because it only handles the sum of the spectral 
features arising from the multiple contaminants, unless the multiple contaminants are also present 
individually, within the library dataset. 
In the analyses conducted here, the datasets were normalised to the average area under the spectra 
dataset [if not stated otherwise] and mean-centred (Eq. 2) before PCA was employed. This is essential 
because	the	first	component	derived	is	normally	the	average	of	the	dataset	and	would	contain	a	large	
proportion of the variance, having the effect of swamping the other components. 
     Xij=xij-xavarage i       (Eq. 2)
Where Xij and xij is the dataset after and before treatment and xavarage i is the average of the rows for xij. 
Autoscaling (Eq. 3), Pareto (Eq. 4) and Vast scaling (Eq. 5) were also employed in some analyses, 
     Autoscaling: Xij=(xij-xavarage i). (xsd i)-1    (Eq. 3)
     Pareto scaling: Xij=(xij-xavarage i).	(√xsd i)-1   (Eq. 4)
     Vast scaling: Xij=(xij-xavarage i)(xsd i)-1. (xavarage i/xsd i)  (Eq. 5)
Where Xij and xij are the dataset after and before treatment, xaverage i is the average of the rows for xij 
and xsd i is the standard deviation of each row. Autoscaling (Eq. 3) normalises the standard deviation to 
one, therefore the data are compared with respect to correlations, not covariances. A disadvantage of 
autoscaling	is	that	the	data	become	dimensionless,	making	it	difficult	to	compare	component	scores.	
On the other hand, this does not occur for Pareto scaling (Eq. 4), which normalises to the square root 
of the standard deviation; the effect being to make large changes less important with respect to small 
changes in the dataset. Variability stability scaling (Vast scaling), scales on the stability of the vari-
able, selecting for variables with a small standard deviation and placing less importance on variables 
with large standard deviations. There are no set rules determining when scaling should be used, but 
mean centring should be used whenever PCA is going to be performed on a dataset. For a protocol to 
be devised for the automated analysis of pharmaceutical Hep with 1H NMR and multivariate analysis, 
a clear set of rules will have to be devised regarding which scaling method should be used (van den 
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Berg et al., 2006; Keun et al., 2003).
USP NMR protocol (Sodium Heparin Stage 2 monograph) 4.2.4. 
500 MHz Pulsed (FT) NMR spectrometer, 16 Scans, 90 ° pulse with a 20 sec delay, recorded at a 
temperature	of	25	°C.	The	N-acetyl	peak	positions	are	defined	as	2.05	±	0.02	and	2.16	±	0.03	ppm,	
respectively for heparin and OSCS. The positions of H1 of ANA/A [5.42 ppm], H1 of IS [5.21 ppm], H2 
of GlcNNS [3.28 ppm (doublet centred at 3.28 ppm)] and the methyl of GlcNNAc [2.05 ppm] must not 
differ by more than ± 0.03 ppm. No signals should be present in the ranges 0.10 – 2.00, 2.10 – 3.20 
and 5.70 – 8.00 ppm, that have a height greater than 4 % of the mean signal height of H1 of ANA/A 
[5.42 ppm] and H1 of IS [5.21 ppm]. There should also be no signal between 3.35–4.55 ppm with a 
height greater than 200 % signal height of the mean of H1 of ANA/A [5.42 ppm] and H1 of IdoA2S 
[5.21 ppm], for porcine heparin (i.e. Fig. 34). 
Effects on molecular conformation and anticoagulant ac-4.3. 
tivities of 1,6-anhydrosugars at the reducing terminal of 
antithrombin-binding octasaccharides isolated from low-
molecular-weight heparin enoxaparin 
AT purification4.3.1. 
Antithrombin	III	(AT;	MW=	58000	Da)	was	purified	from	a	pharmaceutical	grade	preparation	(Kib-
ernin P 1000, ZLB Behring, Milan, Italy). Kibernin P 1000 was dissolved in dH2O to reach 4 mg/
mL and it was loaded on two 10 MWCO Centricon YM-10 (Millipore, Milan, Italy) and they were 
centrifuged	at	5000	rpm,	40	min	(flow-through	from	every	single	steps	were	stored	and	check	later	
to test protein concentration); for every single tube, remaining volume (~0.3 ml) was diluted with 
1.7 ml dH2O and they were centrifuged at 5000 rpm, 40 min; dilution and centrifugation steps were 
repeated at least 5 times. Finally remaining volume (~0.3 ml) was diluted up to 1 mL with dH2O, 
the Centricons were loaded up side down into the centrifuge and they were centrifuged at 2500 rpm, 
5 min. Protein concentration was measured by Cary 50 UV-Vis spectrophotometer (Varian, Torino, 
Italy)	at	λ=	280	nm.
1D and 2D NMR spectroscopy for octasaccharide: AT interaction 4.3.2. 
analysis
All mono-dimensional and bi-dimensional NMR spectra were measured at 21 °C, on a Bruker Avance 
600 (operating at 600.13 MHz 1H observation frequency) and Bruker Avance 900 spectrometer (op-
erating at 900.05 MHz 1H observation frequency) both equipped with a cryogenic TXI 5 mM probe 
(Bruker, Karlsruhe, Germany). For 1H	detection,	350	μgr	of	octasaccharide	samples	were	dissolved	
in D2O (99.9%) and freeze-dried to remove residual water. After exchanging the samples three times, 
samples were dissolved in 0.7 mL of 10 mM Na2HPO4 pH 7.4, 0.15 M NaCl with 3 mM ethylen-
ediaminetetraacetic acid (EDTA) in D2O (99.996%) (PBS). For the binding studies, samples were 
prepared	by	dissolving	200	μgr	and	400	μgr	of	each	octasaccharide	sample	in	the	PBS	so	as	to	reach	
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a 1:10 or 1:40 AT/octasaccharide molar ratio for trNOE and STD experiments, respectively. Proton 
spectra were recorded with presaturation of the residual water signal, with a recycle delay of 8 s and 
128 scans. 1H-1H TOCSY (Bax and Davis, 1985; Hwang and Shaka, 1995) spectra were acquired us-
ing	32	scans	per	series	of	2K	×	512W	data	points	with	zero	filling	in	F1	and	a	shifted	squared	cosine	
function was applied prior to FT. For all NOESY and trNOE experiments spectra were recorded using 
the standard Bruker sequence. Experiments were performed with a total of 48 scans collected for each 
free-induction	decay	(matrix	2K	×	512	points)	and	data	were	zero-filled	to	4K	×	2K	points	before	FT.	
Mixing time values of 100, 200 and 300 ms were used. All 1D STD experiments were measured at 
900 MHz and it was employed a pulse sequence with spoil sequence to destroy unwanted magnetisa-
tion, includes a 25 ms spinlock pulse to eliminate the broad resonances of the protein and water sup-
pression (Mayer and Meyer, 1999). A train of 40 Gaussian-shaped pulses of 50 ms each was applied 
to	produce	selective	saturation.	The	on-resonance	irradiation	was	performed	at	the	low	field	protein	
resonances (7.25 ppm), whereas the off-resonance control irradiation was performed at 24 ppm. The 
number of scans and dummy scans were 1024 and 16, respectively. Following saturation time was 
used: 0.5, 0.8, 1.3, 2 s. All spectra were acquired and processed by TOPSPIN (v. 2.2) software sup-
plied by the manufacturer.
Computational studies on octasaccharide-AT complexes4.3.3. 
The octasaccharide models were created by Macromodel version 4.0 (Schrödinger, Mannheim, Ger-
many) starting from previously reported structures (Mulloy et al., 1993; Guerrini et al., 2008 [b]) 
where IdoA and I2S are in 2S0 conformation while glucosamines and glucuronic acid residues are in 4C1 
conformation, as shown from NMR experimental evidences. Molecular Dynamics (MD) simulation 
of	Octa-3,	Octa-5	and	Octa-6	were	performed	using	AMBER*	force	field	included	in	MAESTRO	
8.0/Macromodel simulation package and macromodel batchmin simulation engine was used for MD 
trajectory production. Simulation were done on models where each octasaccharide molecule was en-
veloped by a water molecules layer at least 12 Å wide. To do that, the free code software “solvate-1.0” 
was used (Helmut Grubmüller and Volker Groll. Theoretical and Computational Biophysic Group, 
Max Planck Institute, Göttingen, Germany). After a short time MD (about 400 ps) Octa-3, Octa-5, 
Octa-6 models were checked in each residues conformation to agree qualitatively with the experimen-
tal seen. Glycosidic geometries of the IS-1,6-anG/M disaccharides were set according to H1–H4 and 
H1–H5 inter-residue distances on the basis of values extrapolated from experimental NOE magni-
tudes. Octa-3, Octa-5 and Octa-6 geometries so obtained were used as ligands for automatic docking 
octasaccharide/AT complex structure determination. Docking simulations were performed using Au-
todock-4.2 program (Morris et al., 1996; Morris et al., 1998). The receptor (AT) geometry was taken 
from	PDB	file	(Protein	Data	Bank	1AZX29).	Explicit	treatment	of	every	hydrogen	was	used	for	both	
ligand and receptor, while atom charges were calculated following Gasteiger approach (Gasteiger, 
1980).	Ligands	were	treated	as	rigid	object	fixing	all	glycosidic	torsional	degrees	of	freedom,	while	
hexocyclic functional group torsional angles (32 degrees of freedom for each complex) were allowed 
to move during docking simulation. About 100 complex geometries were generated using a Lamarck-
ian Genetic Algorithm with local search, characterised by the following set of parameter: population 
size	was	fixed	to	500,	maximum	number	of	energy	evaluation	per	run	was	chosen	to	be	5	x	106	and	
2.7 x 105 maximum generation number. Others parameters are left as default settings. Results were 
analysed by a fast cluster analysis: generated complex geometries were ranked by a rmsd cut-off of 
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2.0 Å. After ranking few clusters, with higher score function and/or most 21 populated having the 
ANAGA*IA sequence in the same position as found in the crystal structure of the pentasaccharide/AT 
complex (Jin et al.,	1997),	that	clusters	were	considered	to	fit	trNOE	data.	Less	populated	clusters,	
having the octasaccharides moved up toward the nonreducing end by about a disaccharide unit from 
the normal AT binding site, were also found and considered. To evaluate the ability of all these com-
plex models to interpret the position of the ligand in the AT binding site, the magnitudes of theoretical 
trNOEs were calculated on different models of octasaccharide/AT complexes using the CORCEMA 
program (Moseley, 1995). The agreement between the theoretical and experimental trNOEs was eval-
uated	by	calculating	the	fitting	quality	parameter	R	factors	as	defined	in	Eq.	6.
     
     R2= ∑(NOE
EXP(tmix) - NOECALC(tmix))2
tmix
∑(NOEEXP(tmix))2
tmix
  (Eq. 6)
R-factor values higher than 0.3 are indicative for a pour local structure description. The values of the 
Kd used to calculate theoretical trNOEs were based on those calculated by equilibrium titration and 
published data (Guerrini et al., 2008 [b]). The correlation times of AT and octasaccharides were con-
sidered as isotropic and estimated from the previous data (Hricovini et al., 2001; Angulo et al., 2005; 
Guerrini et al., 2008 [b]). However, due to the slightly different condition used (temperature and ion 
strength) the Kd and the off-rate (koff) used in the calculations varied during the optimisation (Kd and 
koff: 0.1 mM and 50 sec-1, respectively).
Role of glycosaminoglicans (GAGs) in Alzheimer pro-4.4. 
gression.
Dynamic Light Scattering aggregation kinetics analysis for Aβ in-4.4.1. 
teraction with and without GAGs
Experiments were performed on a Viscotek 802 DLS (Malvern Instruments Ltd, Worcestershire, 
United	Kingdom)	90	°angle	fixed	detector	at	25	°C.	A	50	mW	fiber	coupled	diode	laser,	single	photon	
counting module operating at a wavelenght of l= 830 nm was used as the light source. Aggregation 
investigation at different pH: Aβ1-40 (GenScript USA Inc., Piscataway, NJ, USA) peptide was dis-
solved	in	10	mM	NaOH	solution	pH	11	pre	filtered	with	Anotop	10	filter	inorganic	membrane	with	
pore of 0.02 mm (Whatman, Maidstone, Kent, United Kingdom). The solution was diluted to a con-
centration of 23 μM (MW
Aβ
= 4329 Da) in 100 mM Na2HPO4+ KH2PO4 pH 7 pre	filtered	with	Anotop	
10	filter, 5 sec vortex and centrifuge 1000 rpm, 30 sec (for 2 times). All measurements were acquired 
and processed with Omnisize 3.0 (Malvern Instruments Ltd, Worcestershire, United Kingdom) ap-
plying 10 % of laser power for 40 round of scans, 4 sec for each scans; Rh was sampled every hour in 
triplicate and the average Rh	is	reported.	The	first	35	and	the	last	150	points	were	manually	removed	
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prior	exponential	fitting.	Aggregation investigation with different buffers: Aβ1-40 (GenScript USA 
Inc., Piscataway, NJ, USA) peptide was prepared in two different conditions. Condition A: the pep-
tide was dissolved to a concentration of 0.92 mM in	10	mM	NaOH	solution	pH	11	pre	filtered	with	
Anotop	10	filter,	5	sec	vortex	and	centrifuge	1000	rpm,	30	sec	(for	2	times).	It was diluted to a final 
concentration of 0.023 mM Aβ1-40 in 100 mM TRIS-HCl pH), 0.05% NaNO3 pre	filtered	with	Anotop	
10	filter. Condition B: the peptide was dissolved to a concentration of 0.92 mM in 10 mM NaOH 
solution	pH	11	pre	filtered	with	Anotop	10	filter, 5 sec vortex and centrifuge 1000 rpm, 30 sec (for 2 
times). It was diluted to a final concentration of 0.44 mM Aβ1-40 in 100 mM TRIS-HCl pH), 0.05% 
NaNO3 pre	filtered	with	Anotop	10	filter. All measurements were acquired and processed with Om-
nisize 3.0 applying 10 % of laser power for 20 round of scans, 4 sec for each scans; Rh was sampled 
every hour.	The	first	25	and	the	last	150	points	were	manually	removed	prior	exponential	fitting.	Sam-
ple at 0.023 mM was kept at 37 °C for the entire experimental duration. Aggregation investigation 
with or without GAGs: Aβ1-40 (GenScript USA Inc., Piscataway, NJ, USA) peptide was dissolved 
to a concentration of 23 μM	in	10	mM	NaOH	solution	pH	11	pre	filtered	with	Anotop	10	filter,	5	sec	
vortex and centrifuge 1000 rpm, 30 sec (for 2 times) One fraction was diluted to a final concentration 
of 0.44 mM Aβ1-40 in 50 mM TRIS-HCl pH 7), 0.05% NaNO3 pre	filtered	with	Anotop	10	filter	and 
the remaining fractions were used to get a solution of 0.44 mM Aβ1-40, 1:1 final mass ratio with GAGs 
(Enoxa, Tinza, Dalte, Hep dp 2, (T) dp 6 and (T) dp 10) in 50 mM TRIS-HCl pH 7, 0.05% NaNO3 pre 
filtered	with	Anotop	10. All measurements were acquired and processed with Omnisize 3.0 applying 
10 % of laser power for 20 round of scans, 4 sec for each scans; Rh was sampled every hour.	The	first	
25	and	the	last	150	points	were	manually	removed	prior	exponential	fitting.	Dynamic	light	scattering	
(DLS) is also known as Photon Correlation Spectroscopy. This technique is one of the most popular 
methods used to determine the size of particles. Shining a monochromatic light beam, such as a laser, 
onto a solution with spherical particles in Brownian motion causes a Doppler Shift when the light hits 
the moving particle, changing the wavelength of the incoming light. This change is related to the size 
of the particle. It is possible to compute the sphere size distribution and give a description of the par-
ticle’s	motion	in	the	medium,	thus	measuring	the	diffusion	coefficient	(Dcoeff) of the particle and using 
the	autocorrelation	function.	This	method	has	several	advantages:	first	of	all	the	experiment	duration	
is short and it is almost all automatised so that for routine measurements an extensive experience is 
not required. Autocorrelation function intensity (Eq. 7) decays as negative exponential (Eq. 8):
     G= I(T)      (Eq. 7)
     G(t)= Ae(-2Gt) +1     (Eq. 8)
Where A is amplitude constant, t is the time (sec), G is the decay constant (Eq. 9 depending on the 
Dcoeff (Eq. 10) and the q factor (Eq. 11):
     G= Dcoeff(t)q2      (Eq. 9)
I(T+t)
(I(T))2
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     Dcoeff=       (Eq. 10)
     q=                    sin     (Eq. 11)
Omnisize 3.0 calculates the average autocorrelation function through all the selected functions prior 
data	fitting,	after	that	it	applies	fitting	routine	called	regularisation	through	a	series	of	negative ex-
ponential regression functions. Rh calculation is based on the assumption that the sample contains a 
single mono-disperse species. In most cases, we do not tend to deal with samples of this type and 
we need a way of extracting more information from the correlation function. Regularisation is the 
process in which we model the correlation function to a distribution of particle sizes. In essence, our 
real correlation function is a combination of a group of virtual mono-disperse functions of differing 
amplitude. Each virtual function has its own decay rate (which relates to its size) and its own ampli-
tude A (which relates to its contribution to the sum. Regularisation determines the best set of virtual 
correlation	functions	that	fit	the	experimental	data.	So	from	this	collection	of	functions	we	can	deter-
mine the distribution of sizes of particles within a sample. Regularisation tends to over estimate the 
contribution	of	the	initial	and	final	part	of	the	autocorrelation	function,	for	this	reason	the	first	the	last	
data points were manually removed. 
kBT
6phRh
4pn(dn/dc)
								λ
Q
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Aim of the work5. 
GAGs are some of the most relevant biological molecules, involved in important biological, physi-
ological activities and also used as pharmaceutical agents. GAG research activities oriented to under-
stand their nature, molecular population composition, characterisation, protein-GAG interaction net-
work and putative pharmaceutical properties are essential to develop new drug with a more controlled 
and described activity. Recently experimental and clinical informations had increased the attention 
over	HS/Hep	coagulant	and	not	coagulant	activity	opening	new	fields	of	research	oriented	to	develop	
new therapeutical strategy involving heparin usage. Heparin mimetics can be extremely helpful from 
this perspective, due to their controlled nature, molecular features and structure, thus they can be em-
ployed as performance drugs. My Ph.D. thesis deals with statistical characterisation of commercial 
and not commercial pharmaceutical heparin, composition and structural characterisation of heparin 
mimetics and characterisation of protein-heparin interaction for drug design strategy. 
Thesis focus was oriented on three different subject:
build a library of accepted and well charaterised heparins, set up a statistical analysis based on 1. 
a	PCA	approach	to	statistically	define	heparin	molecular	nature	and	to	develop	a	new	heparin	
quality control procedure.
1D/2D NMR interaction studies (2. 1H, TOCSY, NOESY, ROESY, trNOE and STD) to understand 
the importance of ANAGA*ISA	flanking	residues	over	AT	activation	on	octasaccharides	bearing	
the	pentasaccharide	sequence	with	normal	or	modified	reducent	residue	in	complex	with	AT.
DLS	studies	on	Aβ-heparin	or	heparin	mimetics	as	a	new	strategy	to	counter	act	Aβ	aggregation	3. 
progression	involved	in	AD	and	better	understand	the	deep	relationship	between	Aβ	peptide	and	
GAGs.
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Results & Discussions6. 
Construction and use of a library of 6.1. bona fide heparins 
employing 1H NMR and multivariate analysis 
     Submitted to The Analyst
Summary6.1.1. 
Heparin is one of the most complex pharmaceutical agent on the market. The lack of uniquely/abso-
lute identity for heparin created the condition for the heparin crisis, together with the lack of interest 
of its structural identity from the international regulatory bodies point of view. One of the most in-
formative methods for the structural analysis of heparin samples is NMR. 1H NMR spectra of heparin 
are rich in detail and structurally relevant information and they are also highly informative regarding 
the presence of organic contaminants. Here, a general approach is proposed, based on the comparison 
of the 1H NMR spectrum of the test heparin to a library of known heparin samples which are of ac-
cepted bona fides, although any other data, including biological activity, could in principle also be 
incorporated into the analysis. The second key point is that the limit of sensitivity of such a compari-
son is also dependent in a fundamental way on the contents of the heparin reference library; the more 
structurally homogeneous (i.e. the more similar are the 1H NMR spectra of the library components) 
the greater will be the power of the technique for discerning spectral (i.e. structural) differences be-
tween that library and the sample under examination. The composition of the library is therefore a key 
factor for those interested in making these comparisons, as is the decision regarding which criteria to 
apply to the question what constitutes bona fide heparin? In particular, not only must the provenance 
and	structural	quality	of	the	samples	be	satisfactory,	but	the	defined	method	of	recording	the	spectrum	
(i.e.	employing	a	standardised	procedure	with	consistent	concentration	and	magnetic	field	shimming,	
etc.) and sample purity (i.e. checking for the presence of salt) must be respected. A general approach 
for	detecting	contamination	proposed	by	the	USP,	for	example,	have	reflected	this	and	the	1H-NMR 
test for the presence of OSCS in the current USP monograph for Heparin Sodium (Materials and 
Methods 4.2.4, Pharmacopeial Forum, 2009) pays particular attention to the presence of the N-acetyl 
signal characteristic of OSCS, which is well-separated from the other signals of heparin. However, it 
is unlikely that contaminants whose NMR signals lack N-acetyl [COCH3] groups (but which could 
comprise, for example, sulfated linear polysaccharides such as dextran sulfate, agarose sulfate etc.) 
would be readily detectable using the proposal by the USP, particularly if these contaminants were 
present in moderate levels (i.e. 2 - 10 %) and their signals fell under the complex heparin signals be-
tween ca. 3.2 - 4.8 ppm (Materials and Methods 4.2.4, Pharmacopeial Forum, 2009). This is because 
in	the	USP	approach,	heparin	samples	are	examined	using	defined	sections	of	the	NMR	spectrum	en 
masse and are compared with other grouped sections with relatively relaxed intensity criteria [i.e. 
have	a	particular	defined	area;	Materials	and	Methods	4.2.4,	Pharmacopeial	Forum,	2009	and	Fig.	
34]. In contrast, approaches employing multivariate analysis of spectra such as the present proposal, 
do not favour detection of signals in one spectral region over those in another. The practical issues in 
taking	the	approach	outlined	here	are	two-fold:	the	first	is	to	establish	an	example	reference	library	of	
1H NMR spectra of recognised heparin samples. It is important to note that this library will inevitably 
contain	intrinsic	structural	variability.	The	second	is	to	define	a	procedure	for	the	objective	measure-
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ment	of	 the	similarity	of	a	 test	sample	with	 this	defined	heparin	 library.	One	form	of	multivariate	
analysis, PCA, has been used to differentiate GAGs (DS from heparin, Ruiz-Calero et al., 2000; 
Ruiz-Calero et al., 2002), heparin mixtures have been unravelled (Ruiz-Calero et al., 2002 [b]) and 
heparin from different animal sources analysed (Rudd et al., 2009). Beyer et al. (2008) proposed the 
use of PCA to assess the purity of heparin samples and attempted to establish the sensitivity of detec-
tion for a particular contaminant (OSCS), using PCA only on the N-acetyl region of the NMR spectra, 
2.0 - 2.3 ppm. The power of any of these approaches, however, is fundamentally limited by the nature 
of	the	comparison:	most	have	not	attempted	to	define	a	library	of	accepted	heparins	but,	rather,	make	
piecemeal comparisons between single samples with and without a contaminant. The ultimate aim of 
the present work is distinct to these and aims to provide the means of obtaining an objective measure 
of	how	similar	a	test	sample	is	to	a	group	of	reference	compounds,	which	has	been	defined	by	the	
user, or analyst, as “heparin”. The analysis is free from bias for any particular contaminant and the 
procedure treats all signals within a spectrum with equal weight. The analysis of a test compound pro-
vides a body of information, which can include a measure of the degree of similarity (or difference) 
between the test sample and the entire contents of the reference library, or any particular selected part 
of it. This last option allows comparison to be made, for example, with chosen standards, heparins of 
particular origins, or those derived by particular manufacturing processes.
Heparin library construction6.1.2. 
An illustrative library of 28 standard bona fide heparin samples from a variety of European manufac-
turers was assembled and their 1H NMR spectra recorded under standardised conditions (Materials 
and Methods 4.2.2; 158 spectra in total, arising from distinct preparations and at least 3 repeats for 
each preparations). Fig. 23 shows the complexity of Hep 1D NMR spectra analysis: contaminats in 
low amount or tainted molecules with high rate of spectra features similarity cannot be detected by 
human analysis. The characteristic features of this library and their use for the comparison of a test 
heparin sample, or number of samples, some containing contaminants, are illustrated (Fig. 24 A, B, 
C and Fig. 25 and Table 5).
The intrinsic structural variability of heparin samples constituting 6.1.3. 
the library
Multiple 1H NMR spectra of each sample of heparin were recorded and used to form the heparin 
library. Porcine mucosal intestinal heparin is naturally heterogeneous, through variation in biosynthe-
sis and this heterogeneity can be further increased by structural changes induced by the manufactur-
ing processes. Before a sample was entered in the library it was validated by 1H and 1H-13C HSQC 
NMR,	since	the	goal	was	to	produce	an	illustrative	(rather	than	definitive),	diverse	library	covering	
some of the possible heterogeneity within pharmaceutical heparin. The heterogeneity of the samples 
can be seen in Fig. 24	A,	where	4	components	describe	the	vast	majority	(>	80	%)	of	the	variabil-
ity	within	the	library.	The	discrete	spectral	features	represented	by	the	first	two	components	can	be	
seen in the component score plots (Fig. 24 C and Fig. 25). 1H-13C HSQC spectra of a selection of the 
heparin samples were recorded to further characterise the library. Most of the HSQC spectra were 
used to calculate the main amine and uronic signal values together with the mean DoS, applying an 
established method (Guerrini et al., 2005; Table 6 and Table 7). The average DoS for the library was 
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determined to be 2.45. Principal component analysis of the library was able to discriminate some 
structural	 changes	 related	 to	 the	manufacturing	 process;	 samples	with	 a	 high	DoS	 (DoS	>>2.45)	
were distinct from samples with a low DoS (DoS <<2.45) (Fig. 24 B), samples with a high level of 
oxidation were differentiated from those with a standard level of oxidation (Fig. 24 B and Fig. 24 C 
inset showing signals from oxidation of N-acetyl groups, 2.1 ppm). Moreover, the method can also 
discriminate different heparin international standards. Analysis was also performed on single samples 
from each heparin group (Fig. 26); samples were chosen with the best line width at half height. In this 
analysis there was a good correlation for DoS (component 1 [38.20%] versus component 3 [16.45%]; 
Fig. 26 C), a good correlation at C6 position of A6S ([component 1 [38.20 %] versus component 2 
[18.90 %] and component 2 [18.90 %] versus component 4 [6.56 %]; Fig. 26 D and Fig. 26 E) and 
a strong correlation for sulfation at C2 position of I2S (component 2 [18.90 %] versus component 3 
[16.45%]; Fig. 26 F).
2.53.03.54.04.55.05.5 ppm
6° Hep Int. St.
5° Hep Int. St.
N_1_1
N_1_2
C_5_1
C_4_1
C_3_1
C_2_3
C_2_2
C_2_1
Ronz. Std.
 Figure 23. 1H NMR spectra of representative heparins belong to heparin library. It was considered spectra from 6.00 ppm to 1.9 ppm (D2O, 600MHz, 
21 °C). No signals are present outside this region for bona fide heparins. Yellow highlighted regions were not considered for PCA.
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PC Exp Var
1 45.42
2 16.80
3 12.43
4 6.14
5->155 19.21
PCA Figure 24. bona fide heparin library. A) Scree plot, each PC represent a percentage of total variance between different heparin samples. Higher 
the variance more that PC represent the most of the variances. B) Loading plot, in which components 1 and 2 together describe 62.22 % of the varia-
tion within the spectra comprising the heparin library (PC 1Expl. Var.= 45.42 %, PC 2Expl. Var= 16.80%. The library contains heparins from 5 manufacturers 
(labeled 1-5); manufacturer 2 provided: normally (2.1), mildly (2.2) and strongly (2.3) oxidised heparin. Samples labeled 6C were candidates for the 6th 
International Standard, while IS5 and IS6 are the 5th and 6th International Standard, respectively. The analysis revealed several distinct groups of heparin 
in the library. Which are plotted as an average of the groups components, 1 and 2, surrounded by an ellipse in which vertical and horizontal dimensions 
represent the standard deviation of component 2 and component 1, respectively. The black dot and ellipse represent the average position of the heparin 
library and variation in component 1 and 2, respectively. C) Score plots, for component 1 and 2, illustrating the features that differentiate the spectra. 
The inset contains an expanded view of the N-acetyl region, highlighting the differences in the N-acetyl signal of heparin, but also the presence of 
dermatan	sulfate	(red	asterisk,	~2.08	ppm)	and	N-acetyl	signals	modified	through	oxidation	(green	asterisk,	~2.1	ppm).	The	score	plot	also	shows	the	5	
regions that were cut before the analysis was performed, labeled i-v. Region i is the water region and regions ii-v contain solvent or signals affected by 
cations. These were removed in this illustrative example to help simplify the analysis. In a rigorous practical analysis, some of these areas may also be 
incorporated to provide additional information.
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1 2 3 4 5
Figure 25. Score plote, for component 1, 2, 3 and 4 illustrating the features that differentiate the spectra at the most (component 1, 2, 3 and 4 together 
describe	>	90%	variance	of	dataset.	Component	1	mainly	describe	variance	variations	for	COCH3 signal, I2S signal and ANNA/A related signals, ATOT 
(ATOT= (ANNS, 6X-I2S)+ (ANNA-I)+ (ANNA-G)). Component 2 mainly describe variance variations for COCH3 signal, I2S signal. Component 3 mainly 
describe variance variations for ANNA+ A6OH signals. Component 4 mainly describe variance variations for A6S signals. Highlighted regions represent: 1) 
ATOT signal, 2) I2S signal, 3) A6S signal, 4) ANNA+ A6OH signals and 5) COCH3 signal.
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DoS
1.1 2,44 11,90 76,50 8,80 7,90 5,30 0,00 0,00 0,00 64,40
1.2 2,35 14,40 76,10 9,60 9,60 4,40 0,90 0,90 0,00 57,50
2.1.1 2,48 11,20 80,00 11,20 9,30 5,60 0,00 2,80 0,00 56,10
2.1.2 2,50 10,70 80,60 8,60 8,60 4,80 0,00 2,90 0,00 61,70
2.1.3 2,54 9,80 82,20 7,10 8,20 5,10 1,00 2,00 0,00 64,70
2.2.1 2,38 12,80 78,10 10,20 8,50 4,20 0,00 1,70 0,00 59,20
2.2.2 2,44 10,70 79,70 9,60 7,80 4,30 0,90 1,70 0,00 60,60
2.2.3 2,47 10,70 80,00 9,50 7,80 5,20 0,00 1,70 0,00 62,60
2.3.1 2,46 10,80 80,60 9,50 8,60 5,70 0,00 1,00 0,00 61,50
2.3.2 2,44 11,60 79,90 10,00 9,10 4,50 0,00 0,90 0,00 60,20
2.3.3 2,48 9,90 79,70 9,40 7,50 4,70 0,00 1,90 0,00 62,70
3.1 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
3.2 2,44 12,90 79,90 9,00 9,00 5,40 0,00 1,80 0,00 57,40
3.3 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
4.1 2,40 12,90 78,50 10,10 5,50 4,60 1,80 0,70 0,00 63,20
4.2 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
4.3 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
4.4 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
4.5 2,52 9,90 80,60 9,80 7,10 5,40 0,90 0,90 0,00 64,20
4.6 2,50 9,40 77,00 10,40 6,60 4,70 0,00 0,90 0,00 67,00
5.1 2,32 15,90 74,70 10,10 8,40 5,00 0,80 2,50 0,00 53,80
5.2 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
5.3 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
6C.1 2,46 10,30 77,40 8,00 7,10 5,30 0,90 1,80 0,00 65,80
6C.2 2,41 12,00 76,30 7,60 6,80 5,10 0,80 2,50 0,00 60,90
6C.3 2,43 13,50 77,50 10,50 9,60 4,40 0,90 2,60 0,00 55,80
IS5 2,45 13,50 78,50 8,80 6,10 6,10 0,90 3,50 0,00 58,40
IS6 2,49 10,50 79,60 9,60 7,80 7,00 0,90 1,70 0,00  
Sample 
code
AN
NAc
H6 
A
6S
H1 
AN
NS
- G
   H1 
AN
NS
- I
2OH
H1 
A*
      H1  
AN
NAc 
! red 
      H1  
AN
NS 
! red 
        H1  
AN
NS 
" red 
H1 
AN
NS
-I
2S
Table 6. Principal amines signals express in percentage and mean DoS values of heparin samples belong to bona fide library. N/A stands for not ac-
quired HSQC spectra. Values were calculated from 1H-13C HSQC NMR signal integration applying the method reported in Guerrini et al., 2005. DoS= 
degree of sulfation; G= glucuronic acid; I= iduronic acid; ANNAc= H atom linked to N atom belonging to the amine group of GlcNNac residue; H6 A6S= 
H atom linked to C6 atom of the saccharidic ring of GlcNNX,6S residue; H1 ANNS-G= H1 atom linked to C1 atom of GlcNNS,6X residue covalently linked 
to G residue; H1 ANNS-I2OH= H1 atom linked to C1 atom of GlcNNS,6X residue covalently linked to I2OH; H1 A*= H1 atom linked to C1 atom of A*; H1 
ANNAc	α	red=	H1	atom	linked	to	C1	atom	of	α-GlcNNAc residue at the reducing end; H1 ANNS	α	red=	H1	atom	linked	to	C1	atom	of	α-GlcNNS residue at 
the reducing end; H1 ANNS	β	red=	H1	atom	linked	to	C1	atom	of	β-GlcNNS residue at the reducing end; ANNS-I2S= H1 atom linked to C1 atom of GlcNNS 
residue covalently linked to I2S.
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L.R.
1.1 73,90 6,10 1,70 0,00 2,60 7,00 7,00 0,00 0,00 5,50
1.2 70,70 7,00 2,60 0,00 2,60 8,60 6,00 0,00 0,00 3,70
2.1.1 75,90 5,10 2,10 0,00 3,10 6,20 4,10 0,00 1,00 5,60
2.1.2 77,20 5,00 2,00 0,00 2,00 5,90 5,00 0,00 1,00 5,10
2.1.3 79,60 5,40 2,20 0,00 2,20 6,50 3,20 0,00 0,00 4,70
2.2.1 70,60 5,90 2,00 0,00 2,90 7,80 5,90 0,00 2,90 4,80
2.2.2 73,50 5,90 2,00 0,00 2,90 6,90 4,90 0,00 2,00 4,40
2.2.3 74,10 6,20 2,00 0,00 3,00 7,10 6,10 0,00 0,00 4,00
2.3.1 68,10 4,40 1,80 0,00 2,70 6,20 6,20 0,00 5,30 2,10
2.3.2 70,70 5,20 2,60 33,30 1,70 6,10 7,00 0,00 3,50 1,80
2.3.3 73,20 4,50 1,80 33,30 1,80 5,40 7,10 0,00 3,60 1,80
3.1 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
3.2 72,50 6,10 2,60 0,00 2,60 6,10 7,00 0,90 0,00 3,10
3.3 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
4.1 71,20 7,20 2,70 0,00 1,80 9,00 5,40 0,00 0,00 2,00
4.2 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
4.3 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
4.4 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
4.5 76,90 6,10 1,70 0,00 1,70 6,20 5,20 0,90 0,00 2,90
4.6 77,50 4,40 2,60 0,00 1,80 6,20 5,30 0,00 0,00 2,30
5.1 70,80 8,00 2,70 0,00 1,80 7,10 6,20 0,90 0,00 4,10
5.2 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
5.3 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
6C.1 74,30 5,30 2,70 0,00 2,70 6,20 7,10 0,00 0,00 5,80
6C.2 74,50 6,40 2,70 0,00 1,80 6,40 5,50 0,00 0,00 7,90
6C.3 76,70 5,00 2,50 0,00 1,70 5,80 5,80 0,00 0,00 1,30
IS5 76,60 5,60 2,80 0,00 2,80 5,60 3,70 0,00 0,00 6,10
IS6 74,80 7,00 2,60 0,00 2,60 6,10 4,30 0,00 0,00 4,60
Sample 
code
H1 I
2S
    H1  
I
2OH
-A
6S
    H1  
I
2OH
-A
6OH
    H1  
I
2S
 ! red
     H1  
G- A*
    H1  
G- AN
NS
    H1  
G-AN
NAc
GalU H2 epox
Table 7. Principal uronic and linkage region signals values express in percentage of heparin samples belong to bona fide library. N/A stands for not 
acquired HSQC spectra. Values were calculated from 1H-13C HSQC NMR signal integration applying the method reported in Guerrini et al., 2005. 
I= iduronic acid; G= glucoronic acid; H1 I2S= H1 atom linked to C1 atom of IdoA2S residue; H1 I2OH-A6S= H1 atom linked to C1 of IdoA2OH residue 
covalently linked to GlcNNX,6S residue; H1 I2OH-A6OH= H1 atom linked to C1 atom of IdoA2OH residue covalently linked to GlcNNX,6OH residue; H1 I2S	α	
red=	H1	atom	linked	to	C1	atom	of	α-IdoA2S residue at the reducing end; H1 G-A* = H1 atom linked to C1 atom of G residue covalently linked to A* 
residue; H1 G-ANNS = H1 atom linked to C1 atom of G residue covalently linked to GlcNNS,6X residue; H1 G-ANNAc = H1 atom linked to C1 atom of G 
residue covalently linked to GlcNNAc,6X	residue;	GalU=	α-D-galactosyl	mannopentaose;	H2	epox=	H2	atom	linked	to	C2	atom	of	the	residue	bearing	an	
epoxy group; L.R.= linkage region.
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A.       B.       C. Degree of Sulfation
D. A6S       E. A6S        F. I2S
PC Exp Var
1 38.20
2 18.90
3 16.45
4 6.56
5->27 19.89
 PCA of Figure 26. bona fide single spectra Hep library. The same dataset was considered for all 5 analysis. A) Scree plot, components 1, 2, 3 and 
4 together describe 80.11% of the variation within the spectra comprising the heparin library (PC 1Expl. Var= 38.20 %; PC 2Expl. Var= 18.90%; PC 3Expl. Var= 
16.45%; PC 4Expl. Var= 6.56%). B) Loading plot, in which components 1 and 2 together describe 57.1 % of the variance within the spectra comprising the 
heparin library; C) Loading plot, for component 1 and 3. Samples characterised by high content of sulfated Hep were discriminated from samples with 
a low content of sulfated Hep; D) Loading plot, for A6S component 1 and 2; more than 50% of samples characterised by high content of GlcN sulfated 
in C6 were discriminated from other Hep samples; E) Loading plot, for A6S component 2 and 4; 100% of samples characterised by high content of GlcN 
sulfated in sulfated C6 were discriminate from other Hep samples; F) Loading plot, for I2S component 2 and 3; samples characterised by high content of 
sulfated C2 were completely discriminated from the other samples. In panels C, D, E and F: black dots represent samples with no informations available 
for DoS and sulfation data.
Differentiation of a heparin sample contaminated with a gradient of 6.1.4. 
OSCS from the heparin library
Principal component analysis of a sample sequentially contaminated with OSCS (0.25 - 100 %) and 
the heparin reference library is shown in Fig. 27 and dataset complexity changes can be appreciated 
in Table 8, in which the spectral range was 6.00 - 1.95 ppm and the data were mean centred. It can be 
seen from the loading plots (Fig. 27) that the threshold for differentiation for a single contaminated 
sample against the heparin library used in this circumstance is ~5 % OSCS; a sample tainted with 3 
% OSCS lying within the heparin library cluster and 7 % lying well outside the heparin library area 
using only components 1 and 2 (Fig. 27). It is also important to state that the ‘limit of detection’ is 
also fundamentally limited by the library composition. Three percent contamination is discernable if 
additional components are used; component 1 Vs component 3, component 1 Vs component 5, com-
ponent 1 Vs component 6 and component 3 Vs component 6 (Table 8 and Fig. 28). 
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PC Exp. Var 
OSCS 
0%
Exp. Var 
OSCS 
0.25%
Exp. Var 
OSCS 
1%
Exp. Var 
OSCS 
3%
Exp. Var 
OSCS 
5%
Exp. Var 
OSCS 
7%
Exp. Var 
OSCS 
15%
Exp. Var 
OSCS 
25%
Exp. Var 
OSCS 
100%
C1 45.42 35.08 34.71 33.66 32.39 30.69 33.70 51.53 91.39
C2 16.80 16.10 16.16 15.98 16.87 19.28 24.73 17.90 3.01
C3 12.43 13.82 13.72 13.55 12.92 12.42 10.24 7.62 1.46
C4 6.14 8.59 8.57 8.85 9.51 10.33 9.18 6.78 1.19
C5 4.18 5.44 5.39 5.69 6.12 6.12 5.09 3.72 0.65
C6 3.76 4.18 4.15 4.17 4.21 4.13 3.40 2.48 0.45
Residual
components
11.27 16.79 17.3 18.1 17.98 17.03 13.66 9.97 1.85
Table 8. Change in explained variance values caused by different percentage of OSCS contamination. Dataset complexity decreases as much as OSCS 
% increases: component 1 explains the 45.42 % of variance without OSCS, but with 100 % OSCS it explains ~90% of variance.
By limiting the analysis to regions of the spectra where isolated spectral features lie, which are spe-
cific	to	the	contaminant	i.e.	the	N-acetyl	signal	of	OSCS	(2.15	±	0.02	ppm),	it	is	possible	to	make	the	
analysis more sensitive. In this case, 1 % OSCS can still be distinguished using components 1 and 2, 
with 0.25 % lying on the fringe of the heparin library (Fig. 29, the dataset span 2.22 - 1.95 ppm, the 
area under the spectra were normalised to 1, the dataset was then mean centered and autoscaled). Us-
ing fewer components it was possible to differentiate a sample contaminated with 0.25 % OSCS from 
the heparin library (Fig. 30, component 1 [33.00 %], component 2 [27.30 %], component 3 [11.94 %] 
and component 4 [6.70 %]).
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Figure 27. OSCS gradient (coloured circles) compared to the heparin library (black circles). A gradient of OSCS (0.25 % to 100 % w/w) samples 
compared to a heparin reference library. Note that at 5 % contaminant, test spectra lay outside the body of the heparin reference spectra but, at 3 %, test 
spectra lay inside. Each PCA was performed with the spectra of the heparin reference library and a single value dilution of OSCS (practically, 3 separate 
preparations whose spectra were each recorded in triplicate). Prior to PCA, the area of each spectrum was normalised to the average spectral area of the 
dataset, the dataset was then mean-centered and Pareto scaled. The signals differentiating the heparin library from the OSCS containing samples in the 
N-acetyl region is a peak at 2.16 ppm, whereas the heparin library is dispersed by signals at ~2.04 ppm (heparin N-acetyl), ~2.08 ppm (dermatan sulfate 
N-acetyl and ~2.1 ppm (oxidation of heparin N-acetyl) respectively.
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Figure 28. PCA Loading plot for Hep library and 3 % OSCS. Addictional component analysis leads to discerne 3 % OSCS out of the library. Prior to 
PCA, the area of each spectrum was normalised to the average spectral area of the dataset, the dataset was then mean-centered and Pareto scaled.
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Figure 29. OSCS gradient (0.25-100%) compared to the heparin reference library analysed by PCA of the N-acetyl region (2.22 - 1.95 ppm), the 
area under the spectra were normalised to the average spectral area, the dataset were then mean-centered and autoscaled. Note that at 1% OSCS the test 
spectra lay outside the main body of the heparin library; by 0.25%, they lay within the library.
64 Results & Discussions
−0.3 −0.2 −0.1 0.0 0.1 0.2
−0
.3
−0
.2
−0
.1
0.
0
0.
1
0.25% OSCS: Component 1−4 loading plots
Co
m
po
ne
nt
 2
 (2
5.
01
 %
)
Component 1 (31.31 %)
−0.3 −0.2 −0.1 0.0 0.1 0.2
−0
.2
0
−0
.1
0
0.
00
0.
10
Co
m
po
ne
nt
 3
 (1
4.
38
 %
)
Component 1 (31.31 %)
−0.3 −0.2 −0.1 0.0 0.1 0.2
−0
.2
−0
.1
0.
0
0.
1
0.
2
Co
m
po
ne
nt
 4
 (7
.8
5 
%
)
Component 1 (31.31 %)
−0.3 −0.2 −0.1 0.0 0.1
−0
.2
0
−0
.1
0
0.
00
0.
10
Co
m
po
ne
nt
 3
 (1
4.
38
 %
)
Component 2 (25.01 %)
−0.3 −0.2 −0.1 0.0 0.1
−0
.2
−0
.1
0.
0
0.
1
0.
2
Co
m
po
ne
nt
 4
 (7
.8
5 
%
)
Component 2 (25.01 %)
−0.20 −0.10 0.00 0.10
−0
.2
−0
.1
0.
0
0.
1
0.
2
Co
m
po
ne
nt
 4
 (7
.8
5 
%
)
Component 3 (14.38 %)
Figure 30. Combinatorial loading plots (components 1-4) derived from the PCA analysis of the OSCS samples with the heparin library, analysis was 
performed on the N-acetyl region only, the area under the spectra were normalised to the average spectral area, the dataset were then mean-centered 
and autoscaled.
Detection of non N-acetylated sulfated polysaccharides6.1.5. 
Since the recent contamination of heparin with OSCS, many approaches for the detection and analy-
sis of contaminants have been published (Beyer et al., 2008; Sitkowski et al., 2008; Wang et al., 2008; 
Bairstow et al., 2009; Bigler and Brenneisen, 2009; Guerrini et al., 2009 [b]; Kakoi et al., 2009; Li et 
al., 2009; Liverani et al., 2009; Somsen et al., 2009; Spencer et al., 2009; Trehy et al., 2009; Volpi et 
al., 2009; Wielgos et al., 2009; Zhang et al., 2009; Bednarek et al., 2010; Beyer et al., 2010; Gemene 
and Meyerhoff, 2010; Hashii et al., 2010; Keire et al., 2010; Keire et al., 2010 [b]; McKee et al., 
2010)	most	of	which	have	concentrated	specifically	on	detection	of	OSCS.	It	has	been	previously	
shown (Beyer et al., 2008; Ruiz-Calero et al., 2000; Ruiz-Calero et al., 2002; Ruiz-Calero et al., 2002 
[b]; Rudd et al., 2009), that it is possible to differentiate porcine heparin from dermatan sulfate (Fig. 
31) and also from bovine lung (BL) heparin (Fig. 32). For both analyses prior mean-centering was 
employed, the spectral areas were not normalised and no other scaling was used. Here, we show that it 
is also possible to differentiate samples tainted with non N-acetylated polysaccharides; over sulfated 
dextran sulfate (OSDxS) and over sulfated agarose sulfate (OSAS) (Table 9; Fig. 33), which is more 
challenging because the N-acetyl group of contaminating GAGs provided a useful marker signal for 
1H NMR that was isolated from other major signals. Samples containing as little as 10 % OSDxS and 
10 %OSAS were differentiated from the current heparin library (Fig. 33). The analysis of these sam-
ples was performed by normalising the area under the spectra to the average area under the spectra 
in the dataset, the dataset was then mean-centered, vast scaled and the PCA performed. However, the 
sample containing 10 % OSAS in Fig. 34 would fail the USP proposed 1H NMR analysis (peak at 2.94 
ppm higher than 4 % of comparative signals), whereas OSDxS would pass (FDA, 2009).
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PC Exp. Var 
Hep li-
brary
Exp. Var 
OSDxS  
2%
Exp. Var 
OSDxS  
5%
Exp. Var 
OSDxS  
10%
Exp. Var 
OSDxS  
20%
Exp. Var 
OSAS  
2%
Exp. Var 
OSAS  
5%
Exp. Var 
OSAS  
10%
Exp. Var 
OSAS  
20%
C1 45.42 35.40 35.03 33.22 29.90 35.42 34.84 33.34 32.82
C2 16.80 16.33 16.21 16.43 20.84 16.37 16.29 16.23 16.13
C3 12.43 13.74 13.54 12.68 11.38 13.76 13.51 12.88 12.66
C4 6.14 7.93 7.89 8.33 10.83 7.89 7.69 7.32 8.43
C5 4.18 5.06 4.97 5.93 6.11 5.08 4.99 6.89 7.14
C6 3.76 4.26 4.22 4.64 4.09 4.27 4.28 4.72 4.62
C	>	6 11.27 17.28 18,14 18.77 16.85 17.21 18.40 18.62 18.20
Principal component Table 9. Expl. Var. values for heparin library with and without OSDxS and OSAS.
Even though PCA is an independent technique, the quality of the analysis is dependent on the sam-
ples	within	the	reference	library.	The	quality	of	the	library	clearly	influences	the	‘limit	of	detection’,	
which is something of a misnomer- ‘limit of differentiation’ might be a better term and it is important 
not to confuse this limit with limits of detection which refer to the much easier task of comparing the 
spectrum of a single sample of heparin with a spectrum of the same material containing a contami-
nant. Such a comparison would be expected to be very sensitive. Here, a reference library was em-
ployed which encompassed some of the intrinsic natural heterogeneity of porcine intestinal mucosal 
heparin. If a reference library contains pre-contaminated samples (i.e., the nature of the contaminant 
is known), this increases the sensitivity of the analysis for that contaminant, as can be seen in the 
loading plots of Fig. 35, which describes PCA of a heparin library against all the OSCS samples. The 
samples containing 3 % OSCS clearly lies outside the body of the heparin reference samples (the 
dataset was normalised to the average area under the spectra and mean-centred before PCA), whereas 
5 % lies outside the body of the heparin reference samples if PCA is performed piecemeal with each 
OSCS contaminated sample (the dataset was normalised to the average area under the spectra, mean-
centred and Pareto scaled before PCA). Therefore, if the comparison is required to estimate a known 
contaminant, rather than assess a general level of similarity between test and library samples, the 
precise method of the interrogation will change. The inclusion of the contaminants in the library tend 
to weight the variance in the dataset so that a sample tainted with the included contaminant becomes 
more	likely	to	be	found	within	the	first	two	components.	This	changes	the	question	that	is	being	asked	
from; how similar is the sample heparin to the library? to; how similar is the sample to a library of 
heparins pre-contaminated with X? These are two distinct analyses. A very useful feature of PCA is 
that with component loadings (differentiating the variables), PCA produces component scores which 
contain information about the features making up the components. In this case it is the spectral fea-
tures that differentiate the contaminated sample from the heparin reference library (Fig. 35).
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Figure 3. Component 1 Score versus Component 2 Score of the PCA of All OSCS samples and the Heparin Multiple 
Library. 
 
 
 
 
S7: DS versus Heparin Library Dataset mean centered before PCA. 
 
Figure 1. Scree plot (A) and Loading plot (B) for the PCA of DS (DS samples are brown in the loading plot) and heparin 
multiple library.  
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Figure 2. Component score plots for the PCA of DS and heparin multiple library. 
 
 
 
 
 
 
 
Figure 3. Component 1 Score v Component 2 Score for the PCA of DS and heparin multiple library. 
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Figure 31. PCA analysis for Hep library and DS. A) Scree plot [component 1 (96.30%) and component 2 (1.52 %)]; B) Loading plot for componet 1 
and componet 2, showing the clear discrimination from DS. C) Score plots, for component 1 and 2, illustrating the features that differentiate the spectra. 
Componet 1 shows that more than 95 % of the variance is described by DS feature (DS peak 2.08 ± 0.02 ppm). The dataset were mean-centered prior 
analysis.
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 S37 
S8: Bovine lung heparin (2
nd
 international standard) versus Heparin Library Data et was mean centered before 
PCA. 
 
Figure 1. Scree plot (A) and Loading plot (B) for the PCA of bovine heparin (the bovine heparin sample is cornflower blue 
in the loading plot) and heparin multiple library.  
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Figure 2. Component Score plots for the PCA of bovine heparin and heparin multiple library.  
 S38 
 
Figure 2. Component Score plots for the PCA of bovine heparin and heparin multiple library.  
Figure 32. PCA analysis for Hep library and BL 2nd heparin international standard. A) Scree plot [component 1 (36.50%) and component 2 (30.70 
%)]; B) Loading plot for componet 1 and componet 2, showing the clear discrimination from BL 2nd heparin international standard. C) Score plots, 
for component 1 and 2, illustrating the features that differentiate the spectra. Componet 1 shows BL 2nd heparin international standard characteristic 
spectrum features mainly and component 2 illustrates that pig mucosa heparin is characterised by ANA COCH3 higher content (COCH3 peak 2.05 ± 0.02 
ppm). The dataset were mean-centered prior analysis.
68 Results & Discussions
A
B
D
C
Figure 33. PCA analysis for heparin library with and without OSDxS and OSAS. A) Scree plots for heparin library with and without OSDxS gradient 
(2 %, 5 %, 10 % and 20 % OSDxS). B) Loading plots for heparin library with and without OSDxS gradient. C) Scree plots for heparin library with and 
without OSAS gradient (2 %, 5 %, 10 % and 20 % OSAS). D) Loading plots for heparin library with and without OSAS gradient. The area under the 
spectra was normalised to the average area under the spectra in the dataset, the dataset was then mean-centered, pareto scaled prior to PCA analysis. 
Note that at 10 % of OSDxS and at 10 % of OSAS the test spectra lay outside the main body of the heparin library.
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Figure 34.  1H NMR spectra of 4.1 heparin contaminated with 7 % OSCS, 10 % OSAS, 10 % OSDxS, analysed by the method outlined by USP 
heparin monoscript 2 (Materials and Methods 4.2.4; FDA, 2009) in which signals in broad regions of the spectrum are treated en masse. Heparin and 
10% OSDxS pass the test, while 10% OSAS and 7% OSCS fail (the spectral features resulting are labeled with a red asterix).
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A
B C
Figure 35. A gradient of OSCS contaminating heparin compared to a heparin library. One component differentiates heparin and OSCS (explaining 
97.30	%	of	the	variance).	The	variation	in	their	spectra	defines	the	intrinsic	variability	within	the	heparin	library	and	imposes	a	fundamental	limit	on	
the ability of the comparison to discern spectral differences between the library and any test heparin. B) Scree plot for gradient of OSCS contaminating 
heparin compared to a heparin library (PC1Expl. Var.= 97.30 % and PC2Expl. Var.= 1.00 %). C) Score ploat for gradient of OSCS contaminating heparin com-
pared to a heparin library, component 1 and 2. Before PCA the dataset was normalised to the average area under the spectra and mean-centered. 
Discussion6.1.6. 
A heparin library, comprising common European commercial heparins, was prepared and character-
ised by 1H and 1H-13C	HSQC	NMR.	Heparins	containing	modifications	induced	by	the	manufacturing	
processes (over oxidation) were also considered. 1H NMR-PCA can differentiate both OSCS con-
taminated samples from the library (5 % OSCS for analysis performed on the full spectrum and 1 % 
OSCS if performed on the N-acetyl region alone) and can also distinguish moderate (10 % OSDxS 
and 10 %OSAS) contaminated samples, which are not N-acetylated, where the USP NMR identity 
test cannot. The spectral features that differentiate the contaminated samples from a heparin reference 
library can be isolated in component score plots and could, if required, be further analysed to help 
identify	the	contaminants.	The	specific	question	that	 is	being	addressed	may	require	a	specific	set	
of compounds to be included in the reference library. For example, here, the question asked is how 
similar is a test heparin sample to the standard reference library of bona fide heparin samples under 
standardised	conditions.	In	this	sense,	the	approach	is	extremely	flexible.	One	potential	development	
would be to conduct the test of an unknown sample repeatedly against the library, contaminated on 
each occasion with a different, known contaminant (e.g. OSCS, solvents, protein, lipid etc) in order to 
facilitate	identification	of	the	unknown	contaminant.	Furthermore,	the	library	could	be	expanded	with	
samples contaminated in this way provided by the manufacturers, the aim being to cover the hetero-
geneity of pharmaceutical porcine intestinal mucosal heparins and, possibly, also heparins from other 
origins, organs and processed by a variety of manufacturing processes. This should provide a better 
model for the differentiation of heterogeneous heparin samples from contaminated heparin. 
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Effects on molecular conformation and anticoagulant ac-6.2. 
tivities of 1,6-anhydrosugars at the reducing terminal of 
antithrombin-binding octasaccharides isolated from low-
molecular-weight heparin enoxaparin
     Published in J. Med. Chem., 2010, epub ahead of print
Summary6.2.1. 
Low molecular weight heparins are widely used in clinics for prevention and treatment of throm-
boembolism (Gray et al., 2008; Linhardt et al., 2003). Here, two novel octasaccharides incorporating 
the	active	pentasaccharide	sequence	with	a	modified	aminosugar	at	the	reducing	end	were	isolated	
from enoxaparin. In these octasaccharides, the most common N-sulfo-6-O-sulfated-glucosamine resi-
due (A) at the reducing end of the ANAGA*IA sequence (Octa-3 from a previous study) is substituted 
by a 1,6-anM (Octa-5) and 1,6-anG (Octa-6) residues (Fig. 36) (Guerrini et al., 2008 [b]). Partially 
modified	ANAGA*ISA sequences are useful models to study the effects of octasaccharides structural 
variations on AT-binding (Guerrini et al., 2008 [b]). Although these two octasaccharides showed 
significantly	lower	affinity	to	AT	as	well	as	a	reduced	anti-FXa	activity	when	compared	with	the	pen-
tasaccharide	Fondaparinux	(the	α-	methyl	glycoside	of	a	synthetic	version	of	ANAGA*ISA with N-SO3 
instead of N-acetyl group at the nonreducing aminosugar residue) and with the ANAGA*ISA contain-
ing octasaccharides so far described, they display essentially the same anti-FXa activity in plasma 
and	in	buffer	solution,	which	supports	the	concept	that	they	specifically	interact	with	AT.	The	struc-
ture and conformational properties of complexes of Octa-5 and Octa-6 with AT were investigated in 
solution by saturation transfer difference (STD), transferred nuclear Overhauser effect spectroscopy 
(trNOESY) NMR experiments, while docking simulation were used to build complex geometries 
agreeing to the experimental data.
Equilibrium dissociation constants and anti-FXa activity of octasac-6.2.2. 
charides
Octasaccharides isolation and equilibrium constant measurements were done in collaboration with 
Prof. Boudier C. (Universite Louis Pasteur, Strasbourg, France). Saturation of constant amounts of 
AT by increasing quantities of Octa-3, -5, and -6 resulted in a ± 30 % increase of the protein intrinsic 
fluorescence	as	observed	for	the	pentasaccharide	ANAGA*ISA (fondaparinux), the reference product. 
Fluorescence data were satisfactorily analysed by assuming a 1:1 binding stoichiometry as already 
reported (Guerrini et al., 2008 [b]) to determine the best estimates of the equilibrium dissociation con-
stant (Kd). Its values for the various oligosaccharides: AT pairs are listed in Table 10. We found that 
in 0.05 M HEPES, 0.1 M NaCl Kd for Octa-5-AT and Octa-6-AT complexes is equal to 0.90 ± 0.08 
μM	and	1.23	±	0.06	μM,	an	affinity	about	50-	and	10-fold	lower	than	that	determined	for	the	fonda-
parinux	and	Octa-3	under	the	same	conditions:	0.021	±	0.001	μM	and	0.12	μM,	respectively.	Because	
of	their	moderate	affinity,	it	was	not	possible	to	determine	Kd for the binding of Octa-5 and -6 to AT 
in the presence of higher salt concentration. Activity measurements were done in collaboration with 
Dr.	Viskov	C.	(Sanofi-Aventis,	Paris,	France).	The	anti-FXa	activity	using	a	purified	factor	Xa	and	
AT was measured in buffer as well as in human plasma for both octasaccharides. Enoxaparin and the 
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synthetic	pentasaccharide	fondaparinux	were	tested	as	reference	agents	(Table	11).	A	specific	activity	
of	120	anti-FXa	IU/mg	in	buffer	was	measured	for	enoxaparin,	which	is	in	the	known	specification	
range (European Pharmacopea, 2008). The activity of fondaparinux of 810 anti-FXa units/mg is in 
line with historical data (Herbert et al., 1996). The anti-FXa activity in human plasma for enoxaparin 
and fondaparinux was slightly lower (13 % and 6 %) compared to that in an aqueous buffer solution. 
In contrast, Octa-5 and Octa-6 shown a lower anti-FXa activity of approximately 50 and 40 anti-FXa 
IU/mg, respectively, but no difference in their anti-FXa activity in plasma and in aqueous buffer solu-
tion.
28 
 
Table 1 Equilibrium dissociation constant Kd (µM) for the interaction of human AT with Octa-5, Octa-6 and 
Octa-3 oligosaccharides purified from enoxaparin with respect that of the pentasaccharide “Fondaparinux” 
(ARIXTRA) determined at 25 °C in 0.05 M Hepes, pH 7.4 containing 0.1, 0.25 or 0.5 M NaCl.  
[NaCl] (M) Octa-5 Octa-6 Octa-3  
0.10 0.90 1.23 0.12  0.0207 
0.25 >10!M > 10!M nd 0.279 
0.50 Nd nd 2,74  3.46 
 
 
Fondaparinux
Equilibrium	dissociation	constant	Kd	(µM)	for	the	interaction	of	human	AT	with	Octa-5,	Octa-6	and	Octa-3	oligosaccharides	purified	from	Table 10. 
enoxaparin with respect that of the pentasaccharide “Fondaparinux” (ARIXTRA) determined at 25 °C in 0.05 M Hepes, pH 7.4 containing 0.1, 0.25 or 
0.5 M NaCl. 
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Table 2 Specific anti-FXa activity measured in human plasma and aqueous buffer solution. 
Data represent mean±SEM n=5. Assay calibration was performed against the 2
nd
 
international standard for LMWH, code No. 01/608. 
 
 
anti-FXa activity (U/mg) 
Compound 
Buffer Plasma 
Enoxaparin 120.0±0.9 104.2±1.3 
Fondaparinux 810.1±10.8 761±11.3 
Octa-5 51.4±0.8 49.6±0.4 
Octa-6 39.6±0.9 39.3±0.8 
IU/mg)
Specific	anti-FXa	activity	measured	in	human	plasma	and	aqueous	buffer	solution.	Data	represent	mean	±	SEM	n=5.	Assay	calibration	was	Table 11. 
performed against the 2nd international standard for LMWH, code No. 01/608.
NMR characterisation of octasaccharides 5 and 66.2.3. 
The anomeric regions of proton spectra of Octa-5 and Octa-6 are shown in Fig. 37 (for chemical 
structure of Octa-5 and Octa-6 Fig. 36). Proton and carbon resonances (Table 12 and 13) were as-
signed using standard homonuclear correlation spectroscopy (COSY) and total correlation spectros-
copy (TOCSY) (not shown) and HSQC spectroscopy (Fig. 38 and 39). NOESY experiments were 
performed to sequentially connect saccharide ring systems (Fig. 40 and Fig. 41). The two octasaccha-
rides,	differing	in	the	C2	epimerisation	of	their	1,6-anydro-hexosamine	residues,	show	significant	1H 
and 13C chemical shift differences of 1,6-anAS resonances and of the preceding IS residues (Table 12 
and 13). Small differences of proton and carbon chemical shifts found for reducing 1,6-anAS residues 
with respect to those previously observed for disaccharides, can be ascribed to the different type of 
uronic acid to which they are linked (Table 12 and Table 13). In fact, the largest differences have been 
observed for the H4/C4 atoms, which are involved in the linkage with the I residue in octasaccha-
rides	and	with	the	2-O-sulfated	4,5-unsaturated	uronic	acid	(ΔU2S) residues in disaccharides (Table 
12 and Table 13) (Mascellani et al., 2007). The three bonds proton-proton coupling constants (3JH-H) 
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Figure 36. Structure of octasaccharides Octa-5 and Octa-6 in comparison with that of the pentasaccharide sequence of the active site for AT and 
Octa-3. Groups highlighted in the circles are essential groups for the activation of AT and those highlighted by dashed circles are also important, but not 
essential	contributors	to	affinity	for	AT.	
of the 1,6-anAS residues, measured on octasaccharides (Table 12), disaccharide and tetrasaccharide 
models (Table 14) indicate that both these residues assume the 1C4 conformation (Mascellani et al., 
2007;	Cčrny	et al., 1984).Moreover, the ROESY spectrum indicates a dipolar interaction between 
H4 and H6a of 1,6-anAS residues, which implies that the 1,6-cycle is located above the pyranose 
ring (Fig. 42). The conformation of uronate residues within and preceding the ANAGA*ISA sequence 
were analysed by 3JH-H and NOEs (Table 12 and 15). The measured values of 3JH1-H2 and of 3JH4-H5 
of unsaturated uronic acid moiety of both octasaccharides indicated a preferred 1H2 half-chair con-
formation of such residue, as observed for similar octasaccharides (Guerrini et al., 2006). In both 
octasaccharides, the measured values of 3JH1-H2 and of 3JH4-H5 of sulfated iduronic acid moiety within 
ANAGA*ISA sequence (IS) are compatible with the presence of both 1C4 and 2S0 forms contributing 
to the conformational equilibrium of these moieties, similarly to what observed in IS residues of all 
previously described octasaccharides in our laboratory (Guerrini et al., 2006; Guerrini et al., 2008 
[b]). However, the 3JH1-H2 and 3JH4-H5 values of IS measured on Octa-5 (3JH1-H2 3.3 Hz and 3JH4-H5 3.0 
Hz) and Octa-6 (3JH1-H2 3.1 Hz and 3JH4-H5 2.9 Hz) spectra are smaller than those measured on Octa-3 
(3JH1-H2 3.8 Hz and 3JH4-H5 3.1 Hz) (Guerrini et al., 2006), accounting for larger contribution of the 2S0 
form to the IS conformational equilibrium of the latter octasaccharide. This difference suggests that 
the steric hindrance generated by the reducing bicyclic anhydro ring disfavours the 2S0 form (Table 14 
A). In contrast, the nonsulfated iduronic acid residues (I) preceding the ANAGA*ISA sequence shows 
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Partial 900 MHz Figure 37. 1H-NMR spectra of Octa-5 and Octa-6. 
smaller 3JH1-H2 and 3JH4-H5 values (Table 12), compatible with a minor contribution of the 2S0 form. 
Since the 1C4 and 2S0 conformations exhibit distinct H5-H2 distances, the observed NOE value can 
be considered as marker of the presence of 2S0 conformation (Ferro et al., 1990; Ferro et al., 1986). 
In both octasaccharides, I and IS	 show	detectable	H5-H2	NOE,	which	 confirms	 a	 contribution	of	
the 2S0 form to the conformational equilibrium of these residues (Table 15).	No	significant	differ-
ence of the conformational equilibrium of I and IS between the two octasaccharides was observed.
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Table 3 600MHz proton chemical shifts (in ppm) and 
3
JHH coupling constants (in Hz) of octasaccharide-5 (a) and octasaccharide-6 (b) residues 
measured at 30°C in phosphate buffer 10mM, pH 7.4 and 0.15 M NaCl. 
3
JH1-H2 couplings in parenthesis were measured on tetra- and disaccharide 
models having 1,6anM and 1,6anG residue at the reducing end respectively (Supp. 5-7; Tab. S1-S2) 
a 
 !US A’ I ANA G A* IS 1,6-anM 
H1 5.533 5.379 5.038 5.418 4.639 5.503 5.344 5.598 
3JH1-H2 3.1 3.9 2.3 3.8 8.2 3.5 3.3 1.9 (1.8) 
H2 4.653 3.311 3.813 3.962 3.414 3.491 4.377 3.503 
3JH2-H3        5.2 (5.4) 
H3 4.353 3.674 4.157 3.798 3.732 4.411 4.237 4.085 
3JH3-H4       3.6 (<2) 
H4 6.018 3.866 4.101 3.758 3.82 4.002 4.183 4.011 
3JH4-H5 4.7  2.4    3.0  (1.6) 
H5  4.008 4.811 4.052 3.82 4.169 4.608 4.854 
3JH5-H6a        (0.9) 
3JH5-H6b        (5.9) 
H6a  4.393  4.367  4.541  4.299 
3JH6a-H6b        (7.8) 
H6b  4.245  4.241  4.284  3.797 
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b 
 !US A’ I ANA G A* IS 1,6-anG 
H1 5.544 5.390 5.046 5.428 4.652 5.491 5.355 5.661 
3
JH1-H2 3.0 3.8 2.1 3.9  3.5 3.1 (<2) 
H2 4.666 3.320 3.826 3.970 3.424 3.504 4.407 3.255 
3
JH2-H3        (<2) 
H3 4.364 3.686 4.163 3.822 3.744 4.432 4.267 3.948 
3
JH3-H4        (<2) 
H4 6.029 3.875 4.112 3.766 3.821 4.003 4.198 3.869 
3
JH4-H5 4.7  2.4    2.9 (<2) 
H5  4.010 4.823 4.061 3.821 4.541 4.696 4.868 
3
JH5-H6a        (1.2) 
3
JH5-H6b        (5.8) 
H6a  4.402  4.375  4.525  4.261 
3
JH6a-H6b        (7.8) 
H6b  4.253  4.253  4.303  3.82 
  A
 B
Proton chemical shifts (in ppm) and Table 12. 3JH-H coupling constants (in Hz) of octasaccharide-5 (A) and octasaccharide-6 (B) residues measured 
at 30 °C in phosphate buffer 10 mM, pH 7.4 and 0.15 M NaCl with a Bruker Avance 600, 600 MHz. 3JH1-H2 couplings in parenthesis were measured on 
tetra- and disaccharide models having 1,6 anM and 1,6 anG residue at the reducing end respectively (Fig. 43 and Fig. 44; Tab 14)
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Table 4 600MHz carbon chemical shifts (in ppm) of Octa-5 (a) and  Octa-6 (b) measured at 30°C  in phosphate buffer 10mM, pH 7.4 and 0.15 M 
NaCl.  
  
 
!US A’ I ANA G A* IS 1,6anM 
C1 100.22 98.48 104.83 99.83 103.86 99.15 102.39 103.76 
C2 77.41 60.03 71.40 56.64 76.39 59.45 79.68 55.03 
C3 65.67 72.48 70.50 71.40 79.18 79.12 72.57 71.16 
C4 108.91 80.97 77.57 80.18 80.1 75.82 78.75 80.83 
C5  71.32 71.92 80.1 72.45 72.34 76.48 76.58 
C6  69.03   69.03   68.79   67.83 
b 
 
!US A’ I ANA G A* IS 1,6anG 
C1 100.02 98.48 104.83 99.83 103.86 99.29 100.91 104.13 
C2 77.41 60.23 71.40 56.64 76.39 59.45 79.12 58.48 
C3 65.67 72.48 70.50 71.40 79.18 79.12 72.08 73.02 
C4 108.98 80.97 77.67 80.18 80.1 75.82 78.65 79.03 
C5  71.58 71.32 72.02 80.1 72.45 72.13 76.24 
C6   69.03   69.03   68.79   67.73 
A
B
Carbon chemical shifts (in ppm) of Octa-5 (Table 13. A) and Octa-6 (B) measured at 30°C in phosphate buffer 10 mM, pH 7.4 and 0.15 M NaCl with 
a Bruker Avance 600, 600 MHZ. 
A B
C
 Figure 38. 1H-13C HSQC spectrum of Octa-5 acquired with a Bruker Avance 600, 600 MHz. (a) anomeric region, (b) ring atoms and (c) glucosamine 
H2/C2 region.
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 Figure 39. 1H-13C HSQC spectrum of Octa-6 acquired with a Bruker Avance 600, 600 MHz. (a) anomeric region, (b) ring atoms and (c) glucosamine 
H2/C2 region.
A
B
NOESY spectra of Octa-5 acquired with a Bruker Avance 600, 600 MHz. (Figure 40. A) H5 IS region, (B) anomeric region.
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A
B
NOESY spectra of Octa-6 acquired with a Bruker Avance 600, 600 MHz. (Figure 41. A) H5 IS region, (B) anomeric region.
 	ΔU2S      A     I2S  1,6 anMNS
H1 5.513  5.383   5.531     5.568
3JH1-H2  3.1      2.5       1.8
 H2 4.633  3.305   4.343     3.476
3JH2-H3         5.0       5.4
 H3 4.316  3.666   4.253     4.049
3JH3-H4          3.4       ~2
 H4 5.922  3.844   4.103     3.988
3JH4-H5   4.7       2.6       2.8
 H5   4.032   4.558     4.821
3JH5-H6a                 0.9
3JH5-H6b                 5.9
 H6a   4.361         4.236
3JH6a-H6b                 7.8
 H6b   4.256         3.775
 	ΔU2S  1,6 anGNS
H1 5.636  5.636
3JH1-H2   2.4     ~1 
 H2 4.652  3.197
3JH2-H3   1.8    1.8 
 H3 4.302  3.818 
3JH3-H4    4.9     ~2 
 H4 6.080  3.939
3JH4-H5         nd 
 H5   4.843
3JH5-H6a        1 
3JH5-H6b       5.8 
 H6a   4.247  
3JH6a-H6b      7.8 
 H6b   3.807  
A                B
Proton chemical shifts (in ppm) and Table 14. 3JH-H coupling constants (in Hz) of (A)	ΔUS-A-IS-1,6 anM model and (B)	ΔUS-1,6 anG model residues. 
measured at 30 °C in phosphate buffer 10 mM, pH 7.4 and 0.15 M NaCl with a Bruker Avance 600, 600 MHz.
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Figure S7     600 MHz ROESY spectrum of !US-A-IS-1,6anM   tetrasaccharide model. 
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ROESY	spectra	of	ΔUFigure 42. S-A-IS-1,6 anM model measured at 30 °C in phosphate buffer 10 mM, pH 7.4 and 0.15 M NaCl with a Bruker Avance 
600, 600 MHz.
 Figure 43. 1H-13C HSQC and 1H	spectra	superimposition	of	ΔUS-1,6 anG model with peak assignment. Spectra were measured at 30 °C in phosphate 
buffer 10 mM, pH 7.4 and 0.15 M NaCl with a Bruker Avance 600, 600 MHz.
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 Figure 44. 1H-13C HSQC and 1H	spectra	superimposition	of	ΔUS-A-IS-1,6 anM model with peak assignment. Spectra were measured at 30 °C in 
phosphate buffer 10 mM, pH 7.4 and 0.15 M NaCl with a Bruker Avance 600, 600 MHz.
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Table 6   Experimental intra- and inter-residues NOESY (in parenthesis) and tr-NOESY values of 
OCTA-5  in buffer solution and in the complex with AT, at three different mixing times.  
   100m 200m 300m 
Intra-residue     
H1 !US H2 4.7 9.3 18.3 (1.6) 
H1 A’ H2 15.2 25.5  37.9 (9.0) 
H5 I H4 15.1 25.2  37.7 (5.9) 
 H2 7.0 14.7  23.1 (2.0) 
H1 ANA H2 9.6 16.4 15.6 (7.8) 
H1A* H2 17.7 28.5  44.4 (6.1) 
H5 IS H4 14.0 26.9 37.5 (5.0) 
 H2 11.7 23.0  39.2 (1.6) 
H1 1,6-anM H2 11.8 19.3 30.2 (3.0) 
Inter-residue     
H1 !US H6 A’ 3.0 7.3  12.6 (2.2) 
 H6' A’ 1.7 4.9 7.8 (0) 
 H4 A’ 9.2 15.4 24.6 (3.5) 
H1 A’ H3 I 16.5 27.3 37.7 (9.4) 
 H4 I 9.9 16.3 24.8 (5.2) 
H1 I H4 ANA  16.8 28.7 38.9 (3.4) 
H1 ANA H4 G 17.3 29.7 42.0 (4.5) 
H1 A* H3 IS 8.7 14.8 23.5 (6.1) 
 H4 IS 5.9 9.2 17.6 (4.4) 
H1 I2S H5 1,6-anM 5.2 10.3 21.8 (2.1) 
 H4 1,6-anM 14.0 23.2 39.0 (2.6) 
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Table 7   Experimental intra- and inter-residues NOESY (in parenthesis) and tr-NOESY values of 
OCTA-6  i  buffer solution and in the complex with AT, at three different mixing times.  
 
   100m 200m 300m 
Intra-residue     
H1 !US H2 6.4 10.9(nd) 22.1  
H1 A’ H2 10.7 19.9(5.4) 32.5  
H5 I H4 11.3 21.5(4.0) 27.7  
 H2 5.9 11.1(1.2) 17.5  
H1 ANA H2 9.2 13.6(4.5) 21.6  
H1A* H2 7.8 12.2(4.9) 16.5 
H5 IS H4 9.7 20.8(3.4) 30.2  
 H2 8.9 18.9(1.1) 32.5  
H1 1,6-anG H2 4.0  7.3 (0.8) 12.5  
Inter-residue     
H1 !US H6 A’ 4.4 6.4(1.2)  11.9  
 H6' A’ 2.5 3.7(nd) 7.4  
 H4 A’ 8.1 13.8(1.8) 22.6  
H1 A’ H3 I 14.0 24.0(6.6) 33.7  
 H4 I 8.0 14.4(3.4) 19.8  
H1 I H4 ANA 14.7 27.3(6.3) 41.3  
H1 ANA H4 G 12.3 21.8(2.8) 34.5  
H1 A* H3 IS 12.2 28.6(3.5) 38.2  
 H4 IS 9.5 19.4(2.6) 30.1  
H1 I2S H5 1,6-anG 6.4 11.0(1.6) 18.8  
 H4 1,6-anG 9.9 16.5(1.5) 29.2  
A       B
Experimental intra- and inter-residues NOESY (in parenthesis) and tr-NOESY values of (Table 15. A) Octa-5 in the complex with AT and (B) Octa-6 
in the complex with AT at three different mixing times. Spectra were measured at 30 °C in phosphate buffer 10 mM, pH 7.4 and 0.15 M NaCl with a 
Bruker Avance 600, 600 MHz.
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STD experiments6.2.4. 
Protocol based on STD NMR spectra is one of the most useful methods to characterise the binding 
interactions at atomic level of a ligand to a protein target. The experimental protocol is based on the 
transfer of saturation from the protein to bound ligands that, exchanging into solution between free 
and bound state, allows to utilize the free ligand signals for detection. The building block of the ligand 
having the strongest contact to the protein shows the most intense NMR signals, enabling mapping of 
the ligand’s binding epitope (Mayer and Meyer, 2001). The experiments were conducted at the proton 
frequency of 900 MHz to minimize signals overlapping and at lower sodium chloride concentration 
(0.15 M instead at 0.5 M) with respect to octasaccharides previously studied (Guerrini et al., 2008 
[b]).	The	difference	in	the	conditions	setup	is	due	to	the	lower	AT	affinity	of	these	octasaccharides.	
STD spectra of Octa-5/AT and Octa-6/AT complexes in comparison with their corresponding refer-
ence spectra are shown in Fig. 45. STD intensities are referred to the most intense STD signal of the 
spectrum (anomeric protons of A*) and the results are summarised in Table 16. 
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Table 5 Relative STD intensities at 900 MHz for Octa-5 and Octa-6 bound to AT.
a
 
 
 
H1 
!US 
H4 
!US 
H1 
A’ 
H4 
I 
H1 
I 
H1 
ANA 
H1 
A* 
H1 
IS 
H4 
IS 
H1 
1,6-anM/G 
H3 
1,6-anM/G 
H2 
1,6-anM/G 
COCH3 
Octa-5 61 35 78 70 74 89 100 (0.25) 60 66 39 48 30 30 
Octa-6 55 28 67 59 68 76 100 (0.23) 47 nd 26 36 nd 28 
a
 The STD NMR values are normalized using the H1 of N-sulfo-3,6-disulfated glucosamine (A*)  as a reference (100%). The corresponding fractional STD effect  
values of A*are shown in parenthesis 27. 
 
 
Relative STD intensities at 900 MHz for Octa-5 and Octa-6 bound to AT. The STD NMR values are normalized using the H1 of N-sulfo-Table 16. 
3,6-disulfated glucosamine (A*) as a reference (100%). The corresponding fractional STD effect values of A* are shown in parenthesis (Mayer and 
Meyer, 2001).
For both octasaccharides the largest STD effects were observed for the anomeric signal of A* and of 
the ANA residues within the pentasaccharide sequence (highlighted in bold in Table 16). Weak STD 
signals	were	observed	for	nonreducing	ΔUS residues of all octasaccharides, indicating that this resi-
due is not located in the proximity of the binding region, whereas medium intensity STD signals were 
observed for the anomeric signal of A’ and both H4 and H1 of I, also belonging from the nonreduc-
ing extension of the molecule. In contrast of what observed for previously studied octasaccharides 
(Guerrini et al., 2008 [b]), weak STD signals were observed among residues of the ANAGA*ISA moi-
ety in both Octa-5 and Octa-6. In fact, whereas the reducing -IS-A disaccharide unit of ANAGA*ISA 
sequence, similarly to the other pentasaccharide moieties, gave strong STD signals in all previously 
studied octasaccharides (i.e. Octa-3 and Octa-4, Guerrini et al., 2008 [b]), the IS-1,6-anM and IS-1,6-
anG disaccharides of Octa-5 and Octa-6 show weak STD signals (Table 16). Such an observation is 
compatible with a minor involvement of this part of the pentasaccharide sequence to the binding with 
AT. In addition, both octasaccharides shown a small STD effect for the N-acetyl signal at 2.08 ppm, 
indicating that this group is oriented toward the opposite side of the AT surface, as observed in all 
previously studied octasaccharides (Guerrini et al., 2008 [b]). No particular differences between STD 
profiles	of	Octa-5	and	Octa-6	were	observed.	The	overall	reduction	of	the	STD	intensities	(about	15-
20 %) observed for Octa-6 with respect to Octa-5 is due to a slightly different protein-ligand ratio of 
the two octasaccharide/AT complexes. 
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A
B
Figure 45. Anomeric region STD spectra of Octa-5/AT (a) and Octa-6/AT (b) complexes measured at 40:1. Reference and STD spectra are shown 
in red and blue, respectively. Spectra were measured at 30 °C in phosphate buffer 10 mM, pH 7.4 and 0.15 M NaCl with a Bruker Avance 900, 900 
MHz.
Conformations of octasaccharide/AT complexes 6.2.5. 
The increase of the proton linewidth signals observed in the presence of AT, together with a very 
small variation of chemical shifts, is consistent with an equilibrium regulated by the intermediate 
dynamic exchange between the free and bound state. The proton NMR spectra of the Octa-5/AT and 
Octa-6/AT complexes (10:1 molar ratio), in comparison with the corresponding reference spectra, are 
shown in Fig. 46 and Fig. 47, respectively. In the presence of AT, anomeric signal linewidths (H1) of 
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ANA and A* increased considerably in both octasaccharides from 5-7 Hz to 15-18 Hz (ANA) and 17-22 
Hz (A*) respectively, indicating a strong involvement of the corresponding residues in the binding. 
On the contrary, a smaller increase of linewidths of H4 of unsaturated uronate and H1 of 1,6-anAS 
residues (from about 3-4 Hz to 5-6 Hz) was observed for both octasaccharides, in agreement with the 
higher degree of freedom of these residues and their minor involvement in AT binding. Since cross-
relaxation rates differ considerably between the free and bound state, there is a great variation in the 
cross-peak intensities among two-dimensional NOESY (free state) and transferred-NOESY (bound 
state) (Table 15). The role of the conformational equilibrium of iduronate residues in the binding was 
also investigated by analysing intra-residue tr-NOE effects. NMR is particularly sensitive to the pres-
ence and relative proportion of conformers. In fact, an H2-H5 NOE was exclusively found in the 2S0 
conformer and not observed in the 1C4 form (Ferro et al., 1990; Ferro et al., 1986). Similarly to what 
observed for the previously studied octasaccharides, the H5-H2/H5-H4 NOE ratio of the 2-O-sulfated 
iduronate residue within the ANAGA*ISA	sequence	of	both	Octa-5	and	Octa-6	significantly	increases	
in the presence of AT (from 0.3 to 1), indicating that the conformation of this residue is driven toward 
the pure 2S0 form by the protein binding. On the contrary, a smaller enhancement of H5-H2/H5-H4 
NOE ratio (from 0.33 to 0.61) was observed for the I residue, suggesting that in this case AT does not 
induce a complete 2S0 conformer selection. This result partially contrasts to what observed previously 
for Octa-3 (Guerrini et al., 2006), in which the conformation of the corresponding I residue, present 
almost exclusively in the 1C4 form in free solution, was completely reversed to 2S0 form in the pres-
ence of AT.
A
B
Anomeric region of Octa-5 proton spectra with (Figure 46. B) and without AT (A) (ligand:AT molar ratio 10:1). Spectra were measured at 30 °C in 
phosphate buffer 10 mM, pH 7.4 and 0.15 M NaCl with a Bruker Avance 600, 600 MHz.
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A
B
Anomeric region of Octa-6 proton spectra with (Figure 47. B) and without AT (A) (ligand:AT molar ratio 10:1). Spectra were measured at 30 °C in 
phosphate buffer 10 mM, pH 7.4 and 0.15 M NaCl with a Bruker Avance 600, 600 MHz.
	The	observed	difference	with	unmodified	octasaccharides	could	be	attributed	to	the	steric	hindrance	
generated by the 1,6 anhydro bicyclic ring which disfavour the 2S0 form. A qualitative analysis of the 
inter-residue tr-NOEs, in comparison with NOEs measured in the absence of AT, indicates that no 
substantial difference in the glycosidic geometries occurred during the binding (Table 15). Molecular 
dynamics and docking procedures (see experimental section) are used to build models of Octa-5/AT 
and Octa-6/AT complexes. Docking procedure was repeated also on Octa-3 under the same condi-
tions. Docked structures of octasaccharide/AT complexes having ANAGA*ISA at the same position 
than observed in crystal structure, together with clusters having shifted structures along the D-helix 
of AT, were obtained. To estimate the ability of these models to reproduce the average geometries of 
the octasaccharide/AT complexes indicated by available NMR data, the magnitudes of theoretical tr-
NOEs were calculated using the CORCEMA program (Mayer and Meyer, 2001). The agreement be-
tween the theoretical and experimental tr-NOEs was estimated by calculating R factors (see Materials 
and	Methods	4.3.3.).	More	specifically,	to	evaluate	the	ability	of	our	models	to	identify	the	position	
of octasaccharide residues along the protein binding region regardless their internal conformation, tr-
NOEs of H1-H2 protons cross-relaxing within aminosugar residues were analysed. Complexes hav-
ing ANAGA*ISA at the same position observed in the structure of pentasacchairide-AT co-crystals (Jin 
et al.,	1997),	showed	a	good	fitting	between	theoretical	and	experimental	data,	whereas	those	having	
shifted	structures	along	the	D-helix	of	AT	gave	significantly	higher	R-factors	(Table	17).	Moreover,	
in disagreement with STD results, these shifted models present also the octasaccharide rotated along 
a direction parallel to the D-helix, with the N-acetyl group oriented toward the opposite side of the 
AT surface (Table 17 and Fig. 48). Docking output models of Octa-5, Octa-6 and Octa-3 that satisfy 
tr-NOE data take similar positions in the AT binding site (Fig. 49 and Fig. 50). In these assemblies 
distances between the pentasaccharide moiety and AT are on the average shorter than those between 
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the	nonreducing	ΔUS-A’-I- moiety and the protein binding region, in other words nonreducing moie-
ties are farest than reducing one (Fig. 51). However, whereas distances between the majority of sugar 
residues of Octa-5 and Octa-6 and the AT interacting aminoacids are similar to those measured for 
Octa-3, the terminal 1,6-anG/M residues are more distant from Arg46 and Arg47 than the terminal N-
sulfo-glucosamine-6-O-sulfate residue of Octa-3.
36 
 
Table 8. R-factor average values calculated  by fitting  between  experimental and theoretical tr-NOEs 
of H1-H2 protons cross-relaxing within hexosamine residues. Values were averaged for different 
octasaccharide-AT complexes obtained from docking and cluster analysis. Each complex is represented 
by an ensemble of three or four geometries with an RMSD distance less than 2Å. In brackets the error at 
the last decimal digit is given by a standard deviation measurement. R-factors calculated on a shifted 
(Octa-5 shifted) and a inverted (Octa-5 inverted) octasaccharide/AT complexes were also reported. 
Thin values indicate poor fitting with the experimental data. 
 
 A’ ANA A* 1,6-anM/G 
Octa-3 0.21(0) 0.18(3) 0.05(3) 0.13(5) 
Octa-5 0.29(0) 0.27(2) 0.21(4) 0.08(1) 
Octa-5 shifted 0.28 0.40 0.15 0.07 
Octa-5 inverted 0.40 0.39 0.50 0.31 
Octa-6 0.22(1) 0.13(1) 0.31(2) 0.04(1) 
R-factor	average	values	calculated	by	fitting	between	experimental	and	theoretical	tr-NOEs	of	H1-H2	protons	cross-relaxing	within	hex-Table 17. 
osamine residues. Values were averaged for different AT-octasaccharide complexes obtained from docking and cluster analysis. Each complex is rep-
resented by an ensemble of three or four geometries with an RMSD distance less than 2Å. In brackets the error at the last decimal digit is given by a 
standard deviation measurement. R-factors calculated on a shifted (Octa-5 shifted) and a inverted (Octa-5 inverted) AT/octasaccharide complexes were 
also	reported.	Thin	fonts	indicate	poor	fitting	with	the	experimental	data.
Octa-5/AT complex model obtained by rigid docking simulation, shifted along the AT binding site of about a disaccharide unit length (yel-Figure 48. 
low) with respect to the same molecule having the ANAGA*ISA sequence in the original position (pink). The AT binding region is shown in green.
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Superimposition of Octa-5/AT (pink) and Octa-3/AT (magenta) model complexes obtained by rigid docking simulation. The AT binding Figure 49. 
region is shown in green.
Superimposition of Octa-6/AT (yellow) and Octa-3/AT (magenta) model complexes obtained by rigid docking simulation. The AT binding Figure 50. 
region is shown in green.
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Moreover,	the	average	distance	between	the	N-sulfo	group	of	1,6-anhydro	residues	and	AT	is	signifi-
cantly larger for 1,6-anG than the 1,6-anM (about 0.75 nm versus 0.5 nm), in agreement with the low-
er	affinity	observed	for	Octa-6	(Fig. 51;	Table	10).	On	the	contrary,	the	terminal	unmodified	residue	
of Octa-3 shows an average distance from AT comparable to that of the other ANAGA*ISA residues, 
indicating its stronger involvement in the binding. These results are in a good agreement with the 
observed STD effects experimentally determined on proton signals of the same residues (Table 16).
Schematic representation of the individual side chain interactions showing average contact distances between octasaccharide residues and Figure 51. 
AT (Octa-3, Octa-5 and Octa-6 red, blue and green bars, respectively). Each distance is averaged on two or three ligand–AT contacts on the ensemble 
of four docking ligand-AT complex generated structures, selected from those that better agree with experimental data (trNOESY). Distance standard 
deviation is shown on the top of each column. Distances are taken between the heteroatom of the monosaccharide interacting group (-SO3, -COO or 
CH-OH)	and	those	of	nearest	AT	aminoacids.	Octa-3	structure	is	shown	at	the	top	of	the	figure	with	sulfated	groups	in	the	ANAGA*ISA sequence essential 
for AT binding highlighted by dashed circles.
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Discussion6.2.6. 
In the present work, two novel AT-binding octasaccharides containing an 1,6-anM and 1,6-anG resi-
due, respectively, at the reducing end (Octa-5 and Octa-6) have been isolated from enoxaparin. Even 
if the presence of terminal 1,6-anhydro rings have been previously described as a major structural 
fingerprint	of	enoxaparin	(Guerrini	et al., 2007; Mourier and Viskov, 2005), the present octasaccha-
rides have the peculiarity to bear an 1,6-anM or 1,6-anG instead of the terminal N-sulfo,6-O-sulfo-
glucosamine of the active pentasaccharide ANAGA*ISA. The AT binding properties of both Octa-5 and 
Octa-6 were measured and compared with those previously described for Octa-3 that contains the un-
modified	pentasaccharide	at	the	reducing	end.	Fluorescence	titrations	indicated	that	the	affinity	for	AT	
of these octasaccharides is characterised by equilibrium dissociation constants about 10 and 50 fold 
lower than those measured for Octa-3 and the synthetic pentasaccharide Fondaparinux, respectively 
(Table	11).	Such	an	evidence	confirms	that	the	lack	of	6-O	sulfo	group	of	the	terminal	glucosamine	
residue A of the pentasaccharide sequence ANAGA*ISA, together with the unusual conformation of 
the residue bearing the 1,6-anhydro cycle, results in weaker binding to AT. On the other hand, the 
decreasing	in	affinity	for	AT	of	Octa-5	and	Octa-6	with	respect	to	Fondaparinux	was	much	larger	than	
that observed just by the removal of 6-O-sulfo group of the terminal reducing glucosamine of the 
pentasaccharide	(van	Boeckel	and	Petitou,	1993).	Although	affinity	values	obtained	from	the	present	
and previous studies are not directly comparable due to somewhat different experimental conditions, 
the relatively larger difference found suggested that also the bicyclic structure of the 1,6-anhydro 
residues	might	 sterically	 interfere	 on	 the	 interaction	with	AT.	Reduction	 in	AT-binding	 affinity	 is	
correlated with a lower anti-FXa activity of Octa-5 and Octa-6 compared to both Fondaparinux and 
enoxaparin (Table 11). Importantly, enoxaparin shows a slight decrease in anti-FXa activity (13 %) in 
human	plasma	compared	to	measurement	in	aqueous	buffer	solution	which	could	be	due	to	unspecific	
protein binding (i.e., albumin) of some AT binding components. In contrast, the activities of Octa-5 
and	Octa-6	are	almost	the	same	in	plasma	and	in	aqueous	solution,	suggesting	a	specific	interaction	
of	both	 compounds	with	AT	 (Table	10).	This	was	 also	 confirmed	 from	STD	and	docking	 results,	
showing that the closest contacts with AT involve the residues of the octasaccharide belonging to the 
sequence ANAGA*ISA and correspond to the ANAGA*- moiety for both Octa-5 and Octa-6. On the 
contrary of what observed for Octa-3 (Guerrini et al., 2008 [b]), weaker STD signals for the terminal 
-IS-1,6-anM/G disaccharides with respect to those of the -AGA*- moiety were observed, indicating 
a larger distance of these residues from AT. Moreover, only model outputs having the ANAGA*ISA 
sequence in the same position adopted in the pentasaccharide/AT complex can interpret both STD and 
tr-NOE	data	(Linhardt	and	Gunay,	1999).	Although	our	models	are	not	sufficiently	accurate	to	define	
the	complex	at	atomic	level	precision	due	to	the	lack	of	suitable	molecular	dynamic	force	field	de-
scription able to satisfy conformational behaviour of highly charged molecules (Forster and Mulloy, 
2006), they clearly show that the -ANA- G-A*-IS sequence of the pentasaccharide moiety is in closer 
contact	with	AT	 than	 the	 trisaccharide	moiety	ΔUS-A’-I- at the nonreducing end and the terminal 
1,6an-AS residues at the reducing end (Fig. 51). Beside the larger average distances between AT ami-
noacids and terminal 1,6-anM/G residue measured for both Octa-5 and Octa-6 with respect to Octa-3, 
significant	differences	were	found	between	the	two	isomers.	Octa-6	shows	higher	averaged	distance	
between the N-SO3 group of its terminal residue and both Arg46 and Arg47 with respect to Octa-5 (Fig. 
51),	paralleling	the	lower	affinity	to	AT	measured	for	this	octasaccharide.	The	single	interaction	of	
the N-SO3 group in terminal 1,6-anhydro residues is expected to reduce the strength of ionic interac-
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tions	between	the	reducing	part	of	 the	pentasaccharide	and	AT	with	respect	 to	unmodified	N,6-O-
sulfated glucosamine. However, even if the absence of the 6-O-sulfo group in the terminal A residue 
reduces	the	affinity	to	AT	(van	Boeckel	and	Petitou,	1993),	no	ionic	interactions	have	been	observed	
between this group and positively charged aminoacid of AT (Petitou et al., 2004; van Boeckel and 
Petitou,	1993).	The	observed	higher	affinity	of	ANAGA*ISA containing oligosaccharides, due also to 
the contribution of the 6-O-sulfo group on the terminal A residue, can be explained by the increasing 
of population of the skew 2S0 conformer of the neighbour IS residue (Ferro et al., 1990), as indicated 
by different 3JH-H values of IS measured on Octa-3 with respect to those of Octa-5 and Octa-6 (Guerrini 
et al.,	2006).	In	fact,	the	higher	affinity	to	AT	of	an	heparin	pentasaccharide,	bearing	an	extra	sulfate	
group at C3 of the terminal A residue, was proposed to be the consequence of a high population (about 
90%) of the 2S0 conformer (Petitou et al., 1991). Moreover, the present results suggest that the manno 
configuration	of	the	1,6-anhydro	residues	promotes	a	better	interaction	with	AT	with	respect	to	the	
gluco form due to its favourite position of the N-SO3 group (Fig. 51). Despite their modest anti FXa 
activity,	those	1,6	anhydro	modified	oligosaccharides	display	a	specific	antithrombotic	activity	which	
cannot	be	neglected	in	the	overall	biological	profile	of	the	LMWH	complex	mixture.	From	a	practi-
cal point of view, since the depolymerisation condition used to prepare enoxaparin strongly affect the 
content of 1,6-anhydro residues, as well as the relative contents of their manno and gluco epimers, 
control of the overall composition and activity requires an accurate optimisation of the manufacturing 
procedures. A more detailed understanding of the role of structural variations on AT binding proper-
ties of heparin oligosaccharides may help in the synthesis of ligand analogues and in the design of 
new	LMWHs	with	an	appropriate	structure	to	ensure	high	affinity	to	AT.	However,	structural	refine-
ment of the obtained structures by means of methods such as full molecular dynamics simulations or 
ab-initio calculations is also necessary to fully interpret experimental data.
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Role of glycosaminoglicans in Alzheimer progression6.3. 
Summary6.3.1. 
Proteoglycans are associated with all the types of amyloid deposits in the human body. In particular 
HS chains, have been reported to be involved in the pathogenesis of Alzheimer’s disease, including 
the genesis of senile plaques, cerebrovascular amyloids and neurofribrillary tangles. Despite the large 
body of data supporting the importance of HS in amyloidogenesis, little is known about the precise 
mechanism by which HS promotes amyloid formation and the effect that this GAG has on the various 
phases of the aggregation process and on the overall aggregation pathway. It has been demonstrated 
that in vitro enoxaparin, a LMWH, is as capable as heparin of attenuating the neurotoxicity and 
proinflammatory	activity	of	Aβ1-42 (Bergamaschini et al., 2002). In vivo prophylactic treatment with a 
clinically relevant dose of enoxaparin reduces reactive astrocytosis and the deposition and total brain 
concentration of amyloid peptides in two different mouse models (Dudas et al., 2002; Bergamaschini 
et al., 2004). Detailed characterisation of HS-oligomers/protein interactions at the molecular level 
may provide useful information to the generation of drugs against amyloid diseases. In order to unveil 
the	molecular	basis	of	Aβ1-40 -GAG	interactions,	we	followed	Aβ1-40 aggregation with and without 
different heparin oligosaccharides; to identify possible inhibitors of HS, we have undertaken a study 
on	the	influence	of	chain	length	and	detailed	structure	of	heparin	oligosaccharides	on	the	aggregation	
of amyloid peptides. To this purpose, the interaction with amyloid peptides with a number of heparin 
oligosaccharides systematically differing in molecular size are being investigated using an advanced 
DLS approache. DLS methods permit to determine the size of molecular aggregates in solution.
Hep, LMWH and derived oligosaccharides preparation and charac-6.3.2. 
terisation
Prior to the interaction investigations, a complete NMR characterisation of the GAGs involved was 
performed. LMWHs were previously characterised by 2D NMR in our laboratory (Bisio et al., 2009; 
for a complete 1D/2D NMR characterisation of UFH and LMWHs see Fig. 52, Fig. 53, Fig. 54 and 
Fig. 55) and by size exclusion chromatography (SEC, Fig. 56), underlining some interesting fea-
tures: enoxaparin has the lowest MW and is mainly composed of oligosaccharides with a degree of 
polymerisation (dp) between 6 and 12; more than the 50 % of tinzaparin is composed of oligosac-
charides	>	dp	18;	dalteparin	lacks	of	oligosaccharides	<	dp	6	with	a	molecular	weight	(MW)	interme-
diate between enoxaparin and tinzaparin (Fig. 53). HP-SEC/ TDA analysis shown that: enoxaparin 
is	composed	of	the	lowest	percentage	of	oligosaccharides	with	MW	>	8000	Da	(10	%),	followed	by	
dalteparin (30 %) and tinzaparin has the highest content of big oligosaccharides compare to the other 
two LMWHs (46 %) (Fig. 56). In order to obtain oligosaccharides well characterised, one batch of 
commercial unfractionated heparin (UFH) was depolymerised through deaminative reduction treat-
ment	 and	 fractionated	 by	 SEC	 (leading	 to	 the	 purification	 of	 oligosaccharides	with	 2,5	 anM6S as 
reducing end); one batch of commercial LMWH (Tinzaparin) was fractionated by SEC (obtaining 
oligosaccharides with homogeneous size) and obtaining a complete oligosaccharides panel from dis-
accharide to dodecasaccharide. Hexasaccharide [(T) dp 6] and decasaccharide [(T) dp 10] derived 
from tinzaparin, were characterised by 1D and 2D NMR, disaccharide derived from UFH depolym-
erisation (Hep dp 2) were characterised by 1D and 2D NMR spectroscopy: 1D/2D assignments for 
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Figure 52. Full assignment of HSQC spectra of UFH. A and B panels show UFH HSQC full window and anomeric region spectra, respectively; UFH 
(40 mg/mL in D2O) spectra were acquired with Bruker Avance 500, 500 MHz spectrometer at 35 °C; L.R= linkage region. H1= H atom links to sac-
charidic C1 atom; H2= H atom links to saccharidic C2 atom; H3= H atom links to saccharidic C3 atom; H4= H atom links to saccharidic C4 atom; H5= 
H atom links to saccharidic C5 atom; H6= H atom links to saccharidic C6 atom.
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Full assignment of HSQC spectra of enoxaparin Figure 53. A and B panels show enoxaparin HSQC full window and anomeric region spectra; enoxa-
parin (40 mg/mL in D2O) spectra were acquired with Bruker Avance 500, 500 MHz spectrometer at 35 °C; L.R= linkage region. H1= H atom links to 
saccharidic C1 atom; H2= H atom links to saccharidic C2 atom; H3= H atom links to saccharidic C3 atom; H4= H atom links to saccharidic C4 atom; 
H5= H atom links to saccharidic C5 atom; H6= H atom links to saccharidic C6 atom.
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Full assignment of HSQC spectra of tinzaparin. Figure 54. A and B panels show tinzaparin HSQC full window and anomeric region spectra, respec-
tively; tinzaparin (40 mg/mL in D2O) spectra were acquired with Bruker Avance 600 spectrometer equipped with cryoprobe at 600 MHz at 30 °C; L.R= 
linkage region. H1= H atom links to saccharidic C1 atom; H2= H atom links to saccharidic C2 atom; H3= H atom links to saccharidic C3 atom; H4= H 
atom links to saccharidic C4 atom; H5= H atom links to saccharidic C5 atom; H6= H atom links to saccharidic C6 atom.
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Full assignment of HSQC spectra of dalteparin. Figure 55. A and B panels show dalteparin HSQC full window and anomeric region spectra, respec-
tively; dalteparin (40 mg/mL in D2O) spectra were acquired with Bruker Avance 600 spectrometer equipped with cryoprobe at 600 MHz at 21 °C; L.R= 
linkage region. H1= H atom links to saccharidic C1 atom; H2= H atom links to saccharidic C2 atom; H3= H atom links to saccharidic C3 atom; H4= H 
atom links to saccharidic C4 atom; H5= H atom links to saccharidic C5 atom; H6= H atom links to saccharidic C6 atom.
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tion. The column was finally washed with 70 ml of equilibrium 
buffer. All the effluent fractions from AT-Sepharose column were 
analysed for uronic acid content by the carbazole reaction (24). 
In each colorimetric assay, the calibration curve was built up 
with an amount of the same LMWH solution loaded onto AT-sep-
harose column. 
Subfractionation of HA fractions 
To separate HA fractions into subfractions having graded affin-
ity toward AT, a preparative AT-Sepharose column was over-
loaded with an amount of LMWH (50 mg) corresponding to 
three times the retention capacity of the resin. After a first chro-
matography, performed as described above, buffer at high ionic 
strength eluted the first HA fraction, named HA1, whereas 
buffer at lower ionic strength eluted a fraction composed by both 
heparin chains devoid of affinity for AT and chains exceeding the 
retention capacity of the resin. This material was loaded again 
onto the column and eluted under the same conditions as above: 
HA2 and a second flow-through fraction were obtained. The re-
loading procedure was repeated twice again until no HA fraction 
was retained by the column. A further HA fraction (HA3) and a 
final fraction depleted of affinity for AT (NA), were obtained. All 
the fractions were analysed for uronic acid content by the carba-
zole reaction. Finally, fractions HA and NA were desalted first 
by ultrafiltration through Amicon chamber (160 ml) with a 500 
Da cut off Millipore filter, then by size exclusion chroma-
tography with TSK-gel HW40S column (2.6 x 58 cm). To re-
move the traces of Tris a cation-exchange chromatography was 
finally performed on Amberlite IR-120 [H+] column (2 x 12.5 
cm). Samples were neutralised with 0.1 N NaOH. 
Molecular weight evaluation 
Molecular weight determinations were performed by HP-SEC-
TDA on a Viscotek (Houston, Texas) instrument equipped with a 
VE1121 pump, Rheodyne valve (100 µl), and triple detector 
array 302 equipped with RI, viscometer, and light-scattering 
(90° and 7°) systems. A G2500 and G3000 7.8mm x 30 cm TSK 
GMPWXL Tosoh columns were used with 0.1 M NaNO3 as 
eluent (flow, 0.6 ml/min). Samples were dissolved in the eluent 
solution at 5 mg/ml. Chromatogram analysis was performed 
with OMNISEC 4,1 software, all molecular weight parameters 
were obtained, number-average mean molecular weight (Mn), 
weight-average mean molecular weight (Mw), and polydisper-
sity (Mw/Mn, D), of each sample. 
NMR spectra 
Spectra were recorded at 25°C on a Bruker Avance 600 spectro-
meter (Karlsruhe, Germany) equipped with 5-mm TCI cryo-
probe. In proton spectra water signal was presaturated during re-
laxation delay. Samples were prepared by dissolution of 2–10 mg 
of heparin in 0.6 ml of deuterium oxide. A recycle delay of 10 
seconds and from 32 to128 number of scans were used, depend-
ing on the sample amount. Two-dimensional heteronuclear 
single quantum coherence (2D-HSQC) spectra were recorded 
with carbon decoupling during acquisition with 320 increments 
of 32–64 scans for each. The polarisation transfer delay (D = 1/[2 
· 1JC–H]) was set with a 1JC–H coupling values of 150 Hz. The ma-
trix size 1K x 512 was zero filled to 4K x 2K by application of a 
squared cosine function prior to Fourier transformation. Inte-
gration of peak volumes was made using standard Bruker TOP-
SPIN 2.0 software. The monosaccharide composition was calcu-
lated following the procedure previously published (13). The 
average degree of polymerisation (dp) is calculated through the 
ratio between the total volume of anomeric signals (uronic acids, 
glucosamines and LR residues) and that of anomeric signal resi-
dues at the reducing end (including the first galactose residue of 
LR at 104.0/4.526 ppm) (25). Mn is obtained by multiplying dp 
value by the average Mw of disaccharide (calculated by NMR 
considering the average acetylation and sulfation degree). 
Figure 1: Gel permeation elution profiles on Bio-gel P10 of the 
three LMWHs studied. 
Oligosaccharides Enoxaparin Tinzaparin Dalteparin
dp 1 to dp 2 3.6 % 1.6 % n.d.
dp 3 to dp 4 8.9 % 3.5 % n.d.
dp 6 10.7 % 4.9 % n.d.
dp 8 17.8 % 5.1 % n.d.
dp 10 12.7 % 6.1 % 10.0 %
dp 12 10.1 % 5.1 % 11.0 %
dp 14 0.5 % 7.5 % 9.2 %
dp 16 9.3 % 7.1 % 17.2 %
dp 18 20.4 % 7.6 % 12.6 %
>	dp	18 6.0 % 51.5 % 40.0 %
LMWH Mn MW D % > 8000 Da
Enoxaparin 3800 5300 1.30 10
Tinzaparin 5900 8300 1.40 46
Dalteparin 5700 6900 1.22 30
A        B
C
Hep dp 2 1D and 1D/2D assignment are shown in Fig. 57, whereas (T) dp 6 and (T) dp 10 1D and 1D/2D 
assignment are shown in Fig. 58; Hep dp 2 HSQC analysis demonstrated that the sample is a pure solution 
of disa charide (there is a single signal in the anomeric region belong to the IS, see red circled anomeric 
signal in Fig. 57). Proton spectra of hexasaccharide and decasaccharide tinzaparin derived shown that 
they are mixture of different sequences and also mixture of hexa/octasaccharide and deca/dodecasac-
charide, respectively, with pr vale ce of hexasaccharide for (T) dp 6 and decasaccharide for (T) dp 10. 
This	reflects	tinzaparin	heterogeneity.	This	permit	to	study	the	dependency	of	Aβ1-40-GAGs interaction 
from	GAGs	chain	length.	Actually,	the	interaction	studies	of	Aβ1-40 with Hep oligosaccharides will give 
information on the importance of the oligosaccharides length and not on oligosaccharides structures. 
Informations about oligosaccharidic structure and/or sulfation/acetylation pattern on protein-GAGs in-
teractions can be obtained using homogeneous oligosaccharide, but the isolation of a single molecular 
population from an heterogeneous pool it is a demanding task and it is out of the objectives of this work. 
Chromatographic characterisation of LMWH. Figure 56. A. Biogel p10 SEC 
profile	of	enoxaparin,	tinzaparin	and	dalteparin.	B. Molecular weight param-
eters determined via HP-SEC/ TDA for enoxaparin, tinzaparin and dalteparin. 
The last column reports oligosaccharide percentage composing LMWH with 
MW	>	8000	Da	C. Evaluation of the relative abundance of the oligosaccharidic 
components of enoxaparin, tinzaparin and dalteparin (weight %) (n.d. not de-
tected). All the percentages were calculated on the basis of the weight recovery 
after the biogel p10 column.
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 NMR investigation of Hep dp 2. Figure 57. A Hep dp 2 1H spectrum with full peaks assignment; B Hep dp 2 1H -13C HSQC with full peaks assign-
ment; Hep dp 2 (33.5 mg/mL) spectra were acquired with Bruker Avance 600, 600 MHz spectrometer, equipped with cryoprobe at 21 °C. Red circled 
anomeric signal shows the only anomeric signal, demonstrating disaccharide purity. H1= H atom links to saccharidic C1 atom; H2= H atom links to 
saccharidic C2 atom; H3= H atom links to saccharidic C3 atom; H4= H atom links to saccharidic C4 atom; H5= H atom links to saccharidic C5 atom; 
H6= H atom links to saccharidic C6 atom.
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NMR investigation of hexasaccharide [(T) dp 6], decasaccharide [(T) dp 10] tinzaparin derived. Figure 58. A (T) dp 6 1H/1H-13C HSQC spectra 
superimposition with anomeric and other majors peaks assignment; B (T) dp 10 1H1H/1H-13C HSQC spectra superimposition with anomeric and other 
majors peaks assignment. Hep dp 2 (33.5 mg/mL), (T) dp 6 (11.5 mg/mL) and (T) dp 10 (4.7 mg/mL) spectra were acquired with Bruker Avance 600, 
600 MHz spectrometer, equipped with cryoprobe at 21 °C. Dashed arrows are threshold peak intensity levels, below those levels peak signals were not 
take in account for HSQC. H1= H atom links to saccharidic C1 atom; H2= H atom links to saccharidic C2 atom; H3= H atom links to saccharidic C3 
atom; H4= H atom links to saccharidic C4 atom; H5= H atom links to saccharidic C5 atom; H6= H atom links to saccharidic C6 atom.
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A6.3.3. β1-40 aggregation kinetics is time dependent and chemo-physical 
condition dependent
Amyloid peptides tends to form protein aggregations; the properties of this phenomena are time de-
pendent	(the	probability	that	two	or	more	monomer	of	Aβ1-40 peptide interact to each other, leading 
to a dimer or oligomer formation, increases as much as the time pass) and concentration dependent 
(higher the monomer/oligomer number in the solution higher the probability to have an interaction 
with the consequence of oligo/polymer formation). It is well known that the transient and prolonged 
misfolding	nature	of	Aβ1-40	makes	it	difficult	to	perform	proper	in vitro studies and obtain consistent 
results	(Kim,	2010).	From	monomers	to	fibrils,	the	aggregated	form	of	Aβ1-40	is	a	significant	hallmark	
in the Alzheimer's disease (AD) cascade and becomes the valuable targets for early diagnosis and 
therapy	for	AD.	Thus,	the	development	of	optimised	in	vitro	fibrillogenic	conditions	to	induce	the	
desired	Aβ1-40 states is essential, as a consequence different solubilisation conditions were tested to 
obtain	the	best	monomer/polymer	ratio	as	starting	point.	Information	regarding	the	size	of	Aβ1-40 and 
the rate of growth can be obtained using laser light scattering (Tomski and Murphy, 1992; Shen et al., 
1993; Murphy and Pallitto, 2000; Di Fede et al., 2009). Dynamic light scattering probes length scales 
on the order of 0.5- 830 nm, making it appropriate for measuring amyloid aggregates. DLS aggrega-
tion kinetics measurements were performed in different chemo-physical condition to demonstrate 
aggregation state dependency from environmental conditions: hydrodynamic radius (Rh) of 23	μM	
Aβ1-40 in H2PO4 and H(PO4)2 100mM solutions at a constant temperature of 25 °C at different pH was 
measured	for	75	h	(Fig.	55).	Acid	pH	(it	means	fully	protonated	protein)	protects	Aβ1-40 from aggrega-
tion with an average initial Rh (t0 Rh)= 61.1 ± 8.5 nm suggesting the presence of a polymer of about 
25	units	(Aβ1-40 monomer Rh= 2.4 ± 0.5 nm), it undergone notable change in molecular population 
state, nevertheless it did not show reliable sign of aggregation, because after 35 h the system led its 
stability (t35 Rh=	101.9	±	14.3	nm/final	Rh, t75 Rh=	120.4	±	16.8	nm).	Neutral	pH	keeps	Aβ1-40 in lower 
aggregation state at starting point (t0 Rh= 50 ± 0.5 nm), but after 24 h aggregation began. Basic pH 
brings the system to an intermediate oligomer state (Rh ~85 ± 0.5 nm), but just after 13 h Rh increased 
showing aggregation (Fig. 59).	The	differences	between	the	kinetics	are	explainable	as	follow:	Aβ1-40 
amino-acid	side	chains	protonation	states	affect	protein	folding,	Aβ1-40 explores different possibilities 
in	order	to	find	the	more	stable	one	and	when	the	system	reaches	the	stable	condition,	the	aggregation	
phenomena starts (between 5 h and 15 h at pH 9, between 25 h at pH 7; a little trend for Rh increasing 
was	measured	until	25	h	after	that	the	system	was	stable).	Aβ1-40 at pH 7 shown higher mobility re-
spect the other two experimental conditions, the aggregation curve slope changed three times during 
the	experiment	(it	cannot	be	found	a	singular	regression	curve,	aggregation	curve	must	be	fitted	with	
three	different	equations:	between	0	h	and	25	h	it	is	possible	to	find	a	0.75	angular	coefficient,	between	
25	h	and	40	h	it	is	possible	to	find	a	11.27	angular	coefficient	and	between	40	h	until	the	end	it	is	pos-
sible	to	find	a	5.66	angular	coefficient).	Aβ1-40 aggregation at pH 9 was measurable just after 5 h from 
experiment beginning, but a constant Rh increase is measurable after 15 h from protein solubilization 
(see Fig. 59). Aggregation kinetics investigation performed by dynamic light scattering demonstrated 
how protein protonation state affect the kinetics aggregations, to better understand what happened at 
molecular	level,	it	is	mandatory	to	analyse	Aβ1-40 local	and	total	charge	profiles,	Table 17.
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PB pH 2 PB pH 7 PB pH 9 
Time (h) Rh (nm) St. Dev. Rh (nm) St. Dev. Rh (nm) St. Dev.
0 61.1 8.5 34.7 4.9 57.2 8.0
5 97.9 13.7 42.2 5.9 90.0 12.6
10 85.7 12.0 44.6 6.2 92.7 11.0
15 103.6 14.5 39.7 5.6 97.1 12.8
20 110.3 15.4 44.5 6.2 125.5 17.3
25 99.3 13.9 60.7 8.5 130.8 18.3
30 138.6 19.4 117.0 16.4 143.2 18.4
35 101.9 14.3 171.3 24.0 170.4 23.8
40 93.4 13.1 230.4 32.2 210.4 29.4
45 104.7 14.6 253.8 35.5 226.9 31.7
50 92.8 13.0 281.8 26.3 244.9 34.3
55 114.5 16.0 319.7 44.7 272.0 38.0
60 116.0 16.2 348.3 48.7 291.5 40.8
65 117.4 16.4 374.6 52.4 309.5 43.3
70 118.9 16.6 399.0 55.8 326.1 45.6
75 120.4 16.8 421.6 59.0 341.6 47.8
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Figure 59. Aβ1-40 aggregation kinetics at different pH. A Rh	values	from	DLS	measurements.	Aβ1-40 (0.1 mg/mL) were kept at 25 °C for the entire 
experiment duration. B. plotted Rh	values	from	DLS	measurement	of:	black	line	and	circles	represent	Aβ1-40 Rh at pH 2, red line and circles represent 
Aβ1-40 Rh at	pH	7	and	purple	line	and	asterisks	represent	Aβ1-40 Rh at pH 9. The red arrow shows protein aggregation beginning at pH 7 and the purple 
arrow shows protein aggregation beginning at pH 9. Rh values	were	sampled	every	hours	and	they	are	the	media	of	three	different	experiments.	Aβ1-40 
(23	μM)	was	kept	at	25	°C	for	the	duration	of	the	entire	experiment.
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Charge_profile
1° 2° 3° 4° 5° 6° 7° 8° 9° 10° 11° 12° 13° 14° 15° 16° 17° 18° 19° 20° 21° 22° 23° 24° 25° 26° 27° 28° 29° 30° 31° 32° 33° 34° 35° 36° 37° 38° 39° 40°
TOT 
charge
AA D A E F R H D S G Y E V H H Q K L V F F A E D V G S N K G A I I G L M V G G V V
Charge pH 2 1 0 1 0 0 1 1 0 0 0 1 0 0 1 1 0 7
Charge pH 4 -1 -1 1 0 -1 1 1 0 0 0 1 0 -1 1 1 -1 1
Charge pH 6 -1 -1 1 -1 -1 1 1 0 -1 -1 1 -1 -1 1 1 -1 -3
Charge pH 7 0 -1 1 -1 -1 1 1 -1 -1 -1 1 -1 -1 1 1 -1 -3
Charge pH 9 0 -1 1 -1 -1 1 1 -1 -1 -1 1 -1 -1 1 1 -1 -3
Pagina 1
Table 18. Aβ1-40 sequence	charge	profiles	at	different	pH.	In	the	second	raw	it	was	reported	1-letter	aminoacid	code,	the	arbitrary	colour	code	stands	
for: blue letters represent aminoacid with acid side chains, red letters represent aminoacid with basic side chains, yellow cells represent a positive charge 
and green cells represent a negative charge.
The peptide is characterised by a neutral region at the C-term except for Val40 that acquire a negative 
charge from pH 4; the N-term part is the most affected by protonation/deprotonation phenomena, in 
fact	high	acidity	condition	(pH	≤	2)	preserves	the	stability	of	H-bond	so	α-helix	structure	might	be	
favoured	[N-term	secondary	structure	is	not	yet	defined,	because	most	of	the	efforts	have	been	done	
to understand C-term structure changing (Riek et al., 2001; Roychaudhuri et al., 2008; Triguero et 
al.,	2008)].	This	putative	structured	region	does	not	fit	properly	with	aggregation	mechanism,	accord-
ing to DLS data, average Rh did not undergo big changes during experimental time. As much as the 
pH became neutral/basic, some amino-acid side chains undergo protonation state change: Asp1, Glu3, 
Arg5, His6, Glu7, Ser8, Tyr10, Glu11, His13, His14, Lys16, Glu22 and Asp23; this leads to N-term internal 
charge neutralisation and H-bond destabilisation that became more pronounced at pH 7 caused to the 
absence of local charge on Asp1 and to the sequence of positive and negative charges characterising 
the peptide from Glu3 to Glu11 (neutral pH induces the formation of different salt bridges through pep-
tide at N-term segment: Glu3- Arg5, Arg5 - His6, Asp7- Ser8, Tyr10- Glu11 and His14- Lys16). It was shown 
that Asp23	is	a	key	residue	for	the	formation	of	the	β-structure	(Petkova	et al., 2002; Urbanc et al., 
2004; Urbanc et al., 2004 [b]), in fact Asp23 deprotonation induced by neutral pH creates the condi-
tion for salt bridges formation (Asp23-Lys28),	this	induces	folding	rearrangement	leading	to	β-structure	
formation	and	stabilisation,	protecting	Aβ1-40 in a pro-aggregation condition. According to DLS data 
amino-acids deprotonation (neutral condition) causes Rh increase (pro-aggregation condition) due to 
H-bond	breakage	and	α-helix	destabilisation	after	amino-acids	deprotonation	(the	following	amino-
acids are deprotonated at pH 7: Glu3, His6, Asp7, Glu11 and His14). Aggregation in basic condition 
happened	at	faster	rate,	anyway	there	is	no	change	in	charge	profile	(Table	17),	this	could	be	due	to	
dramatically change in chemical equilibrium between the structures explored by molecules, in fact Rh 
increase at pH 9 was triggered in the half time compare to the DLS aggregation kinetics at pH 7 (Fig. 
55).	Together	this	data	shown	that	Aβ1-40 aggregation is time dependent and chemo-physical depend-
ent, moreover they demonstrated what is the best chemo-physical condition to study the alteration 
of	Aβ1-40 aggregation: buffer solution at pH 7 allows to measure peptide aggregation (starting from 
25	h),	the	initial	and	final	monomer/oligomer	dimensions	are	in	the	order	of	magnitude	to	eventualy	
show aggregation perturbations by external agents (Hep and mimetics) and it gives the opportunity to 
study in vitro an in vivo phenomena in reliable conditions (pH and salt concentration).
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Experimental condition affects Aβ6.3.4. 1-40 aggregation kinetics
Aggregation is a concentration dependent phenomenon, for this reason protein concentration at start-
ing point is extremely important for kinetics; to test the reliability of previously shown aggregation 
data, experimental conditions were changed and aggregation progression was measured by DLS: re-
cently it was shown that is possible follow a fast aggregation kinetics using NaOH (as solubilisation 
solution) and TRIS-HCl pH 7 (as buffer solution) at 37 °C with a low aggregation state as starting 
point (Di Fede et al.,	2009),	so	Aβ1-40 was prepared in NaOH 10mM, TRIS-HCl 100 mM, pH 7 and 
aggregation	kinetics	was	followed	for	75	h	and	later	on	compared	to	Aβ1-40 aggregation in PB. Two 
preparations	were	tested:	23	μM	Aβ1-40 in	NaOH	10mM,	TRIS-HCl	100	mM,	pH	7	and	462	μM	Aβ1-
40 in NaOH 10mM, TRIS-HCl 100 mM, pH 7 (Fig. 60).	The	first	interesting	thing	is	that	change	in	
solubilization condition led to a better oligomer stabilisation: t0 Rh are different in the three different 
conditions, but, at the same concentration, TRIS solubilisation shown a more pronounced effect over 
aggregation protection compare to PB solubilisation (the starting aggregation state is higher for TRIS 
solubilisation	(23	μM	Aβ1-40 in PB t0 Rh=	34.7	nm;	23	μM	Aβ	in	TRIS	t0 Rh= 162.8 nm). Aggregation 
progression	profiles	are	completely	different,	in	fact	the	fold	aggregation	state	(f.a.s.,	ratio	between	t75 
Rh and t0 Rh)	of	Aβ1-40	solubilsed	in	PB	is	much	higher	than	the	f.a.s.,	of	Aβ1-40 solubilsed in TRIS (23 
μM	Aβ1-40	in	PB	f.a.s.=	12.4,	whereas	23	μM	Aβ1-40 in TRIS f.a.s.= 2.03). Notably, higher temperature 
does	not	seem	to	affect	TRIS	aggregation	protection	(aggregation	experiment	of	23	μM	Aβ1-40 in TRIS 
was performed at 37 °C; higher temperature means more kinetics energy, this condition should induce 
a	pro-aggregation	condition,	because	Aβ1-40 monomer-monomer interactions happened at higher ra-
tio) (Fig. 60).	As	it	shown	in	Fig.	60	Aβ1-40 at low or high concentration is stable at least for 40 h if it 
is buffered with a TRIS solution, instead the aggregation started after only 25 h in PB; also see Fig. 
59).	Aβ1-40 at higher concentration shown a completely different aggregation behaviour, because the 
t0 Rh	of	462	μM	Aβ1-40 buffered with TRIS was an intermediate value compare to t0 Rh	of	23	μM	Aβ1-40 
conditions (Fig. 60). It was stable for the first 40 h, but between 45 h and 55 h it shown a dramatic Rh 
increase	showing	a	clear	hallmark	of	fast	and	complete	aggregation.	This	last	condition	(Aβ1-40 462 
μM,	NaOH	10	mM,	TRIS-HCl	pH	7,	25	°C)	was	selected	to	performed	amyloid	interaction	studies	
with GAGs. In this condition protein stability is guaranteed for 40 h (much more than the 24 h need 
from the peptide to aggregate in the PB solubilisation condition), the inhibition or attenuation of the 
aggregation induced by an external agents (as Hep or mimetics/derivatives) must continues over this 
lag time phase, assuring the efficacy of the treatment. Taken together the solubility investigations sug-
gest	that	a	better	experimental	setting	to	study	Aβ1-40 aggregation progression is represented by a not 
phosphated	buffer	with	higher	Aβ1-40 starting concentration.
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A
B
Time (h) Rh (nm) St. Dev Rh (nm) St. Dev Rh (nm) St. Dev
0 34.7 4.9 162.8 22.8 57.8 8.1
5 42.2 5.9 169.0 23.6 96.6 13.5
10 44.6 6.2 230.9 32.3 109.9 15.4
15 39.7 5.6 251.1 35.1 124.1 17.4
20 44.5 6.2 265.4 37.1 136.6 19.1
25 60.7 8.5 276.6 38.7 150.3 21.0
30 117.0 16.4 285.6 40.0 176.3 24.7
35 171.3 24.0 293.3 41.0 169.7 23.7
40 230.4 32.2 300.0 42.0 180.0 25.2
45 253.8 35.5 305.9 42.8 187.2 26.2
50 281.8 26.3 311.1 43.5 946.4 132.4
55 319.7 41.3 315.9 44.2 2453.2 343.1
60 348.3 42.1 320.2 44.8 2784.1 389.4
65 374.6 43.0 324.2 45.3 3088.5 432.0
70 399.0 43.9 327.9 45.9 3370.1 471.3
75 421.6 44.7 331.3 46.3 3632.8 508.1
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Figure 60. Aβ1-40 aggregation kinetics in different conditions: A Rh values from DLS measurements in 2 different buffer conditions (PB and TRIS) and 
at	2	different	concentrations	(23	μM	and	462	μM);	B plotted Rh values from DLS measurements in 3 different conditions; red line and triangles represent 
Rh	values	for	23	μM	Aβ1-40 dissolved in PB, purple line and squares represent Rh	values	for	23	μM	Aβ1-40 dissolved in TRIS and yellow line and triangles 
represent Rh	values	for	462	μM	Aβ1-40	dissolved	in	TRIS;	red	arrow	shows	aggregation	starting	point	for	Aβ1-40 in PB, purple arrow shows aggregation 
starting	point	for	Aβ1-40	in	TRIS	(23	μM	Aβ1-40)	and	yellow	arrow	shows	aggregation	starting	point	for	Aβ1-40	in	TRIS	(462	μM	Aβ1-40). During all the 
experimental	time	the	sample	was	kept	at	25	°C	apart	Aβ1-40	23	μM	in	TRIS,	because	it	was	kept	at	37	°C.	
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Amyloid peptide aggregation is affected by heparin and heparin like 6.3.5. 
molecules interaction
The	next	step	was	 to	follow	the	Aβ1-40 aggregation with or without heparin and mimics. As it has 
been reported free sulfated molecules partially inhibit the aggregation phenomenon (Fraser et al., 
1992; Kisilevsky et al., 1995; Kisilevsky and Svarek, 2002), thus using the previously described Hep, 
LMWH	and	oligosaccharide	Hep	derived,	we	demonstrated	the	efficacy	and	reliability	of	this	new	
treatment. It was used an UFH, three different kind of LMWH (Enoxa, Tinza and Dalte; all described 
and characterised in session 6.3.2) and three different oligosaccharides [Hep dpm 2, (T) dp 6 and (T) 
dp 10) derived from tinzaparin depolymerisation; all described and characterise in session 6.3.2]. In 
that experimental conditions, heparin was able to counteract amyloid aggregation, t75 Rh values with 
and without heparin were sensibly different, thus supporting a theoretical starting point (in the pres-
ence of UFH, t75 Rh	of	Aβ1-40 was reduced to the 16 % compare to t75 Rh	of	Aβ1-40 alone; Fig. 62, panel 
A and B):	f.a.s.	of	Aβ1-40 alone increases more than 62 times during the experimental time (Table 19). 
DLS results show that more the GAG length increase more its properties resemble UFH aggregation 
attenuation	properties,	in	fact	tinzaparin	that	is	characterised	by	oligosaccharides	>	8000	Da	(see	Fig. 
56 B) shown an attenuation effect comparable to UFH, whereas enoxaparin and dalteparin strongly 
attenuate the aggregation progression (Fig. 62, panel A and B; Table 19). This approach allows to 
focus the attention on oligosaccharide dimension effect.
Treatment t0 Rh t75 Rh F.a.s. Δ f.a.s.
Aβ1-40 57.8 3632.8 62.8 1
+ UFH 63.7 606.2 9.5 6.6
+ Enoxaparin 32.7 182.4 5.6 11.2
+ Tinzaparin 27.9 447.1 16.0 3.9
+ Dalteparin 32.4 169.7 5.2 12.0
+ Disaccharide 49.5 179.0 3.6 17.4
+ Exasaccharide 51.7 199.4 3.8 16.5
+ Decasaccharide 45.3 126.5 2.8 22.4
Table 19. Initial	and	final	hydrodynamic	radius	values	for	Aβ1-40 with or without UFH, LMWH and Hep mimetics/derivatives and relatively fold ag-
gregation	state	values	(f.a.s.).	Δ	f.a.s.	is	the	ratio	Aβ1-40 f.a.s./ treatment f.a.s.
As it was shown in section 6.3.2., enoxaparin, tinzaparin and dalteparin are characterised by different 
oligosaccharidic composition and DLS data shown that they differently contribute to amyloid aggre-
gation. Those different effects might related to the LMWHs oligosaccharidic composition, thus to test 
if	different	oligosaccharides	could	induce	different	effects	over	Aβ1-40 aggregation, it were selected 
oligosaccharides	with	 homogeneous	 length	 and	used	 them	 for	 interaction	 studies	with	Aβ1-40 (oli-
gosaccharides were previously characterised in section 6.3.2.). It was measured a comparable effect 
for hexasaccharide and disaccharide, that it was much stronger than UFH effect (Table 19; Fig. 63, 
panel A and B). Interestingly, a stronger inhibition effect was also shown by the decasaccharide (Fig. 
63, panel A and B). Oligosaccharides attenuate aggregation as enoxaparin and dalteparin (Table 19), 
this suggests that LMWH effectivenss could driven by just a part of the oligosaccharide population 
104 Results & Discussions
composing the LMWH. In particular the subpopulation of small chain oligosaccharides that cannot 
act as UFH (enoxaparin and dalteparin are mainly composed of oligosaccharides < 8000 Da ~dp 22), 
these oligosaccharides could interfere in the early and late fibril formation stage (for a schematic 
representation of plaque formation state Fig. 20) and as a consequence of their limited dimensions, 
they	cannot	act	as	Aβ1-40 aggregation site. This resulted in a stronger aggregation attenuation effect. 
The consideration that hexasaccharide and disaccharide shown weaker effects over aggregation at-
tenuation, suggests that anti-aggregation oligosaccharides might be able to exert a certain bridge 
effect. In fact smaller chain oligosaccharides (< dp 10/12) are able to interfere with the aggregation 
phenomenon, but they form soluble aggregates less stable than the one generate by the presence of 
bigger oligosaccharides. During aggregation lag phase (from 0 h to 48 h) amyloidic seeds and proto-
filaments tend to reach the stability and without any agents, attenuating the aggregation, the system 
can overcome this step accessing to the exponential fibril formation step (Fig. 60, Fig. 62 and Fig. 63 
blue aggregation profile). Oligosaccharides could interfere soon after seeds formation (t0 Rh with and 
without	GAGs	are	comparable)	stabilizing	soluble	aggregates	(like	soluble	protofilaments,	Rh< 200 
nm) and avoiding bigger aggregates formations, whereas with UFH just a weak aggregation attenua-
tion	can	be	observed	(Fig.	62).	Fig.	61	represents	a	model	for	Aβ1-40 aggregation interference caused 
by GAGs.
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~ 600 nm200 nm ->300 nm
Model	of	 the	possible	attenuation	of	Aβs	aggregation	by	UFH,	LMWH	and	oligosaccharides.	1)	Amyloid	aggregation	without	GAGs	Figure 61. 
proceeds	until	fibril	formation	causing	plaque	accumulation.	2)	Heparin	and/or	tinzaparin	mildly	attenuate	Aβs	aggregation	and	fibril	formation	still	oc-
curs. 3) Oligosaccharides (dp 6 < X < dp 12) and/or LMWHs characterised by anti-aggregation oligosaccharides (dp < 22) are able to strongly attenuate 
amyloid aggregation with no fibrils formation. 
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A
B
Time (hh)
R
h 
(n
m
)
Time (h) Rh (nm) St. Dev Rh (nm) St. Dev Rh (nm) St. Dev Rh (nm) St. Dev Rh (nm) St. Dev
0 57.8 8.1 63.7 3.2 32.7 1.6 27.9 1.4 32.4 1.6
5 96.6 13.5 111.0 15.5 49.7 7.0 64.1 9.0 44.4 6.2
10 109.9 15.4 150.4 21.0 59.9 8.4 92.2 12.9 53.0 7.4
15 124.1 17.4 173.5 24.3 69.3 9.7 106.5 14.9 62.0 8.7
20 136.6 19.1 169.5 23.7 80.0 11.2 118.8 16.6 69.2 9.7
25 150.3 21.0 188.9 26.4 92.5 12.9 135.3 18.9 77.2 10.8
30 176.3 24.7 219.2 30.7 97.6 13.7 170.4 23.8 88.9 12.4
35 169.7 23.7 245.5 34.3 107.0 15.0 184.5 25.8 97.9 13.7
40 180.0 25.2 274.8 38.4 116.5 16.3 199.9 28.0 106.9 14.9
45 187.2 26.2 223.2 31.2 128.8 18.0 216.9 30.3 110.4 15.4
50 946.4 132.4 307.8 43.0 128.0 17.9 303.6 42.5 126.7 17.7
55 2453.2 343.1 385.7 53.9 144.7 20.2 353.0 49.4 133.8 18.7
60 2784.1 389.4 431.9 60.4 154.2 21.6 371.9 52.0 142.8 20.0
65 3088.5 432.0 483.5 67.6 163.6 22.9 393.6 55.1 151.8 21.2
70 3370.1 471.3 594.0 83.1 174.8 24.4 418.5 58.5 160.0 22.4
75 3632.8 508.1 606.2 84.8 182.4 25.5 447.1 62.5 169.7 23.7
+ Dalteparin+ EnoxaparinAβ1-40 + UFH (Heparin) + Tinzaparin
1000.0
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AβFigure 62. 1-40 aggregation kinetics with and without Hep/LMWH. A Rh values	from	DLS	measurements	of	Aβ1-40 with and without UFH and 
LMWHs. B plotted Rh values	from	DLS	measurements	of	Aβ1-40	with	and	without	UFH	and	LMWH;	yellow	line	and	circles	represent	Aβ1-40 aggrega-
tion	trend	alone;	green	line	and	scores	represent	Aβ1-40	aggregation	trend	with	UFH;	clear	blue	line	and	squares	represent	Aβ1-40 aggregation trend with 
tinzaparin;	brown	line	and	scores	represent	Aβ1-40	aggregation	trend	with	enoxaparin;	clear	purple	line	and	squares	represent	Aβ1-40 aggregation trend 
with dalteparin. During all the experimental time the sample was kept at 25 °C. 
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Time (h) Rh (nm) St. Dev Rh (nm) St. Dev Rh (nm) St. Dev Rh (nm) St. Dev
0 57.8 8.1 49.5 2.5 51.7 2.6 45.3 2.3
5 96.6 13.5 67.3 9.4 70.7 9.9 58.0 8.1
10 109.9 15.4 80.2 11.2 72.4 10.1 64.0 8.9
15 124.1 17.4 90.2 12.6 78.2 10.9 68.8 9.6
20 136.6 19.1 98.4 13.8 84.5 11.8 73.6 10.3
25 150.3 21.0 95.4 13.3 91.3 12.8 78.4 11.0
30 176.3 24.7 119.8 16.8 113.0 15.8 83.2 11.6
35 169.7 23.7 119.3 16.7 106.6 14.9 88.0 12.3
40 180.0 25.2 125.9 17.6 115.2 16.1 92.8 13.0
45 187.2 26.2 119.3 16.7 124.5 17.4 97.6 13.7
50 946.4 132.4 137.0 19.2 134.5 18.8 102.4 14.3
55 2453.2 343.1 146.6 20.5 145.4 20.3 107.2 15.0
60 2784.1 389.4 153.9 21.5 157.1 22.0 112.0 15.7
65 3088.5 432.0 161.7 22.6 169.8 23.7 116.9 16.3
70 3370.1 471.3 149.2 20.9 142.3 19.9 110.1 15.4
75 3632.8 508.1 179.0 25.0 199.4 27.9 126.5 17.7
+ (T) dp 6 
(Hexasaccharide)
Aβ1-40 + Hep dp 2 (Disaccharide)
+ (T) dp 10 
(Decasaccharide)
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AβFigure 63. 1-40 aggregation kinetics with and without Hep mimetics/derivatives. A Rh values	from	DLS	measurements	of	Aβ1-40 with and without 
oligosaccharides. B plotted Rh values	from	DLS	measurements	of	Aβ1-40	with	and	without	oligosaccharides;	yellow	line	and	circles	represent	Aβ1-40 
aggregation	trend	alone;	orange	line	and	squares	represent	Aβ1-40	aggregation	trend	with	Hep	dp	2;	grey	line	and	squares	represent	Aβ1-40 aggregation 
trend	with	(T)	dp	6;	azure	line	and	triangles	represent	Aβ1-40 aggregation trend with (T) dp 10. During all the experimental time the sample was kept at 
25 °C. 
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Discussion6.3.6. 
A complete DLS study was performed and through it was demonstrated that DLS is a reliable tech-
nique	to	measure	changes	in	Aβ1-40 fold aggregation state. Following aggregation kinetics it was pos-
sible	to	test	chemo-physical	and	experimental	conditions	effects	on	the	Aβ1-40 aggregation properties, 
in fact the protein behaved differently changing the pH of the solution [this suggests that protonation 
state is strictly related to the conformational change involved in fibril formation (Petkova et al., 2006; 
Tycko, 2006; Yu et al.,	2009)].	Aβ1-40 shown changing in aggregation properties related to the buffer 
and protein concentration (the protein underwent aggregation phenomena only after stabilisation of 
internal	salt	bridges	and	secondary	structures	stabilization	and	aggregation	seed	formation).	Aβ1-40 
aggregation is characterised by a lag phase (molecules explore different conformations and create the 
aggregation seed reaching a soluble protofilaments state condition), an exponential phase (the real 
aggregation step) and a final plateau representing the end of the aggregation (fibrils/ little plaque). An 
external agent can perturb this chain of events and it should inhibit or dramatically attenuate aggrega-
tion, thus leading to the formation of little soluble aggregates. DLS measurement demonstrated that 
UFH and tinzaparin attenuate aggregates formation and the final aggregate dimensions are sensibly 
smaller	 than	aggregate	dimensions	in	 the	presence	of	Aβ1-40 alone (heparin weekly attenuate fibril 
formation and no plateau was reached in the experimental conditions): enoxaparin and dalteparin are 
capable to cause a stronger attenuation of amyloid aggregation than UFH and tinzaparin, in fact the 
final aggregation state is smaller in the presence of this two LMWHs than in the presence of tinza-
parin. Importantly a protofibrillar condition is stabilized by enoxaparin and dalteparin. According to 
LMWHs chromatographic characterisation this effect seems MW related (Fig. 56). Hexasaccharide 
and disaccharide shown a comparable attenuation effect as enoxaparin and dalteparin, suggesting 
that LMWHs attenuation effects could be driven by a subpopulation of oligosaccharides (strong at-
tenuators, Fig. 61). Soluble aggregates and protofilaments were of lower dimensions in the presence 
of decasaccharide: strong attenuators seem to stabilise amyloid aggregates in the protofibril forms 
(100-200 nm in diameter). Recently Hoshi, M. et al. (2010) suggested that amyloids toxicity could be 
driven by amylospheroid (ASPD, amyloidic spheroid moiety ranging from 4 nm to 18 nm in diameter 
and ~30 KDa MW; MTT viability test were performed on primary cultures from rat septum regions 
showing that isolated ASPD inhibits MTT activity), with high stability (2 months at 4 °C, Hoshi, 
2010). According to our data, strong GAGs attenuators inhibit ASPD stabilisation, forcing the system 
to stay in an higher f.a.s, but probably with less toxic aggregates. The molecular mechanism is still 
not clear, thus further studies will help enlightening it. LMWHs are mixture of oligosaccharides, we 
wondered whether the equilibrium between different molecular populations (sequence composition, 
sulfation/acetylation content) could be a key parameter to understand this phenomenon. Using se-
lected oligosaccharides is possible to avoid to consider the contemporary effect of different molecular 
population	on	the	same	compounds.	In	addiction	selected	oligosaccharides	chemically	modified	in	
specific	oligosaccharidic	position	(reducing	or	nonreducing	residues	and/or	sulfation/acetylation	pat-
tern) could help to understand the molecular basis behind this phenomenon. Such an experimental 
strategy could lead to a better drug design approach.
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Conclusions7. 
GAGs are polyelectrolites with a central biological relevance of which the HS/Hep family recover an 
important role contributing to regulate exchanges between the outer cell space (the extracellular ma-
trix) and the inner cell space (cytosol) through GAG binding proteins. This Ph.D. thesis was oriented 
to	understand	not	clear	aspects	of	Hep	defined	as	a	pharmaceutical	agent,	as	an	AT	interactor	and	as	
amyloidic protein interactor that have not been cleared so far:
 Heparin was statistically described throughout s heparin library which was prepared and char-
acterised using by 1H and 1H-13C HSQC NMR. Common European commercial heparins and heparin 
containing	modifications	induced	by	the	manufacturing	process	(over	oxidation)	were	also	consid-
ered. PCA is able to differentiate both polluted N-acetylated molecules from the library and can also 
highlights non N-acetylated contaminated samples, whereas the USP NMR identity test failed. Our 
data demonstrate how NMR in combination with chemometrics techniques as PCA can be used as 
a reliable quality control procedure to certify pharmaceutical heparin, and hopefully this approach 
could help to avoid an eventual new heparin crisis. In the next future the heparin library will be 
expanded	reaching	a	total	number	of	100	heparins	as	the	final	library	and	different	pollutants	like	
solvents (EtOH, peracetic acid, acetone, MetOH, etc.) and organic/biological molecule (amino acids, 
lipids, etc) will be considered. The feasibility of the method suggests the possibility to expand the 
library with samples provided by the manufacturers with the aim to cover the heterogeneity of phar-
maceutical porcine intestinal mucosal heparin and, possibly, also heparins from other origins, organs 
and processed by a variety of manufacturing processes.
 Two octasaccharides isolated from low-molecular-weight heparin enoxaparin bearing a 1,6-an-
hydrosugars at the reducing terminal were investigated (Octa-5 and Octa-6). Combinatory approach 
of NMR and docking studies demonstrated that Octa-5 and Octa-6 interact differently with AT clari-
fying	that	at	molecular	basis.	According	to	affinity	data	Octa-5	and	Octa-6	equilibrium	dissociation	
constants to AT are lower of 43 fold and 59 fold than fondaparinux, respectively. STD data shown 
that the closest contacts with AT involve the residues of the octasaccharide belonging to the sequence 
ANAGA*ISA and correspond to the ANAGA*-moiety for both Octa-5 and Octa-6. On the contrary of 
what was observed for Octa-3, weaker STD signals for the terminal -IS-1,6-anM/G disaccharides with 
respect to those of the -ANAGA*- moiety were observed, indicating a larger distance of these residues 
from	AT.	The	investigations	underline	that	the	manno	configuration	of	the	1,6-anhydro	residues	pro-
motes a better interaction with AT with respect to the gluco form due to its favourite position of the 
N-SO3 group. A more detailed understanding of the role of structural variations on AT binding prop-
erties of heparin oligosaccharides may help in the synthesis of ligand analogues and in the design of 
new	LMWHs	with	an	appropriate	structure	to	ensure	high	affinity	to	AT
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	Aβ	aggregation	properties	with	 and	without	Hep	and	 its	 fractions	or	mimetics/derivatives	
were described by DLS approach. The protein is strongly affected by the chemo-physical environ-
mental condition (pH 2 is a anti-aggregation condition; pH 7 keeps the system stable for 24 h, but 
after that the aggregation starts exponentially; pH 9 is an unstable condition and after 15 h aggrega-
tion exponential starts) and by the buffer condition (PB shown a low stabilization effect over the ag-
gregation phenomenon, whereas TRIS was able to counteract the aggregation progression for a longer 
time).	DLS	data	also	demonstrated	that	Aβ1-40 aggregation is strongly affected by heparin presence 
(aggregation proceeds much slower with heparin), but LMWHs and Hep oligosaccharides shown a 
much stronger effect over the aggregation. DLS investigation qualitatively demonstrated the effect of 
sulfated molecules over amyloidosis progression, but it cannot give any information about structural 
features involved in this phenomenon. Thus future NMR interaction studies and DLS investigation 
involving	modified	GAGs	could	help	 in	understanding	 the	molecular	basis	of	Aβs-GAGs	interac-
tions.
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